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INTRODUCTION 
 
For decades an acute condition or chronic illness is being clinically treated 
through delivery of drugs to the patients in form of some pharmaceutical dosage 
forms like tablets, capsules, creams, liquids, ointments, aerosols, etc. 
To attain and maintain the concentration of an administered drug within 
therapeutically effective range, it is often required to take drug dosage several 
times and this result in a fluctuating drug level in plasma. Controlled or sustained 
drug delivery systems have been introduce to overwhelm the problem of 
fluctuating drug levels related with conventional dosage forms (Vyas.S.P & 
Khar, 2002) ,  (Jaiswal.S.B et al., 2007). (Figure 1.) 
Fundamentally, there are three modes of drug delivery which are,  
 
 SUSTAINED RELEASE DRUG DELIVERY SYSTEM 
 
 CONTROLLED RELEASE DRUG DELIVERY SYSTEM 
 
 TARGETED DRUG DELIVERY SYSTEMS  
 
CONVENTIONAL DRUG DELIVERY SYSTEM  
Conventional drug delivery system is known to provide a prompt release of 
drug; therefore, to attain as well as to maintain the drug concentration within the 
therapeutically effective range needed for treatment, it is often necessary to take 
these types of drug delivery system several times a day. This result in a 
significant fluctuation in drug levels (Chien Y.W, 1982; Jaiswal.S.B et al., 2007). 
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Figure 1(a): Plasma drug concentration-time profile for conventional 
dosage 
 
 
Drawbacks of Conventional Dosage Forms:  
 Poor patient compliance 
 
 Increased chances of missing the dose of a drug 
 
 Shorter half life 
 
 To attain steady-state plasma concentration is difficult. 
 
 Fluctuations in drug levels (Shalin A. Modi et al., 2011; Chien Y.W, 1992).    
A) SUSTAINED RELEASE DRUG DELIVERY  
Sustained release drug delivery system, which means the release of 
active agent is slower than any conventional formulation, but is significantly 
affected by an external environment. The onset of its pharmacological action is 
delayed, and the duration of therapeutic effect is sustained. That means, to 
retard the release of a therapeutic agent in the systemic circulation is delayed 
and/or prolonged and its plasma profile is sustained (Jaiswal.S.B et al., 2007; 
Shalin A. Modi et al., 2011). 
 
B) CONTROLLED RELEASE DRUG DELIVERY SYSTEM 
 
Controlled release systems provide a release profile independent of external 
environment and predominantly controlled by the design of the system. It implies 
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a predictability and reproducibility in the drug release kinetics. That means, the 
release of drug ingredient(s) from a controlled-release drug delivery system 
proceeds at a rate profile that is predictable kinetically, and also reproducible 
from one unit to another (Xiaoling Li et al., 2005; Brahmankar D.M et al., 
1995). The plasma level of drug should be maintained within the safe margin and 
effective range, for this proper and calculated dose of the drug need to be given 
at different time intervals by conventional dosage forms (Shalin A. Modi et al., 
2011). 
 
C) TARGETED DRUG DELIVERY SYSTEM 
  
Targeted delivery refers to the systemic administration of a drug carrier 
with the goal of delivering the drug to specific cell types, tissues, or organs. 
The distribution of other tissues seems unnecessary, and a potential cause of 
toxicity. Most of diseases treated by cytotoxic agents not only demand for 
controlled drug delivery but also the pattern of delivery is directed to be specific, 
precise and defined at quantitative levels. 
Approaches are being adopted either to control the distribution of drug by 
incorporating it in a carrier or altering the structure of the drug at the molecular 
level, or by controlling the input of the drug into the bioenvironmental to ensure a 
programmed and desirable biodistribution (Vyas.S.P & Khar, 2002).   
 
RATIONALE OF SUSTAINED, CONTROLLED AND TARGETED DRUG 
DELIVERY: 
 
The drug delivery system are usually known by terms like sustained, controlled, 
targeted, novel, and therapeutic and programmed. However, the basic rationale 
for these varied delivery modules is the alteration or manipulation of 
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pharmacokinetic and pharmacodynamic of pharmacologically active moieties. 
This can be achieved either by using novel delivery devices (like Liposome, 
Transdermal patches or Matrix or Membrane controlled devices) , or by modifying 
the structure in molecular level (Prodrug or Chemical delivery system) and/or 
physiological parameters inherent by route of administration selected (like rectal 
route to avoid first pass metabolism). A drug delivery system may be thought of 
as one in which three components are included: the drug input function: the 
pharmacokinetic responses (metabolism): and the pharmacodynamic responses 
(therapeutic and side effects) (Xiaoling Li et al., 2005; Brahmankar D.M et al., 
2002). 
 
It is important to critically evaluate different terms used under broad 
category of novel drug delivery systems: 
 
 Sustained or controlled drug delivery systems provide drug action at a 
predetermined rate by providing a prolonged or constant (zero-order) release 
respectively, at therapeutically effective levels in the circulation. 
 
 Localized drug delivery devices through spatial or temporal control of drug 
release (usually rate-limiting) in the vicinity of the target. 
 
 Rate-preprogrammed drug delivery systems, by the release of drug molecules by 
system design, which controls the molecular diffusion of drug molecules. Fick’s 
laws of diffusion are followed. 
 
 Targeted drug delivery by using carriers either meant for passive 
preprogrammed or active preprogrammed or self-programmed approach or 
usually appended with suitable site-directing molecules which recognize their 
receptor or carbohydrate determinants at the target. 
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RECENT DEVELOPMENTS  
Controlled-released formulations have been widely developed and 
marketed over the past 30years under various terms such as sustained release, 
prolonged-release, timed-release, or other similar names that are often ill-defined 
and misleading. 
 
Recently, a number of novel drug delivery systems that uses unique 
concepts have been studied intensively. Some of the strategies include targeted 
delivery, self-regulated release, biofeedback mechanisms, and drug attached to 
biological carriers (Vyas.S.P & Khar, 2002; Xiaoling Li et al., 2005). 
Controlled-release formulations can be designed for any route of 
administrations as follows: 
• Oral 
 
• Parenteral 
 
• Implants 
 
• Transdermal 
 
• Other routes: ocular, nasal, vaginal, etc.  
 
 
Reasons for Interest in New DDS 
 
 Improving conventional dosage forms 
 
 Exclusivity for existing drugs 
 
 High cost for developing new drugs 
 
 Delivery of bioengineered compounds 
 
 Enhanced efficacy and safety  
Some of the potential benefits and drawbacks of controlled-release and novel 
drug delivery systems are as follows: 
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Potential Benefits of Novel Drug Delivery System  
 
 Convenience in dosing 
 
 Higher patient compliance 
 
 Better utilization of drugs 
 
 Reduced adverse effects 
 
 Improved efficacy  
 
Potential Problems of Novel Drug Delivery 
 
 Delivery of drugs to the target tissues/organs 
 
 Extravasations of drugs/carriers in the tissues/organs 
 
 Liberation of drugs from the carrier  
 
 Penetration into specific cells/cell components 
 
 Control of residence time at the receptor site.  
 
ORAL CONTROLLED RELEASE FORMULATIONS 
 
Oral route has been the commonly selected and most suitable for the drug 
delivery. Oral route of administration has more attention in the pharmaceutical 
field because of the more flexibility in the designing of dosage form than other 
routes of drug delivery (Stanley S.Davies et al., 2005; Shalin A. Modi et al., 
2011). 
The oral controlled drug delivery systems are mostly solids and based on 
diffusion, dissolution or combination of both mechanisms in the control of release 
rate of drug. 
Novel oral drug delivery systems are broadly classified into two categories 
as they may control release dosage forms as well as targeting dosage forms. 
General controlled manner in the GIT for systemic uptake and no particular area 
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of GIT specified. In contrast, targeted preparations are releasing the drug in a 
specified area or tissue of the GI (e.g. floating drug delivery system). 
 
Targeting systems are either releasing drug in controlled manner or in one 
burst at the specific area. The goal of a targeted oral drug delivery system 
(TODDS) is to achieve better therapeutics success compared to conventional 
dosage form. This can be achieved by improving the pharmacokinetic profile, 
patient convenience and compliance in therapy (Stanley S.Davies et al., 2005). 
 
 
 
Advantages of TODDS  
 
 Reduced dosing frequency 
 
 Better patient convenience and compliance 
 
 Reduced GI side effects and other toxic effects. 
 
 Less fluctuating plasma drug level 
 
 More uniform drug effect 
 
 Less total dose 
 
 Better stability of the drug (Brahmankar D.M et al., 1995; Vyas S.P & 
Khar, 2002). 
 
Disadvantages of TODDS: 
 
 Higher cost 
 
 Relatively poor in vitro-in vivo correlation 
 
 Possible dose dumping 
 
 Reduced potential for dose change or withdrawal in the event of toxicity 
(Brahmankar D.M et al., 1995). 
 
CHAPTER-01  INTRODUCTION 
 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC,MADURAI. Page 8 
 
Targeting of drugs through oral route involves control of time of release or 
location of release. On the basis of environmental, anatomical and physiological 
factors these drug delivery system can be classified with respect to target site as 
follows: 
 
 Systems targeted to stomach/duodenum 
 
 Systems targeted to small intestine 
 
 Systems targeted to large intestine/colon 
 
 Systems targeted to lymphatic.    
 
Classification of oral controlled drug delivery system 
 
1. Continuous release system 
 
 Dissolution controlled release system 
 
 Diffusion controlled release system 
 
 Diffusion and dissolution controlled release system. 
 
 Ion exchange resin drug complexes 
 
 Slow dissolving salt and complexes  
 
 pH independent formulations. 
 
 Osmotic pressure controlled systems 
 
 Hydrodynamic pressure controlled systems.  
 
2. Delayed transit and continuous release systems 
 
 Altered density system. 
 
 Mucoadhesive system. 
 
 Size based systems.      
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3. Delayed Release system 
 
 Intestinal release system. 
 
 Colonic release system.    
 
Advantages of controlled drug delivery systems 
 
 Improved patient convenience and compliance 
 
 Reduction in fluctuation in steady state levels. 
 
 Increased safety margin of high potency drugs. 
 
 Reduced GI side effects. 
 
 Reduced dosing frequency. 
 
 Better patient acceptance and compliance. 
 
 Less fluctuation at plasma drug levels. 
 
 Dose dumping. 
 
 Need of additional patient education (Jain N.K, 2002; Vyas S.P & Khar, 2002). 
 
   
Disadvantages of controlled drug delivery systems 
 
 Decreased systemic availability. 
 
 Poor invitro-in vivo correlations. 
 
 Chances of dose dumping. 
 
 Dose withdrawal is not possible. 
 
 Higher cost of formulation.        
 
CHAPTER 2 
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CHAPTER  2  GRDDS- A REVIEW 
 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY,MMC,MADURAI. Page 10 
 
GASTRO RETENTIVE DRUG DELIVERY SYSTEM-  REVIEW 
 
 
Oral administration is the most convenient and preferred means of any 
drug delivery to the systematic circulation. Oral controlled release drug delivery 
have recently been of increasing interest in pharmaceutical field to achieve 
improved therapeutic advantages, such as ease of dosing administration, 
patient compliance and flexibility in formulation. Drugs that are easily absorbed 
from gastrointestinal tract (GIT) and have short half-lives are eliminated quickly 
from the systemic circulation. Frequent dosing of these drugs is required to 
achieve suitable therapeutic activity (Amit Kumar Nayak et al., 2010). 
 
To avoid this limitation, the development of oral sustained-controlled 
release formulations is an attempt to release the drug slowly into the 
gastrointestinal tract (GIT) and maintain an effective drug concentration in the 
systemic circulation for a long time. After oral administration, such a drug 
delivery would be retained in the stomach and release the drug in a controlled 
manner, so that the drug could be supplied continuously to its absorption sites 
in the gastrointestinal tract (GIT). 
 
These drug delivery systems suffer from mainly two adversities: the short 
gastric retention time (GRT) and unpredictable short gastric emptying time 
(GET), which can result in incomplete drug release from the dosage form in the 
absorption zone (stomach or upper part of small intestine) leading to diminished 
efficacy of administered dose. To formulate a site-specific orally administered 
controlled release dosage form, it is desirable to achieve a prolong gastric 
residence time by the drug delivery. Prolonged gastric retention improves 
bioavailability, increases the duration of drug release, reduces drug waste, and 
improves the drug solubility that are less soluble in a high pH environment. Also 
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prolonged gastric retention time (GRT) in the stomach could be advantageous 
for local action in the upper part of the small intestine (e.g. treatment of peptic 
ulcer, etc) (Amit Kumar Nayak et al., 2010). 
 
 
BIOLOGICAL ASPECTS OF GRDDs 
 
Anatomy of the gastrointestinal tract:  
The gastrointestinal tract is divided into three main regions namely: 
 
 Stomach. 
 
 Small intestine (Duodenum, Jejunum and Iieum).  
 
 Large intestine.  
The GIT is a muscul ar tube, from the mouth to the anus, which f unctions 
to take in nutrients and eliminate waste by secretion, motility, digestion, 
absorption and excretion, which are known as physiological processes (Shiv 
Kumar Yadav et al., 2011). 
 
Figure 2(a):  Anatomy of Gastro Intestinal Tract
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Basic gastrointestinal tract physiology:  
 
The stomach is an expanded section of the digestive tube between the 
oesophagus and small intestine. The wall of the stomach is structurally similar 
to th e other parts of the digestive tube, with the exception that stomach has an 
extra, obliq ue layer of smooth muscle inside the circular layer, which aids in the 
performance of complex grinding  motions. In the empty state, the stomach is 
contracted and its mucosa and sub mucosa are thrown up into distinct folds 
called rugae (Natasha Sharma et al., 2011).   The stomach is anatomically 
divided into three parts, 
• Fundus 
 
• Body 
 
• Antrum (or pylorus). 
 
 
   
Figure 2(b) : Physiology of stomach 
 
The proximal stomach, made up of the fundus and body regions, serves 
as a reservoir for ingested materials while the distal region (antrum) is the major 
site of mixing motions, acting as a pump to accomplish gastric emptying. 
Gastric emptying occurs during fasting as well as fed states. The pattern of 
motility is however distinct in the 2 states. During the fasting state an 
interdigestive series of electrical events take place, which cycle both through 
stomach and intestine every 2 to 3 hours. This is called the interdigestive 
myloelectric cycle or migrating myloelectric cycle (MMC), which is further 
divided into following 4 phases as described by Wilson and Washington (Neha 
Narang et al., 2011). 
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Figure 2(c) : Schematic representation of Interdigestive Motility 
 
  
 
 
Table 2(a): Four phases in migrating myoelectric complex (MMC) 
 
(Shweta Arora et al., 2005) 
 
  PHASES 
 
 
 
PHASE I 
It is a quiescent period lasting from 30 to 60  minutes with 
no contractions. 
 
 
PHASE 
II 
It consists of intermittent contractions that gradually 
increase in intensity as the phase progresses, and it lasts 
about 20 to 40 minutes. 
Gastric discharge of fluid and very small particles begins 
later in this phase. 
 
 
PHASE 
III 
This is a short period of intense distal and proximal gastric  
contractions (4–5 contractions per minute) lasting about 10 
to 20  
minutes; these contractions, also known as ‘‘House-keeper 
wave,’’ sweep gastric contents down the small Intestine. 
 
 
PHASE 
IV 
This is a short transitory period of about 0 to 5minutes, and 
the contractions dissipate between the last part of phase III 
and quiescence 
of phase I. 
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Need for gastroretention 
 
 Drugs that are absorbed from the proximal part of the gastrointestinal tract 
(GIT). 
 
 Drugs that are less soluble or that degrade at the alkaline pH. 
 
 Drugs that are absorbed due to variable gastric emptying time. 
 
 Local or sustained drug delivery to the stomach and proximal small intestine to 
treat certain conditions. 
 Treatment of peptic ulcers caused by H.Pylori infections (Amit Kumar Nayak 
et al., 2010). 
 
 
POTENTIAL  DRUG  CANDIDATES FOR  GASTRORETENTIVE  DRUG   
DELIVERY SYSTEMS 
 
 Drugs those are locally active in the stomach.  
 
 Drugs that have narrow absorption window in gastrointestinal tract (GIT) 
 
 Drugs those are unstable in the intestinal or colonic environment 
 
 Drugs that disturb normal colonic microbes 
 
 Drugs that exhibit low solubility at high pH values (Amit Kumar Nayak et al., 
2010) 
 
 
DRUGS  THOSE  ARE  UNSUITABLE FOR  GASTRORETENTIVE  DRUG  
DELIVERY SYSTEMS  
 
 Drugs that have very limited acid solubility e.g. Phenytoin etc. 
 
 Drugs that suffer instability in the gastric environment e.g. Erythromycin etc. 
 
 Drugs intended for selective release in the colon e.g. 5- amino salicylic acid and 
corticosteroids etc (Amit Kumar Nayak et al., 2010). 
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Formulation aspects for GRDDS  
 
 It must be effective retention in the stomach to suit for the clinical demand. 
 
 It must be convenient for intake to facilitate patient compliance. 
 
 It must have sufficient drug loading capacity and control drug release profile. 
 
 It must have full degradation and evacuation of the system once the drug 
release is over. 
 
 It should not have effect on gastric motility including emptying pattern. 
 
 It should not have other local adverse effects (Vinod K.R. et al., 2010)  
 
 
Factors affecting gastric retention 
 
The gastric retention time (GRT) of dosage form is controlled by several 
factors that affect their efficacy as a gastro retentive system (Vinod K.R. et al., 
2010; Vaishali Sharma et al., 2011).  
1. Density: Gastric retention time (GRT) is a function of buoyancy of dosage form 
that is dependent on the density. 
 
2. Size: Dosage form units with a diameter of more than 7.5 mm are reported to 
have an increased GRT compared with those with a diameter of 9.9 mm. 
 
3. Shape: Tetrahedron and ring shaped devices with a flexural modulus of 48 and 
22.5 kilo pounds per square inch (KSI) are reported to have better GRT 90% to 
100% retention at 24 hours compared with other shapes. 
 
4. Single or Multiple unit formulation: Multiple unit formulations show a more 
predictable release profile and insignificant impairing of performance due to 
failure of units, allow co-administration of units with different release profiles or  
containing incompatible substances and permit a larger margin of safety  
against dosage form failure compared with single unit dosage forms. 
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 5. pH (Hydrogen Ion Concentration) – The mean pH (+ S.D.) along the G.I.  
 
               Tract in normal subjects are given by: 
   
 
    
Figure 2(d) : pH of Gastro Intestinal Tract 
 
 
6. Fed or unfed state: Under fasting conditions, the GI motility is characterized 
by periods of strong motor activity or the migrating myoelectric complex (MMC) 
that occurs every 1.5 to 2hrs. The MMC sweeps undigested material from the 
stomach and, if the timing of administration of the formulation coincides with 
that of the MMC, the GRT of the unit can be expected to be very short. 
However, in the fed state, MMC is delayed and GRT is considerably longer. 
 
7. Nature of meal: Feeding of indigestible polymers or fatty acid salts can change 
the motility pattern of the stomach to a fed state, thus decreasing the gastric 
emptying rate and prolonging drug release. 
   
8. Caloric content: GRT can be increased by 4 to 10 hours with a meal that is 
high in proteins and fats. 
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9. Frequency of feed: The GRT can increase by over 400 minutes when 
successive meals are given compared with a single meal due to the low 
frequency of MMC. 
 
10. Gender: Mean ambulatory GRT in males (3.4±0.6 hours) is less compared with 
their age and race matched female counterparts (4.6±1.2 hours), regardless of 
the weight, height and body surface. 
 
11. Age: Elderly people, especially those over 70, have a significantly longer GRT. 
 
12. Posture: GRT can vary between supine and upright ambulatory states of the 
patient. 
 
13. Concomitant drug administration: Anticholinergics like atropine, 
propantheline, opiates like codeine and prokinetic agents like Metoclopramide 
and Cisapride, can affect floating time. 
 
14. Biological factors: Diabetes and Crohn’s disease etc. 
 
 
 
 
Approaches to Gastric retention 
 
Various approaches have been pursued to increase the retention of an oral 
dosage form in the stomach. These systems include (Vinod K.R. et al., 2010; 
Vaishali Sharma et al., 2011), 
 
 
Figure 2(e): In vivo picturisation of various gastro retentive formulations  
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Figure 2(f): Schematic representation of various Gastro retentive 
formulations 
 
1. High density (sinking) system or non- floating drug delivery system: 
 
This approach involves formulation of dosage forms with the density that 
must  exceed density of normal stomach content (~ 1.004 gm/cm3). These 
formulations are prepared by coating drug on a heavy core or mixed with inert 
materials such as iron powder, barium sulphate, zinc oxide and titanium oxide 
etc. The materials increase density by up to 1.5- 2.4 gm/cm3. (Amit Kumar 
Nayak et al., 2010).  
Figure 2(g): High density systems  
 
 
2.Floating system or Low density system:  
Floating Drug Delivery Systems (FDDS) have a bulk density lower than gastric 
fluids and thus remain buoyant in the stomach, (Figure 9), for a prolonged period 
of time, without affecting the gastric emptying rate and the drug is released slowly 
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at a desired rate from the system, results in an increase in the gastric residence 
time and a better control of fluctuations in the plasma drug conentrations and after 
complete release of the drug, the residual system isemptied from the stomach 
(Neha Narang et al., 2011).  
 
Figure 2 (h):  Low density systems (Floating system) 
 
 
3.Expandable, unfoldable and swellable systems: 
 
These systems are also called as “Plug type system”, since they exhibit 
tendency to remain logged in the pyloric sphincters. These polymeric matrices 
remain in the gastric cavity for several hours even in fed state. By selection of 
polymer with the proper molecular weight and swelling properties controlled and 
sustained drug release can be achieved. Upon coming in contact with gastric 
fluid, the polymer imbibes  water and swells.
 
 
 
 
 
Figure 2(i): Swellable tablet in stomach 
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 (Amit Kumar Nayak et al., 2010). 
 
 
 
Figure 2(j) : Drug release from swellable systems 
 
Expandable systems have some drawbacks like problematical storage of much 
easily hydrolysable, biodegradable polymers relatively short-lived mechanical 
shape memory for the unfolding system most difficult to industrialize and not 
cost effective. Again, permanent retention of rigid, large single-unit expandable 
drug delivery dosage forms may cause brief obstruction, intestinal adhesion 
and gastropathy. 
 
4. Bioadhesive or Mucoadhesive drug delivery systems: 
 
Bioadhesive drug delivery systems are used as materials commonly 
used for bioadhesion are poly acrylic acid, chitosan, cholestyramine, sodium 
alginate, hydroxypropyl methylcellulose (HPMC), sucralfate, tragacanth, dextrin, 
polyethylene glycol (PEG) and polylactic acids etc. Even though some of these 
polymers are effective at producing bioadhesive, it is very difficult to maintain it 
effectively because of the rapid turnover of mucus in the gastrointestinal tract 
(GIT).  
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Figure 2(k) : (Amit Kumar Nayak et al., 2010; )
 
 
   5.Magnetic Systems 
 
This approach to enhance the gastric retention time (GRT) is based on the 
simple principle that the dosage form contains a small internal magnet, and a 
magnet placed  on the abdomen over the position of the stomach. Although 
magnetic system seems to work, the external magnet must be positioned with a 
degree of precision that might compromise patient compliance. 
(Anand S. Surana et al., 2010; Sunil Kumar et al., 2012). 
 
Figure 2(l):  Magnetic systems 
 
6. Super porous hydrogel systems:   (Harshil P Shah et al. 2017)  
These swellable systems differ sufficiently from the conventional types to 
warrant separate classification. In this approach to improve gastric retention 
time (GRT) super porous hydrogels of average pore size >100 micro meter, 
swell to equilibrium size within a minute due to rapid water uptake by capillary 
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wetting through numerous interconnected open pores . They swell to a large 
size (swelling ratio: 100 or more) and are intended to have sufficient 
mechanical strength to withstand pressure by gastric contraction. This is 
advised by co-formulation of hydrophilic particulate material (Sunil Kumar et 
al., 2012) 
 
Figure 2 (m): Typical swelling and mechanical properties of the SPH 
generations.   
7. Raft-forming systems: 
 
These systems, contain gel-forming solution (e.g. sodium alginate solution 
contents, swells and forms a viscous cohesive gel containing entrapped CO2 
bubbles, releases drug slowly in stomach by forming the raft layer on the top of 
gastric fluid. These formulations contain antacids such as calcium carbonate or 
aluminium hydroxide to reduce gastric acidity (Neha Narang et al., 2011; Shah 
S.H et al., 2009). 
  
Figure 2(n) : Schematic illustration of the barrier formed by a raft-forming 
system  
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FLOATING DRUG DELIVERY SYSTEM-REVIEW   
The concept of FDDS was first described in the literature as early as 
1968, when Davis (1968) disclosed a method to overcome the difficulty 
experienced by some persons of gagging or choking after swallowing 
medicinal pills. The author suggested that such difficulty could be overcome 
by providing pill having a density of less than 1.0g/cm3, so that pill will float on 
water surface. Since then several approaches have been used to develop an 
ideal floating drug delivery system. 
 
  
MECHANISM OF FLOATING DRUG DELIVERY SYSTEM  
 
Floating drug delivery systems (FDDS) have a bulk density less than 
gastric fluids and so remain buoyant in the stomach without affecting the 
gastric emptying rate for a prolonged period of time. While the system is 
floating on the gastric contents (Figure 1), the drug is released slowly at the 
desired rate from the system. After release of drug, the residual system is 
emptied from the stomach. This results in an increased GRT and a better 
control of the fluctuations in plasma drug concentration (Praveen Nasa et al., 
2010). 
 
However, besides a minimal gastric content needed to allow the proper 
achievement of the buoyancy retention principle, a minimal level of floating 
force (F) is also required to keep the dosage form reliably buoyant on the 
surface of the meal. The floating force kinetics is measured using a novel 
apparatus by determining the resultant weight (RW). The RW apparatus 
operates by measuring continuously the force equivalent to F (as a function of 
time) that is required to maintain the submerged object. 
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The object floats better if RW is on the higher positive side. This apparatus 
helpsin optimising FDDS with respect to stability and durability of floating 
forces produced in order to prevent the drawbacks of unforeseeable 
intragastric buoyancy capability  variations (Shah et al., 2009). 
RW or F = F buoyancy - F gravity  
= (Df - Ds) gV,  
Where,  
RW = total vertical force, 
Df = fluid density, 
 
Ds = object density, 
V = volume and  
g = acceleration due to gravity. 
 
In case of gas generating systems, carbon dioxide is released, causing the 
beads to float in the stomach. And in case of non-effervescent systems, the 
air trapped by the swollen polymer confers buoyancy to these dosage forms.  
   
 
Figure 3(a): Mechanism of Floating systems   
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CLASSFICATION 
 
Based on the mechanism of buoyancy, two different technologies have 
been used in development of floating drug delivery systems (Praveen Nasa 
et al., 2010). These include: 
 
a) Non- Effervescent system.  
 
b) Effervescent system.  
 
NON-EFFERVESCENT SYSTEM  
 
The Non-effervescent FDDS is based on mechanism of swelling of 
polymer or bioadhesion to mucosal layer in GI tract. The most commonly used 
excipients in noneffervescent. FDDS are gel forming or highly swellable 
cellulose type hydrocolloids, hydrophilic gums, polysaccharides and matrix 
forming materials such as polycarbonate, polyacrylate, polymethacrylate, 
polystyrene as well as bioadhesive polymers such as chitosan and carbopol 
(Amit Kumar Nayak et al., 2010).  
 
The various types of this system are as  
 
1. Single layer floating tablets. 
 
2. Bilayer floating tablets. 
 
3. Alginate beads. 
 
4. Hollow microspheres.  
 
1.Single layer floating tablets  
They are formulated by intimate mixing of drug with a gel-forming hydrocolloid, 
which swells in contact with gastric fluid and maintains bulk density of less than 
unity. They are formulated by intimate mixing of drug with low-density enteric 
materials such as HPMC (Vinod K.R et al., 2010). 
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2.Bilayer floating tablets 
 
A bilayer tablet contain two layer one immediate release layer which 
release initial dose from system while the another sustained release layer 
absorbs gastric fluid, forming an impermeable colloidal gel barrier on its 
surface, and maintain a bulk density of less than unity and thereby it remains 
buoyant in the stomach (Vinod K.R et al., 2010). 
 
3.Alginate beads 
 
Multi-unit floating dosage forms were developed from freeze dried calcium 
alginate. Spherical beads of approximately 2.5 mm diameter can be prepared 
by dropping sodium alginate solution into aqueous solution of calcium 
chloride, causingprecipitation of calcium alginate leading to formation of 
porous system, whichmaintain a floating force for over 12 hours. hours (Shah 
S.H et al., 2009; VinodK.R et al., 2010).  
 
4.Hollow microspheres 
 
Hollow microspheres (microballons), loaded with drug in their outer 
polymer shells were prepared by a novel emulsion-solvent diffusion method 
(Figure 3). The ethanol: dichloromethane solution of the drug and an enteric 
acrylic polymer was poured into an agitated aqueous solution of PVA that was 
thermally controlled at 400C. The gas phase generated in dispersed polymer 
droplet by evaporation of dichloromethane formed an internal cavity in 
microsphere of polymer with drug. The microballons floated continuously 
over the surface of acidic dissolution media containing surfactant for more 
than 12 hours in vitro (Vinod K.R et al., 2010). 
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Figure 3(c) : Formulation of floating hollow microsphere or microballoon   
 
EFFERVESCENT SYSTEM  
 
A drug delivery system can be made to float in the stomach by 
incorporating a floating chamber, which may be filled with vacuum, air or inert 
gas. The gas in floating chamber can be introduced either by volatilization of 
an organic solvent or by effervescent reaction between organic acids and 
bicarbonate salts (Shayeda et al., 2009). 
These effervescent systems further classified into two types:  
 
1) Volatile liquid or vacuum containing systems.  
 
2) Gas generating systems.   
Volatile liquid or vacuum containing systems  
 
(a) Intragastric floating gastrointestinal drug delivery system  
This system floats in the stomach because of floatation chamber, which 
is vacuum or filled with a harmless gas or air, while the drug reservoir is 
encapsulated by a microporous compartment (Vinod K.R et al., 2010). 
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Figure 3(d): Intragastric floating gastrointestinal drug delivery device  
 
b) Inflatable gastrointestinal delivery systems  
 
These systems are incorporated with an inflatable chamber, which 
contains liquid ether that gasifies at body temperature to inflate the chamber 
in the stomach. After oral administration, the capsule dissolves to release the 
drug reservoir together with the inflatable chamber. The inflatable chamber 
automatically inflates and retains the drug reservoir compartment in the 
stomach. The drug is released continuously from the reservoir into gastric fluid 
(Vinod K.R et al., 2010; Sunil Kumar et al., 2012). 
               
Figure 3(e): Inflatable gastrointestinal delivery system  
  
 
(c) Intragastric osmotically controlled drug delivery system: 
 
This system is comprised of an osmotic pressure controlled drug delivery device 
and an inflatable floating support in a biodegradable capsule, . The inflatable 
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support inside forms a hollow polymeric bag which contains a liquid that gasifies at 
body temperature to inflate the bag and it is deformable. The drug reservoir 
compartment is enclosed by a pressure responsive collapsible bag, which is 
impermeable to liquid and vapour and has a drug delivery orifice. The osmotically 
active compartment contains an osmotically active salt and is enclosed within a 
semi-permeable housing. In the stomach, the osmotically active salt present in the 
osmotically active compartment is dissolved by absorbing the water continuously 
present in the GI fluid through the semi-permeable membrane. An osmotic 
pressure is thus created which acts on the collapsible bag and in turn forces the 
drug reservoir compartment to reduce its volume and activate the drug reservoir 
compartment to reduce its volume and activate the drug release of a drug solution 
formulation through the delivery orifice. (Amit Kumar et al., 2011; Vinod K.R et 
al., 2010). 
 
Figure 3(f): Intragastric osmotically controlled drug delivery system   
GAS GENERATING SYSTEM  
 
These buoyant delivery systems utilize effervescent reactions between 
carbonate/bicarbonate salts and citric/tartaric acid to liberate CO2, which gets 
entrapped in the gellified hydrocolloid layer of the systems thus decreasing its 
specific gravity and making it to float over chyme (Sunil Kumar et al., 2012).  
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 Figure 3(g): Drug release from effervescent (gas generating) 
systems 
A) Tablets:  
 
1. Intragastric single layer floating tablets or Hydrodynamically 
Balanced System (HBS) 
These formulations have bulk density lower than gastric fluids and thus 
float in the stomach that increases the gastric emptying rate for a prolonged 
period, (Figure 8). These are formulated by intimately mixing the gas (CO2) 
generating agents and the drug within the matrix tablet. The drug is released 
slowly at a desired rate from the floating system and the residual system is 
emptied from the stomach after the complete release of the drug. This leads 
to an increase in the gastric residence time (GRT) and a better control over 
fluctuations in plasma drug concentration ( 
 
 
 
 
 
 
 
Figure 3(h): Intragastric single layer floating tablet  
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2. Intragastric bilayer floating tablets  
 
These are also compressed tablets, containing two layers (Figure 9):  
 Immediate release layer 
 
 Sustained release layer.    
                                                                   
Figure 3(i):Intragastric bilayer floating tablet 
 
 
B) Floating capsules  
 
These floating capsules are formulated by filling with a mixture of 
sodium alginate and sodium bicarbonate. The systems float as a result of the 
generation of CO2 that was trapped in the hydrating gel network on exposure 
to an acidic environment (Vinod K.R et al., 2010). 
 
C) Multiple unit type floating pills  
 
These multiple unit type floating pills are sustained release pills, known 
as ‘seeds’, which are surrounded by two layers (Figure 10). The outer layer is 
of swellable membrane layer while the inner layer consists of effervescent 
agents. This system sinks at once and then it forms swollen pills like balloons 
which float as they have lower density, when it is immersed in the dissolution 
medium at body temperature. The lower density is due to generation and 
entrapment of CO2 within the system (Amit Kumar et al., 2011; Vinod K.R et 
al., 2010). 
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Figure 3(j): Multiple unit type floating pills 
 
 
 
D) Floating system with Ion-Exchange resins 
 
Floating system using bicarbonate loaded ion exchange resin was 
made by mixing the beads with 1M sodium bicarbonate solution, and then the 
semi-permeable membrane is used to surround the loaded beads to avoid 
sudden loss of CO2. On contact with gastric contents an exchange of 
bicarbonate and chloride ions takes place that results in generation of CO2 
that carries beads towards the top of gastric contents and producing a floating 
layer of resin beads (Amit Kumar et al., 2011). 
  
 
Advantages of Floating drug delivery system (kirti et al., 2013)  
 
1. The FDDS are advantageous for drugs absorbed through the 
stomach (e.g. ferrous salts) and for drugs meant for local action in the 
stomach and treatment of peptic ulcer disease (e.g. Antacids). 
 
2. Acidic substances like aspirin cause irritation on the stomach 
wall when come in contact with it. Hence FDDS may be useful for the 
administration of aspirin and other similar drugs. 
 
3. Administration of prolongs release floating dosage forms, tablet 
or capsules, will result in dissolution of the drug in the gastric fluid. They 
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dissolve in the gastric fluid would be available for absorption in the small 
intestine after emptying of the stomach contents. 
 
4. Drug will be fully absorbed from floating dosage forms if it 
remains in the solution form even at the alkaline pH of the intestine (Natasha 
Sharma et al., 2011) 
 
5. FODDS provides advantages such as the delivery of drugs with 
narrow absorption windows in the small intestinal region (Vaishali Sharma et 
al., 2011) 
 
Disadvantages of Floating drug delivery system 
 
1. These systems require a high level of fluid in the stomach for 
drug delivery to float and work efficiently coat, water. 
 
2. Drugs that are significantly absorbed through out 
gastrointestinal tract, which undergo significant first pass metabolism, are only 
desirable candidate (Natasha Sharma et al., 2011) 
  
              3.Drugs that may irritate the stomach lining or are unstable in its 
acidic environment should not be formulated in gastro retentive systems 
(Vaishali Sharma et al.,2011) 
 
 
Limitations of gastro retentive drug delivery system: 
  
 The residence time in the stomach depends upon the digestive state. 
Hence, FDDS should be administered after the meal. 
 The ability to float relies on the hydration state of the dosage form. In 
order to keep these tablets floating in vivo, intermittent administration of 
water (a tumbler full, every 2 h) is beneficial. 
 The ability of drug to remain in the stomach depends upon the subject 
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being positioned upright. 
 FDDS are not suitable for the drugs that have solubility or stability 
problems in the gastric fluid. 
 Drugs like nifedipine, which is well absorbed along the entire GIT and 
which undergoes significant first pass metabolism, may not be desirable 
candidates for FDDS since the slow gastric emptying may lead to the 
reduced systemic bio-availability. 
  
EVALUATION OF FLOATING DRUG DELIVERY SYSTEMS 
 
 1.PRELIMINARYEVALUATION: 
a) Buoyancy Lag Time 
 
It is determined in order to assess the time taken by the dosage form to 
float on the top of the dissolution medium, after it is placed in the medium. 
These parameters can be measured as a part of the dissolution test. 
 
b) Floating Time 
 
Test for buoyancy is usually performed in SGF-Simulated Gastric Fluid 
maintained at 370C. The time for which the dosage form continuously floats on 
the dissolution media is termed as floating time. 
 
 
2)IN VITRO DISSOLUTION TESTS 
 
In vitro dissolution test is generally done by using USP apparatus with 
paddle and GRDDS is placed normally as for other conventional tablets. But 
sometimes as the vessel is large and paddles are at bottom, there is much 
lesser paddle force acts on floating dosage form which generally floats on 
surface. As floating dosage form not rotates may not give proper result and 
also not reproducible results. Similar problem occur with swellable dosage 
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form, as they are hydrogel may stick to surface of vessel or paddle and gives 
irreproducible results. In order to prevent such problems, various types of 
modification in dissolution assembly made are as follows. 
  
(3) IN VIVO EVALUATION (kirti et al., 2013) 
 
a) Radiology 
 
X-ray is widely used for examination of internal body systems. Barium 
Sulphate is widely used Radio Opaque Marker. So, BaSO4 is incorporated 
inside dosage form and X-ray images are taken at various intervals to view 
GR. 
    
b) Scintigraphy 
 
Similar to X-ray, emitting materials are incorporated into dosage form and 
then images are taken by scintigraphy. Widely used emitting material is 99Tc. 
   
c)Gastroscopy 
 
Gastroscopy is per oral endoscopy used with fibre optics or video 
systems. Gastroscopy is used to inspect visually the effect of prolongation in 
stomach. It can also give the detailed evaluation of GRDDS. 
 
 
d)Magnetic Marker Monitoring 
 
In this technique, dosage form is magnetically marked with 
incorporating iron powder inside, and images can be taken by very sensitive 
bio-magnetic measurement equipment. Advantage of this method is that it is 
radiation less and so not hazardous. 
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e)Ultrasonography 
 
Used sometimes, not used generally because it is not traceable at 
intestine (Shweta Arora et al., 2005; Gopalakrishnan S et al., 2011). 
    
APPLICATIONS OF FLOATING DRUG DELIVERY SYSTEM  
 
 Sustained drug delivery: (kirti et al., 2013)  
Hydrodynamically Balanced System (HBS) type are dosage forms 
which have bulk density less than one, relatively large in size and did not 
easily pass through pylorus, releases the drug over a prolonged period of time 
by retaining in the stomach for several hours and by increasing the gastric 
residence time (Kwon H. Kim et al., 2000). 
 
 Site specific drug delivery:  
Floating drug delivery systems are particularly useful for drugs having 
specific absorption from stomach or proximal part of the small intestine e.g. 
riboflavin, furosemide etc. The absorption of captopril has been found to be 
site specific, stomach being the major site followed by duodenum (Amit 
Kumar et al., 2011). 
 
 Absorption enhancement:  
Drugs that have poor bioavailability, because of their absorption is 
restricted to upper GIT are potential candidates to be formulated as floating 
drug delivery systems, thereby improving their absolute bioavailability. 
 
 
 Minimized adverse activity at the colon  
Retention of the drug at the stomach (HBS system), minimizes the 
amount of drug that reaches the colon, that prevents the undesirable activities 
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of the drug in colon. This Pharmacodynamic aspect provides the rationale for 
GRDF formulation for betalactam antibiotics that are absorbed only from the 
small intestine, and whose presence in the colon leads to the development of 
microorganism’s resistance. 
 
 Reduction in plasma fluctuations:  
Patients with advanced Parkinson’s disease, experienced pronounced 
fluctuations in symptoms while treatment with standard L-dopa. A HBS 
dosage form provided a better control of motor fluctuations although its 
bioavailability was reduced by 50-60% of the standard formulation. 
 
 Peptic ulcer treatment:  
H. Pylori, causative bacterium for peptic ulcers and chronic gastritis. 
Patients require high concentration of drug, to be maintained at the site of 
infection that is within the gastric mucosa. The floating dosage form due to its 
floating ability was retained in  stomach and maintained high concentration of 
drug in the stomach. A sustained liquid preparation of Ampicillin, using sodium 
alginate was developed that spreads out and adheres to gastric mucosal 
surfaces and releases the drug continuously. 
 
 Suitable for poorly absorbed drugs.  
Floating drug delivery systems are particularly useful for drugs which 
are poorly soluble or unstable in intestinal fluids and acid stable drugs and for 
those which undergo abrupt changes in their pH-dependent solubility due to 
pathophysiological conditions of GIT, food and age, e.g. floating system for 
furosemide lead to potential treatment of Parkinson’s disease. Approximate 
30% drug was absorbed after oral administration (Shweta Arora et al., 2005). 
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LITERATURE  REVIEW  ON FLOATING DRUG DELIVERY SYSTEMS 
 
 
EFFERVESCENT  FORMULATIONS: 
 
 
Rahim bahiri-najafi et al .,2017, developed, floating dosage form containing 
acyclovir was developed to increase its oral bioavailability. Effervescent floating 
tablets containing 200 mg acyclovir were prepared by direct compression method 
with three different rate controlling polymers including Hydroxypropyl methylcellulose 
K4M, Carbapol 934, and Polyvinylpyrrolidone. Optimized formulation showed good 
floating properties and in vitro drug release characteristics with mean dissolution 
time and dissolution efficacy of about 4.76 h and 54.33%, respectively. X-ray 
radiography exhibited that the tablet would reside in the stomach for about 5 ± 0.7 h. 
After oral administration of floating tablet containing 200 mg acyclovir, the Cmax, 
Tmax, and AUC0–∞ of optimized gastroretentive formulation were found to be 551 ± 
141 ng/mL, 2.75 ± 0.25 h and 3761 ± 909.6 ng/mL/h, respectively. 
Bharat W Tekade et al., 2017, formulated and evaluated the floating drug 
delivery system containing Cefpodoxime Proxetil using polymer HPMC K4M, Guar 
Gum. Effervescent floating tablets containing Cefpodoxime proxetil were prepared 
by direct compression technique using varying concentrations of different grades of 
polymer.Physical parameters like hardness, weight variation, thickness and 
friability were within pharmacopoeial limit. Percentage drug content in all floating 
tablet formulations was found to be 90% to 110%. The floating time was found to 
be more than 12 H. floating lag time was found to be 10±2.99 second..% drug 
release of formulation batch F8 was found to be 96.66% in 0.1 N HCL. 
Somnath Bhinge, et al .,2017, developed optimized gastric floating drug 
delivery system (GFDDS) of candesartan celexetil floating tablets by using various 
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polymers like Eudragit and MCC. In the present work, attempts have been made to 
prepare candesartan celexetil by direct compression method by using Citric acid, 
NaHCO3 , Magnesium stearate, Eudragit and MCC. Formulation F4 of sustained 
release tablet of Candesartan celexetil containing a combination of both polymers 
was found to be the optimized formulation for 13 hours release as it fulfilled all the 
requirement of floating drug delivery system of sustained release dosage form. 
Adukondalu devendla et al .,2017,  developed a novel gastro retentive 
floating tablets of Enalapril Maleate. The main objective is to increase 
bioavailability and increase gastric residence time. There are 12 formulations were 
prepared by using different ratios of natural gums & synthetic polymers. Xanthum 
gum is used for floating property so as to target the delivery of drug to a specific 
region in the GIT. HPMC K 100 is used as hydrophilic polymer. sodiumbicarbonate, 
citric acid is used as gas generating agent, Lactose is used as adsorbent, 
suspending agent. F11was the optimized formulation having floating time more 
than 20 hrs. 
Beena kumari et al .,2017, investigated the effect of concentration of 
HPMC K4M (X), concentration of guar gum (X), concentration of sodium 
bicarbonate (X) on the release of 1 2 3 atorvastatin calcium using central 
composite design.The floating tablets were formulated using atorvastatin calcium 
(20% w/w), HPMC K4M (5-15% w/w), guar gum (5-15% w/w), sodium bicarbonate 
(4-12% w/w), lactose (q.s.), talc (2% w/w) and magnesium stearate (1% w/w). 
Atorvastatin calcium floating tablets were evaluated for physical characterization 
viz. hardness, swelling index, floating capacity, weight variation, friability, in vitro 
drug release and kinetic studies. 
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Kharwade RS et al ., 2017, evaluated the floating tablets of domperidone 
that prolongs the gastric residence time using Hibiscus rosa-sinensis mucilage. 
The directly compressible floating tablets of domperidone were formulated using 
varying amount of hydroxypropyl methylcellulose K100 M, carbopol 934P and H. 
rosa-sinensis mucilage. The effervescent components sodium bicarbonate is used 
for the generation of CO2 gas. Further, tablets were evaluated for in vitro release 
characteristics. The concentration of H. rosa-sinensis mucilage with a gas-
generating agent was optimized to get the sustained release of domperidone. The 
% cumulative drug release of all formulation from F1 to F6 was within the range of 
81.37% to 98.62% for 18 hrs. The release kinetics of all the dosage forms was 
calculated using zero order, first order, Higuchi, and Korsmeyer–Peppas. It 
concludes that the release followed zero order release, whereas the correlation 
coefficient (r2 value) was higher for zero order release. 
 Hakim singh rajput et al., 2017, designed sustained release tablets of 
Captopril as gastroretentive drug delivery dosage form of a drug meant for 
management of treat high blood pressure (hypertension), congestive heart failure, 
kidney problems caused by diabetes, and to improve survival after a heart attack. 
Formulation of gastroretentive drug delivery dosage forms are done based on 
optimization under factorial design of formula and classed formulation batches in 
which concentration of polymer HPMC of various grades (HPMC K15 M, HPMC 
K100M and HPMC K4M) varied with the ration of sodium bi carbonate and 
microcrystalline cellulose.  
Singh et al., 2016, developed a floating matrix tablets of Clarithromycin                  
employing Simplex lattice design. Hydroxypropyl methylcellulose (HPMC) and    
Ethyl Cellulose (EC) were used as matrix forming agents; Sodium bicarbonate 
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and citric acid as effervescence producing agents. Total floating time of the 
formulations was more than 12hours and the drug content was in the range of 
98.54±0.46 to 99.92±0.32. 
Kanwar N et al., 2016, developed the, Floating tablets of pregabalin were 
prepare Using different concentrations of the gums (xanthan gum and guar gum), 
Carbopol 974P NF and HPMC K100. In vitro drug release was higher for tablet 
batches containing guar and xanthan gum as compared to the batches Containing 
Carbopol 974P NF. The formulation for a longer period (>12 h). 
Ijaz H et al., 2015, developed a Gastric floating lisinopril maleate and 
Metoprolol tartrate bilayer tablets were formulated by direct compression method 
using the sodium starch glycolate, croscarmellose sodium for IR layer. Eudragit 
L100,Pectin, acacia as sustained release polymersin different ratios for SR 
metoprolol tartrate layer and sodium bicarbonate, citric acid as gas generating 
agents for the floating extended release layer. From the study it is evident that a 
promising controlled release by floating bilayer tablets of lisinopril maleate and 
metoprolol tartrate can be developed successfully. 
Kadivar A et al., 2015, developed an Imatinib mesylate is an antineoplastic 
agent which has high absorption in the upper part of the gastrointestinal tract (GIT). 
Floating sustained-release Imatinib mesylate tablets were prepared using the wet 
granulation method. Tablets were formulated using Hydroxypropylmethylcellulose 
(HPMC K4M), with Sodium alginate (SA) and Carbomer 934P (CP) as release-
retarding polymers, sodium bicarbonate (NaHCO3) as the effervescent agent and 
lactose as a filler. Formulation to develop 24-hour sustained-release tablets with 
optimum floating behavior and Satisfactory physicochemical characteristics. 
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Gao Y et al., 2015, developed a gastro-floating sustained-release tablets of 
troxipide and a further study on in vitro release and in vivo bioavailability. Under the 
circumstances of direct powder compression, the floating tablets were successfully 
prepared with HPMC as main matrix material, Carbopol as assistant matrix 
material, octadecanol as floating agent and sodium bicarbonate as foaming agent 
to float by gas-forming. 
Zhao Q (1) et al., 2015, developed a Gastro-floating tablets of ascaridole, a 
volatile oil were developed to prolong the gastric residence time and thereby, 
enhance local therapeutic efficacy. The tablets were optimized and prepared by 
direct compression techniques using Hydroxypropylmethylcellulose (HPMC K15M) 
and polyethylene oxide (PEO WSRN-750) as Hydrophilic matrices and calcium 
carbonate (CaCO3) as a gas- generating agent. 
Loh ZC et al., 2015, developed a Metronidazole which has swelling and 
floating properties as a gastro retentive controlled-release drug delivery system to 
improve drug bioavailability. Fifteen different formulations of effervescence-forming 
floating systems were designed using HPMC K15M, xanthan gum, crospovidone, 
Eudragit® RL PO,pluronic® F- 127 and/or polypropylene foam powder as swelling 
agents and sodium bicarbonate with/ without citric acid as gas-forming agents at 
different compositions. Drug dissolution studies which were carried out using 0.1M 
HCl at 37°C for 8 hours. Combinations of HPMC K15M and xanthan gum as 
swelling agents show synergistic effect in retarding drug release and are suitable in 
providing the most sustained drug release system. 
Kesarla RS et al., 2015, developed a Conventional sustained dosage form 
of Ranitidine hydrochloride (HCl) does not prevent frequent administration due to 
sIts degradation in colonic media and limited absorption in the upper part of GIT. 
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FT-IR and DSC indicated no significant incompatibility with selected Excipients. 
Klucel-LF, POLYOX WSR N 60 K and l-menthol were selected as binder, Polymer 
and sublimating material, respectively, for factorial design batches after preliminary 
screening. From the factorial design batches, optimum concentration to release the 
drug within 12 h was found to be 420 mg of POLYOX and 40 mg of l-menthol. 
Stability studies indicated the formulation as stable. Ranitidine HCl matrix floating 
tablets were formulated to release 90%of drug in stomach within 12 h. 
Lohithasu D et al., 2014. developed the Lafutidine is H2-receptor 
antagonist. Guar gum is an efficient matrix forming agent in floating tablets by 
generating gas. Drug release from the prepared tablets was slowed over more 12 h 
and depended on the composition of guar gum and sodium bicarbonate. Lafutidine 
release was diffusion controlled and follows zero order kinetics. Floating tablets 
containing 10 mg of lafutidine could be prepared by wet- granulation technique 
employing guar gum of different grades as floating polymer and release retardant, 
methocel K100LVCR, methocel K15M as floating enhancers and sodium 
bicarbonate as a gas generating agent. Although the tablets with guar gum were 
able to float for more than 12 h. Resultant tablets blend did not have any 
incompatibilities showed in FT- IR studies. 
El-Zahaby SA et al.,2014, developed Gastro retentive levofloxacin (LVF) 
floating mini-tablets for the eradication of Helicobacter pylori (H. pylori) were 
prepared using thematrix forming polymer hydroxypropyl methylcellulose (HPMC 
K100M), alone or with Carbopol 940P indifferent ratios by wet granulation 
technique. Buoyancy of mini-tablets was achieved by an addition of an 
effervescent mixture consisting of sodium bicarbonate and anhydrous citric acid to 
CHAPTER  4  LITERATURE REVIEW 
 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY,MMC,MADURAI. Page 44 
 
some formulations. The optimized formula was subjected to further studies: FT-IR, 
DSC analysis. 
Uğurlu T et al., 2014, developed to prepare and evaluate clarithromycin 
(CLA) floating tablets using experimental mixture design for treatment of 
Helicobacter Pylori provided by prolonged gastric residence time and controlled 
plasma level.Ten different formulations were generated based on different 
molecular weight of Hypromellose (HPMC K100, K4M, K15M) by using simplex 
lattice design (a sub-class of mixture design) with Minitab 16 software. Sodium 
bicarbonate and anhydrous citric acid were used as gas generating agents. Tablets 
were prepared by wet granulation technique. 
Rao KR et al.,2014, the formulated and evaluated Clopidogrel floating 
tablets were prepared by direct compression technique by the use of three 
polymers xanthan gum, hydroxyl propyl methylcellulose (HPMC) K15M and HPMC 
K4M in different concentrations (20%, 25%and 30% w/w). Sodium bicarbonate 
(15% w/w) and microcrystalline cellulose 30%w/w) were used as gas generating 
agent and diluent respectively. In-vitro dissolution studies in 0.1 N hydrochloric acid 
(1.2 pH) The drug release from all the formulations was  by non-Fickian diffusion 
mechanism. 
Yin L et al., 2013, developed the Gastro-floating tablets of cephalexin were 
developed to prolong the residence time in major absorption sites. Gastro-floating 
tablets were prepared and optimized using hydroxypropyl methylcellulose (HPMC 
K100M) as matrix and sodium bicarbonate as a gas-forming agent. The properties 
of the tablets in terms of floating lag time, floating time and in vitro release were 
evaluated. Compared with conventional capsules, the gastro-floating tablets 
presented a sustained-release behavior with a relative bioavailability of 99.4%, 
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while the reference sustained-release tablets gave a relative bioavailability of only 
39.3%. 
Lakshmi P et al., 2013, developed the prepare lamotrigine (LM) bilayered 
and single layered floating tablets and to compare their release profiles. LM floating 
tablets were prepared by direct compression method. Drug, hydroxyl propyl methyl 
cellulose K4M, lactose monohydrate and polyvinyl pyrrolidone K30 constitute 
controlled release layer components and floating layer components includes 
polymers and sodium bicarbonate..Formulation LFC4 was found to be optimized 
with dissolution profile of zero order kinetics showing fickian diffusion. 
Pawar HA et al., 2013, developed the floating tablets of Atenolol to increase 
the gastric retention, to extend the drug release, and to improve the bioavailability 
of the drug. The floating tablets were formulated using hydrophilic polymers as 
Hydroxy propyl methyl cellulose (HPMC K4M and HPMC K15M), hydrophobic 
retardant as a hydrogenated cottonseed oil (HCSO), and sodium bicarbonate as a 
gas generating agent to reduce floating lag time. The in vitro release study of the 
tablets was performed in 0.1 N HCl as dissolution media. The study also revealed 
the effectiveness of HCSO as retardant in combination with HPMC. 
Gharti K et al., 2012, developed the preparation and in vitro  evaluation of 
floating tablets of hydroxypropyl methyl cellulose (HPMC) and polyethylene oxide 
(PEO) using ranitidine hydrochloride as a model drug. The floating tablets were 
based on effervescent approach using sodium bicarbonate a gas generating agent. 
The tablets were prepared by dry granulation method. The effect of polymers 
concentration and viscosity grades of HPMC on drug release profile was 
evaluated. The effect of sodium bicarbonate and stearic acid on drug release 
profile and floating properties were also investigated.  
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Sathiyaraj S et al., 2011, formulated lornoxicam floating tablets proved 
that a hydrophobic drug can be designed as modified release dosage form with 
desired qualities, using hydrophilic polymer HPMC K15M and calcium carbonate 
as a buoyancy initiator. Additionally, ease of manufacturing process by direct 
compression implies that it ensures the capability of commer cial utility by large 
scale production with satisfactory industrial feasibility. 
NON-EFFERVESCENT FORMULATIONS: 
B.Heeralal et al., 2017, prepared and evaluated non-effervescent drug 
delivery system of Famotidine HCl ,with different  polymers and checked for 
compatibility using FTIR and DSC. All the formulations were evaluated for 
differnet parameters like weight variation, drug content and various physic 
chemical properties.The optimized formulation had controlled formulation upto 12 
hrs.Since the value of ncalculated for Korsmeyer-peppas equation was found to 
be less than 1.0, it indicated that the drug release followed anamolous transport. 
C.Haranath et al., 2017, prepared and evaluated Cimetidine non-effervescent 
floating tablets with Ozokeritewax . Pure drug and optimized formulation FCDO16 
were subjected to the drug excipient compatibility studies using FTIR and DSC. The 
studies revealed that there is no interaction between the drug and excipients. Four 
formulations were prepared using Ozokerite wax and lactose (FCDO1-FCDO4), it was 
clearly observed that the drug release was only 16%, 22%, 26% and 32% 
respectively at the end of 12hr. Therefore in order to increase the drug release 
different types of superdisintegrants of different categories were chosen along with 
HPMC K15M as matrixing agent which protects the channels formed by lactose. 
Superdisintegrants gives the initial startup to the drug release. The super 
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disintegrants acts as a swelling agent by adsorbing large amounts of aqueous fluids 
and swells.  
Ali Raza et al., 2017,  formulatedgastroretentive floating tablets of 
minocycline hydrochloride with Simplex lattice mixture design to get experimental 
layout. Methocel K100LV (X1), Methocel K15M (X2) and Carbopol 934 (X3) were 
selected as independent variables. Ten formulations (F1 to F10) were developed 
by direct compression and were evaluated for physical parameters, swelling index, 
floating lag time, floating time and in-vitro drug release rate. Furthermore, FTIR 
spectroscopic studies were performed to determine drug polymer interaction. 
Floating lag time (Y1), floating time (Y2), cumulative drug release at 3 h (Y3), 6 h 
(Y4) and 12 h (Y5) were selected as dependent variables. Results showed that 
floating lag time and floating time were decreased by presence of Carbopol 934 in 
formulation while increased by Methocel K100LV and Methocel K15M.. Concisely, 
concluded that Carbopol 934 and Methocel 100LV can be used to fabricate 
gastroretentive floating tablets of minocycline hydrochloride with good buoyancy 
properties and sustained release action. 
Amiya  kumar prusty et al .,2017,  developed Gastroretentive floating 
matrix tablets of the antihyperlipidemic drug Rosuvastatin were successfully 
prepared using hydrophilic polymers like HPMC K4M and Carbapol. From the 
Preformulation studies for drug excipients compatibility it was observed that there 
was no compatibility problem with the excipients used in the study. The Formulated 
tablets gave satisfactory results for various physicochemical evaluation studies like 
Weight variation, Floating lag time, Content uniformity, Total floating time, 
Mucoadhesion time, mucoadhesive strength and in vitro drug release and shows a 
floating time of around 12 hrs.  
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Rajendra kumar jadi et al., 2016, developed extended release non-
effervescent floating tablets of Propranolol Hydrochloride(PPH) to extend the gastric 
residence time and prolong the drug release after oral administration.Different 
viscosity grades of HPMC are used as drug release retardants. Glycerylbehinate and 
Glycerylmonostearate are used as low density lipids in order to get the desired 
buoyancy over a prolonged period of time. The drug excipients compatibility was 
studied using DSC.The prepared tablets wereevaluated for their physical characters, 
in vitro drug release and in vitro buoyancy.The release and floating property depends 
on the polymer type, polymer proportion, lipid type and lipid proportions.; The studies 
revealed a mean gastric residence time of 5 ±1.73 h. 
Khalid El-Say et al., 2016, developed optimized non-effervescent floating 
tablets of Carvedilol by direct compression usinghpmc and carbopol 940 as release 
retarding polymers.The quality attributes of the tablet are evaluated.The buoyancy 
lag time , total floating time,swelling ability and in vitro release studies  are carried 
out in 0.1NHCl(ph1.2).Statistical data analysis revealed that the optimized 
formulation containing 21.91%HPMC and 15% Carbopol940 had acceptable 
hardness, optimum floating behavior and 24h controlled release pattern. 
          Swaroopa  Arpavalli  et al., 2016,developed and evaluatedgastroretentive 
drug delivery system of fluoroquinolone antibiotics (Balofloxacin). These floating 
tablets were prepared with the objective to obtain site-specific drug delivery and to 
extend its duration of action. More over the non effervescent system of balofloxacin 
will provide increased local and systemic action in stomach. Floating non-
effervescent tablets were formulated by various materials like hydroxypropyl 
methylcellulose HPMC (K 15M, E50), Xanthum gum, Guar gum, Carbopol 976P, 
polypropylene foam powder were used. All the formulations were evaluated for 
CHAPTER  4  LITERATURE REVIEW 
 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY,MMC,MADURAI. Page 49 
 
floating properties, swelling characteristics and drug release studies. The floating lag 
time were found to be significantly increased with the increasing concentration of the 
polymers. After the dissolution study of prepared balofloxacin non-effervescent 
floating tablet was concluded that the formulation NF9 with HPMC K15 and carbopol 
976P show best controlled release effect (98.24%).  
Dr.Abdul Hasan Sathali et al., 2016,prepared   non effervescentfloating  
tablets of Tolcaponemethod by using Natural Polymer (Psyllium husk) as floating 
agent. Psyllium husk is gastric protectant so we can overcome the gastric irritancy 
caused by the other added chemical excipients. The study included formulation of 
floating tablets using polymerslikeHydroxy Propyl Methyl Cellulose (HPMC K100, & 
HPMC K15M), Sodium carboxy methyl Cellulose and Eudragit RS100. The tablets 
were prepared by direct compression technique. The in-vitro drug release pattern 
of Tolcapone floating tablets  fitted to different kinetic models which showed 
highest regression for zero order kinetics & all the formulations followed Non-
fickian diffusion. Thus the prepared non-effervescent floating tablet of Tolcapone 
can be used for the treatment of Parkinsonism for more than 12 hrs with single 
dose administration. 
Rakhi Negi et al., 2016., formulated and evaluated microbaloons for 
Telmisartan which is having poor bioavailability.Telmisartan belongs to class II 
drug i.e., having high solubility and permeability. The microbaloons for Telmisartan 
were prepared by using different polymers and ratios.The polymers include ethyl 
cellulose and HPMC.The obtained microballoons formulations were evaluated for 
percentage yield, drug content,in-vitro release studies.The optimized formulation 
was further evaluated. 
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Meka Vs et al., 2016, formulated non-effervescent floating tablet of Glipizide 
, a poorly water soluble drug. The solubility of drug initially enhanced using solid 
dispersion with the help of hydrophobic carriers such as polaxomer,cyclodextrin, 
and povidone.The optimized formulation was further formulated into non-
effervescent floating tablets by using matrix ballooning inducers, such as cross 
povidone and release retarding agents including HPMC and PEO.All the 
formulations were within pharmacopoeial limits and all the formulations exhibited 
good floating behavior.In vitro dissolution studies showed that non-effervescent 
floating drug delivery systems provide a promising method of achieving prolonged 
gastric retention time. 
Dr. Abdul Hasan Sathali et al., 2015, formulated non-effervescent floating 
tablets of Valsartan using polymers like HPMC k15M, HPMC k100M, Sodium 
carboxy methyl cellulose and Eudragit RS100 as a matrix forming agents.Peanut 
husk powder  was used as floating agent.The tablets were prepared by direct 
compression technique.The in –vitro drug release pattern of valsartan floating 
tablets  fitted into  different kinetic models which showed highest regression for 
zero ordee and koresmeyer-peppas and most of the formulation followed Non-
fickian diffusion. 
Acharya S et al.,2014, developed the study was to optimize HPMC K4M and 
Carbopol 934 concentration in the development of non-effervescent floating tablets 
(NEFTs) of glipizide as model drug using 3(2) factorial design. The time required 
for releasing drug of 50% and 80% and similarity factor were the target responses. 
HPMC K4M and Carbopol 934 concentrations were the variables. The response 
surface methodology and optimized polynomial equations were used to select the 
optimal formulation with desired responses. The excipients used in tablets were 
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compatible with glipizide as per the results of isothermal stress testing and DSC 
study. The drug release of entire NEFTs followed zero order kinetics and non-
Fickian diffusion mechanism. 
Getyala A et al., 2013 developed the solubility and bioavailability of Losartan 
Potassium, by employing non effervescent floating drug delivery (tablet dosage 
forms). The study included formulation of floating tablets using polymers like 
Chitosan and Karaya gum as matrix forming agents. Accurel (®) MP1000 was 
used as floating agent. The tablets were prepared by direct compression 
technique. FTIR, DSC studies conformed that there was no incompatibility between 
the polymer and the drug. Tablet showed zero lag time, continuances of buoyancy 
for >12 h. The tablet showed good in vitro release. Drug release was through 
swelling and abided by the gellation mechanism. In vivo X-ray studies depicted that 
tablets continued to float in the GIT for 12 h. 
Rajhans S et al., 2011, reported that swellable gastro retentive drug delivery 
system was developed using combination of polyethylene oxide and HPMC 
K100LV by wet granulation process. based on the release kinetics it can be 
concluded that this combination of polyox W SR 303 and HPMC K100LV is 
particularly suitable as gastro retentive drug delivery system of valsartan as 
extended release drug delivery system. 
Yasir M et al., 2010, developed one daily SR floating matrix tablet for 
theophylline using psyllium husk as release controlling polymer and compared the 
release pattern with synthetic polymer HPMC K100M. It can be concluded that 
psyllium husk can be a promising polymer for GRFDDS in combination with 
synthetic polymers (HPMC K15M), and enhanced the floating duration and help to 
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maintain the dimensional stability at initial stage, which is necessary in case of 
once daily formulations.  
  
 
LITERATURE REVIEW ON SOLID DISPERSION 
Uddhav Bagul S et al., 2017, prepared and evaluated  Glipizide floating 
tablets.Glipizide belongs to class II drug, hence the solubility must be enhanced. 
Therefore, the solubility of glipizide was increased by solid dispersion method 
followed by formulation of floating tablets using 32 full factorial designs. Solid 
dispersion of PEG 4000 and 6000 with glipizide at dIfferent ratio was prepared by 
fusion method. The floating tablets were prepared by direct compression method, 
using HPMC K4M, HPMC K15M and sodium bicarbonate was used to maintain 
buoyancy. The floating tablets were evaluated for various physiochemical 
properties and in vitro drug release studies. The saturated solubility of pure 
glipizide was 7.9^g/ml which was enhanced to 204.3^g/ml, after preparation of 
solid dispersion, in 1:6 ratios with PEG 6000. The glipizide-PEG complex was 
confirmed by FT-IR spectroscopy and DSC thermo gram.  
Gaurav Subash Katore, et al., 2017. Formulated and evaluated  controlled 
release floating tablets of ciprofloxacin with improved solubility & dissolution rate. 
In present study solid dispersion using various carriers like mannitol & lactose in 
different ratios were prepared by solvent evaporation method. The prepared solid 
dispersions were characterized for drug content, solubility & dissolution rate. The 
dissolution rate substantially improved for ciprofloxacin from its solid dispersions 
compared with pure drug. Dissolution rate increased with increase in carrier 
content. The dissolution rate was increased 3 folds with solid dispersions 
containing 1:4 of drug: lactose. The granules of ciprofloxacin solid dispersion 
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containing 1:4 of drug: lactose ratio was prepared by wet granulation method using 
polymer such as ethyl cellulose & HPMC. 
Bhujbal Trupti, et al., 2017, developed formulation on  nifedipine in the 
form of bilayer floating sustained release tablet. Bilayer tablet consist of a two 
layers, immediate release layer and second sustained release layer, compressed 
in single unit dosage form. Immediate release layer contains surface solid 
dispersion of nifedipine and floating sustained release layer also contain surface 
solid dispersion of nifedipine by using HPMC K100M and HPMC K15M as 
sustained release polymer. Nifedipine is an antihypertensive drug. Surface solid 
dispersion of nifedipine was prepared by solvent evaporation method with different 
super disintegrant as a polymer for improvement of solubility resulting in improved 
bioavailability. Immediate release layer releases the drug immediately and floating 
sustained release layer floats on gastric fluid for upto 12 hours and releases the 
drug in sustained manner, subsequently it prolongs duration of action.  
Al  Zahra  Al Ashmway  et al., 2016, prepared and evaluated floating tablets 
of Atorvastatin Calcium . Physical mixtures of ATC were prepared by mixing the 
appropriate amounts of ATC and carriers (PVP k-2000, PEG 6000 and skimmed 
milk) in geometric proportions using a mortar and pestle, until a homogeneous 
mixture was obtained. Solid dispersions of ATC with all carriers   were prepared at 
ratios of (1:1, 1:3, 1:5, 1:7 and 1:9 drug to carrier ratio w/w) by three methods, 
kneading method, solvent evaporation and melting method. Evaluation of solid 
dispersion was done by studying the phase solubility, in-vitro dissolution, FTIR 
spectroscopy, DSC and X-ray powder diffractometry. The selected solid dispersion 
formulation was incorporated in floating tablets which were prepared by melting 
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granulation method. PEG 6000, PVP k-2000 and skimmed milk increased the 
solubility of ATC by 180, 290 and 1200 folds, respectively.  
Yang Zhao. et al ., 2014, prepared enteric solid dispersion (SD) for 
Nimodipine delayed release tablets via melting method. The physical state of the 
dispersed NMD in the polymer matrix was characterized by differential scanning 
calorimetry (DSC), powder X-ray diffraction (PXRD) and dissolution studies. 
Compared with pure drug and physical mixture, the dissolution of NMD-SD was 
enhanced dramatically (about 80%). As shown in the dissolution studies, the tablet 
released less than 10% in the artificial gastric acid in the initial 2 h and released 
32.1%, 75%, more than 90% at 4, 10 and 14 h respectively in the artificial intestinal 
fluid. This investigation has solved the problems of oral solid dosage forms of 
NMD, and it has the good industry prospect. 
LITERATURE REVIEW ON FEBUXOSTAT 
Ketan Savjini et al., 2015,  had  developed a modified release 
formulation of febuxostat that can serve the dual purpose of increasing the 
efficacy and decreasing the toxicity, thereby improving safety. Pharmacokinetic 
and pharmacodynamic data, including drug concentration profile, efficacy data 
and toxicity data have been reviewed thoroughly. Based on available data, 
target pharmacokinetic profile had been identified as about 50 % reduction in C 
max. The developed formulation was a potential candidate for filing to a 
regulatory agency with the advantage of higher efficacy and less toxicity, which 
will be beneficial to the patient population and has good commercial viability. 
Mukesh Sharma et al., 2014, prepared  swellable gastro retentive 
floating tablet  by direct compression technique and evaluated for their swelling 
characteristics (Swelling index, water uptake), floating capacity (floating lag time 
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and duration), Invitro drug release and stability studies. Factorial design was 
employed to optimize formulation components. The floating lag time and time 
required for 90% (t90%) of drug release were selected as dependent variables. 
Polymer with lower viscosity (HPMC K4M) was shown to be beneficial than 
higher viscosity polymer (K15M and K100M) in improving the floating properties 
of GRDDS. 
Prashanth Bhide et al., 2012,  developed  sublingual formulation by 
direct compression method, where superdisintegrants like crospovidone, Kyron 
T-114®, sodium starch glycolate, croscarmellose sodium, Tulsion 339® and 
Indion 234® were used to enhance solubility and drug release rate. The tablets 
were evaluated for hardness, thickness, friability, weight variation, drug content, 
wetting time, in-vitro disintegration time, water absorption ratio and in-vitro 
dissolution studies. It was concluded that sublingual tablet containing Kyron T-
114® and crospovidone showed the highest release (95.37%) at the end of 8 
minutes.  
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AIM OF  WORK 
A conventional dosage forms can only partly satisfy the therapeutic and 
biopharmaceutical needs, as it doesn’t take into account the site specific 
absorption rates within the GIT, therefore there is a need for developing 
delivery system that release the drug at the right time, at the specific site and 
with the desired rate. 
 
To overcome these problems, different approaches have been proposed 
to retain dosage form in the stomach. One of the most feasible approach for 
achieving a prolonged and predictable drug delivery in the GIT is to control the 
Gastric Residence Time ( GRT) (i.e. Gastro retentive dosage form). This 
dosage form can be retained in the stomach and assist in improving the oral 
sustained delivery of drugs that have an absorption window in a particular 
region of the GIT, thus ensuring optimal bioavailability. Gastro retention can be 
achieved via Intragastric floating drug delivery system, High density system, 
Swelling (or) Expandable system and Superporous hydrogels. 
 
The purpose of the present work was to develop an optimized floating 
drug   delivery system for the treatment of gout using xanthine oxidase inhibitor 
Febuxostat. 
 Febuxostat is insoluble in  water, solubility of Febuxostat enhanced by solid 
dispersion using PEG 6000 as a hydrophilic carrier by melting technique. 
Hydrophilic carrier forms hydrophilic bond with the drug which controls release 
of drug, improving solubility in acidic environment, and reduces the initial burst 
effect due to gas generating agent. 
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Gout is the collective name for several disorders that are characterized by 
the formation and deposition of monosodium urate (MSUr) crystals. The 
condition is associated with recurrent episodes of acute joint pain due to the 
deposition of MSUr crystals in the synovial fluid. The half life of Febuxostat is 
about 3 to 5 h. Therefore to avoid the repetitive administration of Febuxostat 
and to reduce total dose the gastroretentive drug delivery of Febuxostat is 
developed. 
 
SOLID DISPERSIONS (Patel B P et al., 2012). 
One of the main drawbacks of effervescent floating formulation is the 
extent of initial burst effect due to excess carbon dioxide generation. 
Reducing the proportion of effervescent compounds could solve the 
problem. 
An alternative way to restrain burst effect is by the use of solid dispersions 
as drug carriers, a technique that is proven to be efficient without the need 
to reduce the proportion of the effervescent agents in the formulation. 
The term ‘solid dispersions’ refers to a family of multi-component 
systems  where by a crystalline or amorphous drug is dispersed into an 
amorphous or semicrystalline polymer matrix. The release rate of the 
resultant formulations is greatly affected by the physical state of the 
dispersed drug, which in turn is defined by the solubility of the drug in the 
polymer. 
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Solid dispersions represent a useful pharmaceutical technique for 
increasing the dissolution, absorption and therapeutic efficacy of drugs in 
dosage forms. The term solid dispersion refers to the dispersion of one or 
more active ingredients in an inert carrier or matrix at solid state prepared by 
the melting (fusion), solvent, or melting- solvent method. 
There are many methods available for enhancing solubility through solid 
dispersion. Here , I have employed  MELTING METHOD. 
In Melting method, drug (FEBUXOSTAT) and carrier(PEG6000)  are mixed 
using mortar and pestle. To accomplish a homogenous dispersion the 
mixture is heated at or above the melting point of all the components. It is 
then cooled to acquire a congealed mass. It is crushed and sieved. 
(Kalaiselvan et al., 2006) 
 
COMPARISION  BETWEEN  EFFERVESCENT TECHNIQUES AND 
NON-EFFERVESCENT TECHNIQUES 
Effervescent floating drug delivery systems are the promising techniques in 
gastro retentive drug delivery systems. Effervescence leads to increase in rate 
and extent of absorbtion of drugs that are known to have poor bioavailability, by  
 Reducing thickness/viscosity of the mucus layer present adjacent to GI 
mucosa. 
 Alteration of tight junctions b/w cells, promoting absorption through paracellular 
route. 
 Increasing hydrophilic environment within cellular membrane. 
 The effectiveness of this type of system can be reduced by fluctuation in gastric 
ph due to factors like disease condition and presence of food. 
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Hence, it is better to have an alternating technique called  
 
NON-EFFERVESCENT technique, which employs a mechanism of swelling 
after swallowing through imbibitions of gastric fluid to an extent that it prevents 
their exit from the stomach. 
In patients who is denied having sodium intake in diseased conditions, this 
technique is more effective. 
Thus , this study is to compare both the effervescent and non-effervescent 
formulations having similar excipients ( Hydrophobic and hydrophillic) and 
determining their properties with respect to each other.  
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PLAN OF WORK 
 
 
 
 
1. STANDARD CALIBRATION CURVES FOR FEBUXOSTAT: 
 
a) Preparation of dissolution medium Acid buffer pH1.2 
 
b) Determination of (Absorbance maximum) λ max of Febuxostat by UV 
Spectrum. 
 
c) Preparation of standard calibration curve for Febuxostat. 
 
 
 
 
2. DRUG - POLYMER COMPATIBILITY STUDIES: 
 
a) Fourier transform Infrared spectroscopic (FTIR) studies. 
 
b) Differential scanning calorimetric (DSC) studies.  
 
 
 
 
   
3. FORMULATION AND EVALUATION OF FEBUXOSTAT GASTRO 
RETENTIVE    FLOATING TABLETS. 
 
a) Formulation of  solid dispersion complexes. 
 
b) Estimation of percentage yield and drug content 
 
c) Formulation of Febuxostat  floating matrix tablets by both Effervescent and 
Non-Effervescent techniques. 
 
d) Invitro dissolution studies 
 
e) Comparision between effervescent drug release and non- effervescent drug 
release patterns. 
 
f) Selection of best formulation. 
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4.EVALUATION OF FEBUXOSTAT GASTRO RETENTIVE FLOATING   TABLETS: 
a) Pre compressional evaluation of powder blend: 
 
 Angle of repose 
 
 Bulk density 
 
 Tapped density 
 
 Compressibility index 
 
 Hausner’s ratio 
 
 Drug content 
 
b) Post compressional evaluation of floating tablets: 
 
 General appearance 
 
 Tablet dimension 
 
 Hardness 
 
 Friability 
 
 Weight variation 
 
 Drug content 
 
 Invitro buoyancy studies 
 
 Swelling studies 
 
 Invitro release studies 
 
 Invitro drug release kinetics studies. 
 
 Selection of best method and  formulation. 
 
 Evaluation of best formulation 
 
 Fourier transform Infrared spectroscopic (FTIR) studies. 
 
 Differential scanning calorimetric (DSC) studies. 
 
  Powder X-Ray diffraction (PXRD)  studies. 
 
 In- vivo X- ray studies. 
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MATERIALS 
 
 
 
 
S.No 
Name of 
material Manufacturer / supplier
Use in 
formulation 
1 
 
FEBUXOSTAT Pure Chem Pvt Ltd. Active ingredient 
2 HPMC K100 Madras Pharma, Chennai. 
Hydrophilic 
polymer 
3 HPMC K4 
 
Madras Pharma, Chennai. Hydrophilic polymer 
4 PVPK30 
 
Madras Pharma, Chennai. Binding agent 
5 
Sodium 
bicorbonate 
 
Fourrts India 
Laboratories 
Pvt Ltd 
Effervescent Agent 
6 Citric Acid 
 
Fourrts India 
Laboratories 
Pvt Ltd. 
Effervescent Agent 
7 
 
Micro 
crystalline 
cellulose 
Paris Dakner Pvt Ltd. Binding agent 
8 
 
Methyl 
cellulose 
Paris Dakner Pvt Ltd. Hydrocolloid 
9 
 
Ethyl cellulose Paris Dakner Pvt Ltd. Buoyancy increasing agent. 
 
10 
 
Talc 
 
Paris Dakner Pvt Ltd 
 
Glidant 
 
11 
 
Magnesium 
stearate 
 
Paris Dakner Pvt Ltd 
 
Glidant 
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EQUIPMENTS 
 
 
 
S.No 
 
EQUIPMENT’S / INSTRUMENTS MANUFACTURER / 
SUPPLIER 
1 Electronic weighing balance A & D company HR 200, 
Japan. 
 
2 
 
Hot air oven RANDS Instruments 
Company, 
Chennai. 
 
3 
 
Multi  Punch tablet compression 
machine 
Fluid pack Co.Pvt., 
Ahmadabad 
4 Vernier caliper Linker, Mumbai. 
5 Monsanto hardness tester Praveen Enterprises, 
Bangalore. 
6 Friability Test Apparatus Indian Equipment Corporation. 
7 pH meter MC Dalal, Chennai 
8 Disintegration apparatus Electrolab, India 
9 Digital Tablet Dissolution Test 
Apparatus 
Disso 2000 Lab India, 
Mumbai. 
 
10 
 
UV-visible spectrophotometer UV-1700 Pharmaspec 
Shimadzu, Japan 
 
11 Fourier transform infra-red 
spectrophotometer 
 
Shimadzu RXI Japan. 
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DRUG DATA: 
 
Febuxostat: 
 
Structure: 
 
IUPAC name: 2-[3-Cyano-4-isobutoxyphenyl]-4-methylthiazole-5-carboxylic acid; 2- [3-
Cyano-4-(2-methylpropoxy) phenyl]-4-methyl-1,3-thiazole-5-carboxylic acid. 
 
Molecular Formula: C16H16N2O3S. 
 
Molecular Weight: 316.37. 
 
CAS Registry Number: 144060-53-7 
 
Solubility: Febuxostat is practically insoluble in water, soluble in methanol, soluble in 
DMSO, sparingly soluble in acetone. 
Half life: Mean elimination half-life of approximately 4 to 6 hours. 
 
Description: Febuxostat is in the crystalline form having off white powder to pale 
yellow in colour. 
Dose: Suggested dose: 40-120 mg daily (40mg, 80 mg two times a day). 
 
Excretion: Febuxostat is eliminated by renal pathway. 
Storage: Store at controlled room temperature 20°C-25°C. 
 Melting point: 238°C to 239 °C. 
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 Pharmacokinetics data: 
        Absorption              :       >49%  
 
       Protein binding        :        99.2% 
 
        Half-life : 5-8 hrs 
        pH range : 1-5 
        pka Value :     3.08 
 
 
       Identification : 317 nm in UV spectrophotometer 
 
Route of administration : oral 
 
       Dose : 40mg, 80mg, 120mg 
 
       Dosage form : tablets 
 
  Therapeutic categories : xanthine oxidase inhibitor 
 
        
 USE    
  
For the treatment of  chronic hyperuricaemia in conditions where urate deposition has 
already occurred (including a history, or presence of, tophus and/or gouty arthritis). 
It is indicated for the prevention and treatment of hyperuricaemia in adult patients 
undergoing chemotherapy for haematologic malignancies at intermediate to high risk of 
Tumor Lysis Syndrome (TLS).  Febuxostat has therapeutic index in the gout disease 
and so pharmacokinetically is safe since normal doses can vary from 40 to 120 mg per 
day with no substantial difference in acute toxicity or effect.  
 
Volume of distribution         :0.7L/kg. 
 
Time to reach peak plasma concentration:5hr            
  
CHAPTER  8  DRUG PROFILE 
 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY,MMC,MADURAI. Page 66 
 
Urinary excretion: Approximately 45%  
 
No dose adjustment is necessary when administering febuxostat in patients with mild to 
moderate renal and hepatic impairment. 
 
Metabolism: 
Febuxostat is extensively metabolized by both conjugation via uridine diphosphate 
glucuronosyltransferase (UGT) enzymes including UGT1A1, UGT1A3, UGT1A9, and 
UGT2B7 and oxidation via cytochrome P450 (CYP) enzymes including CYP1A2, 2C8 
and 2C9 and non-P450 enzymes. The relative contribution of each enzyme isoform in 
the metabolism of febuxostat is not clear. The oxidation of the isobutyl side chain 
leads to the formation of four pharmacologically active hydroxy metabolites, all of 
which occur in plasma of humans at a much lower extent than febuxostat. In urine and 
feces, acyl glucuronide metabolites of febuxostat (~35% of the dose), and oxidative 
metabolites, 67M-1 (~10% of the dose), 67M-2 (~11% of the dose), and 67M-4, a 
secondary metabolite from 67M-1 (~14% of the dose), appeared to be the major 
metabolites of febuxostat in vivo. 
 
PHARMACODYNAMIC MECHANISM OF ACTION:  
Febuxostat is a non-purine selective inhibitor of xanthine oxidase. It works by non- 
competitively blocking the molybdenum pterin center which is the active site on 
xanthine oxidase.      Xanthine       oxidase       is       needed       to       successively       
oxidize both hypoxanthine and xanthine to uric acid. Hence, febuxostat inhibits 
xanthine oxidase, therefore reducing production of uric acid. Febuxostat inhibits 
both, oxidized as well as reduced form of xanthine oxidase because of which 
febuxostat cannot be easily displaced from the molybdenum pterin site. 
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Clinical efficacy: 
 
Many long and short-term clinical trials have proved the efficacy of Febuxostat in the 
treatment of gout and lowering uric acid levels. Febuxostat was found to be superior 
to Allopurinol in reducing the serum uric acid levels. 
Febuxostat versus Allopurinol Controlled Trial (FACT): Serum urate levels were 
reduced below 6.0 mg/dL at the last three monthly observations in a significantly 
greater proportion of patients with gout and hyperuricemia receiving febuxostat 80 or 
120 mg once daily than in those receiving allopurinol 300 mg once daily in a 52-
week, randomized, double-blind trial. 
Allopurinol Placebo controlled Efficacy study of febuXostat (APEX): Febuxostat 80, 
120 or 240 mg once daily showed significantly greater urate-lowering efficacy than 
allopurinol 100 or 300 mg once daily in a 28-week, randomized, double-blind, 
placebo- controlled trial in patients with gout and hyperuricemia.(GOUT UPDATE 
BPJ ISSUE 62). 
Side effects: 
 
The adverse effects associated with febuxostat therapy include nausea, diarrhea, 
arthralgia, headache, increased hepatic serum enzyme levels and rash. 
 
Drug interaction: 
 
Drugs metabolized by xanthine oxidase (eg, azathioprine, mercaptopurine, 
theophylline). Plasma concentrations of these agents may be increased, leading to 
toxicity. Coadministration with febuxostat is contraindicated. 
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Toxicity : 
Liver test abnormalities have been reported to occur in 2% to 13% (average 
~3.5%) of patients receiving febuxostat, but the levels are generally mild-to-
moderate and self-limited. The height, nature and timing of these abnormalities 
have not been described. However, liver test elevations were the major reason 
for febuxostat discontinuation for adverse events (~2%) in clinical trials, despite 
the fact that no cases of jaundice or acute hepatitis were reported. The product 
labeling for febuxostat, however, lists potential side effects of hepatic steatosis, 
hepatitis and hepatomegaly. Another unrelated, nonpurine xanthine oxidase 
inhibitor (benzbromarone) was not approved for use in the United States because 
of its potential for hepatic toxicity. 
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HYDROXYPROPYL METHYL CELLULOSE : 
 
Structural Formula: 
 
 
 
Where, R is H, CH3, or CH3 CH (OH) CH2 
 
Non-proprietory Names: 
 
BP: Hypromellose 
USP: Hydroxypropyl methyl cellulose 2208, 2906, 2910 
Synonyms: 
 
Methyl hydroxypropyl cellulose, Methocel, Methyl cellulose  
Chemical Name and CAS Registry Number: 
 
Cellulose Hydroxypropylmethyl ether [9004–65–3] 
 
 
Solubility: 
Soluble in cold water, forming a viscous colloidal solution, 
practically insoluble in chloroform, ethanol (95%), and ether, but soluble in 
mixtures of ethanol & dichloro methane. 
PH: 
5.5–8.0 for a 1% w/w aqueous solution. 
 
Melting point: 
 
Browns at 190–200°C, chars at 225–230°C. Glass transition 
temperature is   170–180°C. 
 
 
Density: 
 
1.326 g/ cm3 
CHAPTER  9  EXCIPIENTS PROFILE 
 
DEPARTMENT OF PHARMACEUTICS, COLLEGE O PHARMACY,MMC,MADURAI. Page 70 
 
Molecular weight: 
 
Approximately 10,000 to 15,00,000 
Functional Category: 
 
Bioadhesive material; coating agent; controlled-release agent; dispersing 
agent; dissolution enhancer; emulsifying agent; emulsion stabilizer; extended-
release agent; film-forming agent; foaming agent; granulation aid; modified-
release agent; mucoadhesive; release-modifying agent; solubilizing agent; 
stabilizing agent; suspending agent; sustained-release agent; tablet binder; 
thickening agent; viscosity- increasing agent. 
Applications in Pharmaceutical Formulation: 
 
 Hypromellose is widely used in oral, ophthalmic, nasal, and topical 
pharmaceutical formulations. 
 In oral products, hypromellose is primarily used as a tablet binder, in film-
coating, and as a matrix for use in extended release tablet formulations. 
Concentrations between 2% and 5% w/w may be used as a binder in either wet- 
or dry-granulation processes. 
 High-viscosity grades may be used to retard the release of drugs from a matrix 
at levels of 10–80% w/w in tablets and capsules. Hypromellose is also used in 
liquid  oral dosage forms as a suspending and/or thickening agent at 
concentrations ranging from 0.25–5.0%. 
 ypromellose is also used as a suspending and thickening agent in topical 
formulations. Compared with methylcellulose, hypromellose produces aqueous 
solutions of greater clarity, with fewer undissolved fibers present, and is 
therefore preferred in formulations for ophthalmic use. 
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Description: 
 
An odorless and tasteless, white or creamy-white fibrous or 
granular powder. 
Solubility: 
 
Soluble in cold water, forming a viscous colloidal solution; practically 
insoluble in hot water, chloroform, ethanol (95%) and ether. 
 
Acidity/alkalinity: 
 
pH = 5.0–8.0 for a 2% w/w aqueous solution. 
Stability and Storage Conditions: 
 
Very stable in dry conditions. Solutions are stable at pH 3.0 – 11.0. 
Stored in a well closed container, in a cool, dry place. 
Incompatibilities: 
 
Hypromellose is incompatible with some oxidizing agents. Since it is 
nonionic, hypromellose will not complex with metallic salts or ionic 
organics to form insoluble precipitates. 
 
Handling Precautions: 
 
Observe normal precautions appropriate to the circumstances and 
quantity of material handled. Hypromellose dust may be irritating to the 
eyes, so eye protection is recommended. Excessive dust generation 
should be avoided to minimize the risks of explosion. Hypromellose is 
combustible. 
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Regulatory Status: 
 
GRAS listed. Accepted for use as a food additive in Europe. 
Included in the FDA Inactive Ingredients Database (ophthalmic and nasal 
preparations; oral capsules, suspensions, syrups, and tablets; topical and 
vaginal preparations).  
 
 
POLYETHYLENE GLYCOL 6000  
 
Polyethylene glycol 6000 (PEG) is a polyether compound with 
many applications from industrial manufacturing to medicine. The 
structure of PEG is (note the repeated element in parentheses): 
 
HO-CH2-(CH2-O-CH2-)n-CH2-OH 
PEG is also known as polyethylene oxide (PEO) or 
polyoxyethylene (POE), depending on its molecular weight. 
Polyethylene glycol, referred to as PEG, is used as an inactive 
ingredient in the pharmaceutical industry as a solvent, plasticizer, 
surfactant, ointments and suppository base, and tablet and capsule 
lubricant. PEG has low toxicity with systemic absorption less than 0.5%. 
Structure 
Nonproprietary   
Names: 
                Carbowax, GoLYTELY 
                 GlycoLax, Fortrans 
                 TriLyte, Colyte 
Boiling Pt:  Min. 250°C (101hPa) 
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Melting Pt: 55 to 62 °C 
Density: 1.13 g/cm³ (20°C) 
 
Appearance White or almost white, waxy or paraffin-like 
 
Solubility: Soluble in water 
 
Synonyms 
           PEG; Macrogol; Polyoxyethlene; Aquaffin; Nycoline alpha-hydro-
omega-hydroxypoly(oxy- 1,2-ethanediyl); polyethylene  glycols;  Poly   
Ethylene   Oxide; Polyoxyethylene;  
Empirical Formula and Mol. Weight 
H(OCH2CH2)nOH [average 6000 g/mol ] 
 
Functional Category 
 
Lubricating agent , solubilizing agent, coating agent 
 
Applications in Pharmaceutical Formulation or Technology 
 
Chemical uses 
 Polyethylene glycol has a low toxicity and is used in a variety of 
products.[16] The polymer is used as a lubricating coating for various 
surfaces in aqueous and non-aqueous environments. 
 Since PEG is a flexible, water-soluble polymer, it can be used to create 
very high osmotic pressures (on the order of tens of atmospheres). It also 
is unlikely to have specific interactions with biological chemicals. These 
properties make PEG one of the most useful molecules for applying 
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osmotic pressure in biochemistry,and biomembranesexperiments, in 
particular when using the osmotic stress technique. 
 Polyethylene glycol is also commonly used as a polar stationary phase for 
gas chromatography, as well as a heat transfer fluid in electronic testers. 
 PEG is often used (as an internal calibration compound) in mass 
spectrometry experiments, with its characteristic fragmentation pattern 
allowing accurate and reproducible tuning. 
 PEG derivatives, such as narrow range ethoxylates, are used as 
surfactants. 
 
 PEG has been used as the hydrophilic block of amphiphilic block 
copolymers used to create some polymersomes. 
                             
 
SODIUM BICARBONATE 
 
Functional Category: 
 
USP: Alkalizing agent 
BP: Antacid; systemic alkalinizing substance 
Synonyms: 
 
Sodium hydrogen carbonate, sodium acid carbonate, baking soda 
Chemical Name and CAS Registry Number: 
 
Carbonic acid monosodium salt [144-55-8] 
 
 
Empirical Formula: NaHCO3 
 
 
Molecular weight: 84.01 
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Applications in Pharmaceutical Formulation: 
 
 Sodium bicarbonate is generally used in pharmaceutical formulations as a 
source of carbon dioxide in effervescent tablets and granules. It is also 
widely used to produce or maintain an alkaline pH in a preparation. 
 Tablets may also be prepared with sodium bicarbonate alone since the 
acid of gastric fluid is sufficient to cause effervescence and disintegration. 
Sodium bicarbonate is also used in tablet formulations to buffer drug 
molecules that are weak acids, thereby increasing the rate of tablet 
dissolution and reducing gastric irritation. 
 Additionally, sodium bicarbonate is used in solutions as a buffering agent 
for erythromycin, lidocaine, local anesthetic solutions, and total parenteral 
nutrition (TPN) solutions. In some parenteral formulations, e.g. niacin, 
sodium bicarbonate is used to produce a sodium salt of the active 
ingredient that has enhanced solubility Sodium bicarbonate has also 
been used as a freeze-drying stabilizer and in toothpastes. 
Table 5: Uses of sodium bicarbonate 
 
 
Use Concentration 
(%) 
Buffer in tablets 10-40 
Effervescent 
tablets 
25-50 
Isotonic 
injection/infusio
n 
1.39 
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Description: 
 
An odorless, white crystalline powder with a slightly alkaline taste. 
The crystal structure is monoclinic prisms. Grades with different particle 
sizes, from a fine powder to free-flowing uniform granules, are 
commercially available. 
 
Acidity/alkalinity: 
pH = 8.3 for a freshly prepared 0.1Maqueous solution at 258C; 
alkalinity increases on standing, agitation, or heating. 
 
Solubility: 
Water: 1 part in 11 parts (20oC), 1 part in 4 parts (100oC), Ethanol 
(95%; 20oC): insoluble; Ether (20oC): practically insoluble. 
 
Melting point: 
 
270oC with decomposition. 
Hygroscopicity: 
 
At relative humidities below 80%, the moisture content is less than 
1%. Above 85% relative humidity, it rapidly absorbs excessive amounts of 
water and may start to decompose. 
 
Stability and Storage Conditions: 
Upon heating at 250oC to 300oC, sodium bicarbonate decomposes 
and is converted into anhydrous sodium carbonate. Sodium bicarbonate 
is stable in dry air but slowly decomposes in moist air and should 
therefore be stored in a well-closed container in a cool, dry place. 
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Incompatibilities: 
 
Sodium bicarbonate reacts with acids, acidic salts and many 
alkaloidal salts, with the evolution of carbon dioxide. It can also intensify 
the darkening of salicylates. In powder mixtures, atmospheric moisture or 
water of crystallization from another ingredient is sufficient for sodium 
bicarbonate to react with compounds such as boric acid or alum. 
 
Handling Precautions: 
 
Observe normal precautions appropriate to the circumstances and 
quantity of material handled. Eye protection and gloves are 
recommended. 
Regulatory Status: 
 
GRAS listed. Accepted for use as a food additive in Europe. 
Included in the FDA Inactive Ingredients Database (injections; ophthalmic 
preparations; oral capsules, solutions, and tablets).  
     
 
CITRIC ACID 
 
Structural Formula: 
Synonyms: 
 
2-hydroxypropane-1, 2, 3-tricarboxylic acid monohydrate 
 
Empirical Formula: 
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C6H8O7•H2O 
 
Molecular weight:  
 
210.14 g/mol 
 
 
Functional Category: 
 
Acidifying agent, antioxidant, buffering agent, chelating agent, 
flavor enhancer. 
 
Description: 
 
Citric acid monohydrate occurs as colorless or translucent crystals, 
or as a white crystalline, efflorescent powder. It is odorless and has a 
strong acidic taste. 
Solubility: 
 
Soluble 1 in 1.5 parts of ethanol (95%) and 1 in less than 1 part of 
water; Sparingly soluble in ether. 
pH : 
 
2.2 (1% w/v aqueous solution 
 
 
Melting point: 
 
≈100°C (softens at 75°C) 
 
Density: 
 
1.542 g/cm3 
 
Incompatibilities: 
 
Citric acid is incompatible with potassium tartrate, alkali and 
alkaline earth carbonates and bicarbonates, acetates, and sulfides. 
Incompatibilities also includeoxidizing agents, bases, reducing agents, 
and nitrates. 
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Applications: 
 
 Citric acid monohydrate is used in the preparation of effervescent 
granules, while anhydrous citric acid is widely used in the 
preparation of effervescent tablets. 
 Citric acid has also been shown to improve the stability of spray-
dried insulin powder in inhalation formulations. 
 In food products, citric acid is used as a flavor enhancer for its tart, 
acidic taste. 
 
 Citric acid monohydrate is used as a sequestering agent and 
antioxidant    synergist. 
 
(Hand book of Pharmaceutical Excipients by Raymond C. Rowe 
et.al., 2009) 
 
 
 
 
MAGNESIUM STEARATE 
 
Structure: 
 
Structural Formula: 
 
[CH3 (CH2)16COO] 2Mgs 
 
Synonyms:  
Dibasic magnesium stearate; Magnesium distearate; 
Magnesiistearas; Magnesium octadecanoate; Octadecanoic acid, 
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magnesium salt; Stearic acid; Magnesium salt; Synpro90. 
Empirical formula: 
 
C36H70MgO4 
 
Molecular weight: 
 
591.24 g/mol 
 
Description: 
 
Magnesium stearate is a very fine, light white, precipitated or 
milled, impalpable Powder of low bulk density, having a faint odor of 
stearic acid and a characteristic taste. The powder is greasy to the touch 
and readily adheres to the skin. 
Functional categories: 
 
Tablet and capsule lubricant. 
 
 
Solubility: 
 
Practically insoluble in ethanol, ethanol (95%), ether and water; 
slightly soluble in warm benzene and warm ethanol (95%). 
Melting point: 
 
117–150˚C 
 
Density: 
 
1.092 g/cm3 
 
Loss on drying: 
 
46.0% 
 
Stability and storage conditions: 
 
Magnesium stearate is stable and should be stored in a well-closed 
container in a cool, dry place. 
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Incompatibilities: 
 
Incompatible with strong acids, alkalis, and iron salts. Avoid mixing 
with strong oxidizing materials. 
Applications: 
 
It is primarily used as a lubricant in capsule and tablet 
manufacture. 
 
 
 
 
TALC 
 
Structure: 
 
Structural Formula: 
 
Mg6 (Si2O5)4(OH) 4 
 
Non proprietary names : 
 
 
BP : Purified talc 
JP and USP : Talc 
 
Synonyms: 
 
MagsilOsmanthus; Magsil Star; Powdered talc; Purified French 
chalk; Purtalc. 
 
Empirical formula: 
 
Mg6 (Si2O5)4(OH)4 
 
Handling Precautions: 
 
            Talc is irritant if inhaled and prolongedexcessive exposure 
may cause Pneumoconiosis. Eye protection, gloves and respirator is 
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recommended. 
Description: 
 
Talc is a very fine; white to grayish-white, odorless, impalpable, 
unctuous, Crystalline powder. It adheres readily to the skin and is soft to 
the touch and free from grittiness. 
Functional categories: 
 
Anticaking agent; glidant; tablet and capsule diluent; tablet and 
capsule lubricant. 
 
Solubility: 
 
Practically insoluble in dilute acids and alkalis, organic solvents, 
and water. 
 
 
Melting point:    150˚ C 
 
Stability and storage conditions: 
 
Talc is a stable material and may be sterilized by heating at 160°C 
for not less than 1 hour. It may also be sterilized by exposure to ethylene 
oxide or gamma irradiation. Talc should be stored in a well-closed 
container in a cool, dry place. 
Incompatibilities: 
 
Incompatible with quaternary ammonium compounds. 
 
Uses of talc 
 
                  Use Concentration (%) 
Dusting powder 90.0–99.0 
Glidant and tablet 
lubricant 
1.0-10.0 
Tablet and 
capsule diluent 
5.0-30.0 
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Applications: 
 
1. It is used as a diluent, lubricant in tablet formulations. 
 
2. In a novel powder coating for extended-release pellets and as an 
adsorbent. 
 
3. In topical preparations, it is used as a dusting powder, used to clarify 
liquids. 
 
4. It is also used in cosmetics and food products. 
 
 
(Hand book of Pharmaceutical Excipients. Pharmaceutical Press, 
London.5th edition) 
 
 
 
MICROCRYSTALLINE CELLULOSE 
Structural Formula: 
 
 
 
           
Synonyms: 
 
Avicel PH; Cellets; Celex; cellulose gel; hellulosum 
microcristallinum; Celphere; Ceolus KG; crystalline cellulose; E460; 
Emcocel Ethispheres; Fibrocel; MCC Sanaq; Pharmacel; Tabulose; 
Vivapur. 
Empirical Formula: 
 
(C6H10O5)n 
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Molecular weight: 
 
36000g/mol 
 
Functional Category: 
 
Adsorbent; suspending agent; tablet and capsule diluent; tablet 
disintegrates. 
 
Description: 
 
Microcrystalline cellulose is a purified, partially depolymerized 
cellulose that occurs as a white, odorless, tasteless, crystalline powder 
composed of porous particles. 
Solubility: 
 
Slightly soluble in 5% w/v sodium hydroxide solution; practically 
insoluble in water, dilute acids, and most organic solvents. 
pH: 
 
pH 5.0-7.5 
 
Melting point: 
 
Chars at 260–2708C. 
 
Density: 
 
 g/cm3 
 
Incompatibilities: 
 
Microcrystalline cellulose is incompatible with strong oxidizing 
agents. 
 
Stability & Storage condition: 
 
Microcrystalline cellulose is a stable though hygroscopic material. 
The bulk material should be stored in a well-closed container in a cool, dry 
place. 
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Applications: 
 
1. Microcrystalline cellulose is widely used in pharmaceuticals, 
primarily as a binder/diluent in oral tablet and capsule formulations where 
it is used in both wet-granulation and direct-compression Processes. 
2. In addition to its use as a binder/diluent, microcrystalline 
cellulose also has some lubricant and disintegrates properties that make it 
useful in tableting. 
3. Microcrystalline cellulose is also used in cosmetics and food products; 
 
Handling precaution: 
 
Microcrystalline cellulose may be irritant to the eyes. Gloves, eye 
protection, and a dust mask are recommended. 
(Hand book of Pharmaceutical Excipients by Raymond C. Rowe et.al. 
2009) 
 
METHYL CELLULOSE 
 
(Raymond C. Rowe et al., 2006) 
 
 
Synonym: 
 
Benecel 
 
Metolose    
Structure: 
      
 
Empirical formula: 
 
Long-chain substituted cellulose containing approximately 27 – 32 % 
of the hydroxyl group in the form of methyl ether. 
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Molecular weight: 
 
10 000 – 220 000 Dalton. 
 
 
Description: 
 
Color: White, fibr ous powder or granules. 
 
Odour: Practically odorless and 
 
Taste: Tasteless. 
 
 
Melting Point: 
 
190–200°C. 
 
 
Solubility: 
 
Practically insoluble in acetone, methanol, chloroform, ethanol (95 
%), ether, saturated salt solutions, toluene and hot water. 
 
In cold water, it sw ells and disperses slowly to form a clear to 
opalescent, viscous, colloidal dispersion. 
 
Functional Category: 
 
 Bulk laxative (5.0 – 30.0 %). 
 
 Emulsifying agent (1.0– 5.0 %), 
 
 Tablet binder (1.0 – 5.0 %). 
 
 Tablet Coating (0.5 -5.0 %). 
 
 Tablet and capsule disintegrate (2.0 – 10.0 %). 
 
Storage Conditions: 
 
It should be stored in an airtight container in a cool, dry place. 
 
Handling Precautions: 
 
 Irritant to the eyes & eye protection should be worn. 
 
 Methylcellulose is combustible. 
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 Spills of the dry powder or solution should be cleaned up immediately, as 
the slippery film that forms can be dangerous. 
 
Regulatory status: 
 
Included in the FDA inactive ingredients. Recognized by GRA S 
status.    
 
ETHYL CELLULOSE 
 
(Raymond C. Rowe et al., 2006) 
 
 
 
Synonyms: 
 
Aquacoat ECD 
 
Aqualon 
 
Ethocel 
 
Structure:           
 
Empirical formula: 
 
C12H23O6(C12H22O5)nC12H23O5 
 
 
Molecular weight: 
 
40 0000 
 
Description: 
 
Color: White to light tan colored powder. 
 
Odour: Odorless. 
 
Taste: Tasteless. 
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Melting point: 
 
1650 - 1850 C 
 
Solubility: 
 
Practically insoluble in propylene glycol, glycerine and water 
 
Freely soluble in chloroform, ethanol, ethyl acetate, methanol and toluene. 
 
 
Functional Category: 
 
 Coating agent. 
 
 Flavouring fixativ e. 
 
 Tablet binder. 
 
 Tablet filler. 
 
 Viscosity-increasi ng agent. 
 
Storage Conditions: 
 
It should be stored at a temperature not exceeding 3280 C (9 00F) in a dry 
area away from all sources of heat. 
 
 
Handling Precautions: 
 
 To prevent fine dust clouds of ethyl cellulose from reaching p otentially 
explosive levels in the air. 
 
 Its combustible 
 
 It may be an irritant to the eyes and eye protection should be w orn. 
 
Regulatory status: 
 
Included in the FDA inactive ingredients. Recognized by GRA S status.   
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PVP K-30 
(Raymond C. Rowe et al., 2006) 
 
 
 
Synonyms :   
 
Kollidone 
Plasdone; 
           Poly[1-(2-oxo-1-pyrrolidinyl)ethylene]; 
 
 
Structural formula :  
 
Nonproprietary Names: 
BP:  Povidone 
JP:  Povidone 
Chemical Name and CAS Registry Number: 
1-Ethenyl-2-pyrrolidinone homopolymer [9003-39-8] 
 
Molecular weight : 
 
  50, 000 
 
Description: 
 
 Colour:  Fine, white to creamy white hygroscopic powder 
             
Odour: Odourless 
 
 
Melting point: 
  
 150o C 
 
Solubility : 
 
Freely soluble in acids, chloroform, ethanol 
          Practically insoluble in ether. 
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Functional category : 
 
 Disintegrant;  
 dissolution enhancer;  
 suspending agent; 
 tablet binder 
 
Storage Precautions: 
 
 Povidone darkens to some extent on heating at 1508C, with a reduction in 
aqueous solubility. It is stable to a short cycle of heat exposure around 110–
1308C. 
 
Incompatibilities: 
 
It forms molecular adducts in solution with sulfathiazole, sodium salicylate, 
salicylic acid, phenobarbital, tannin, and other compounds. 
 
Handling precautions: 
Observe normal precautions appropriate to the circumstances andquantity 
of material handled. Eye protection, gloves, and a dust mask are 
recommended. 
 
Regulatory status: 
 
Accepted for use in Europe as a food additive. Included in the FDA 
Inactive Ingredients Database (IM and IV injections; ophthalmic 
preparations; oral capsules, drops, granules, suspensions tablets; 
sublingual tablets; topical and vaginal preparations). 
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Applications: 
 
 In tableting, povidone solutions are used as binders in wet-granulation 
processes. 
 Povidone is also added to powder blends in the dry form and granulated 
in situ by the addition of water, alcohol, or hydroalcoholic solutions. 
  Povidone is used as a solubilizer in oral and parenteral formulations, and 
has been shown to enhance dissolution of poorly soluble drugs from solid-
dosage forms. 
 
 
 
 
 
 
 
 
 
 
Uses Concentration(%) 
Carrier for drugs 
Dispersing 
agent 
Tablet binder, 
diluents, coating 
agent 
10-25 
 
Upto 5 
 
0.5 - 15 
CHAPTER 10 
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EXPERIMENTAL PROTOCOL 
 
1. STANDARD CURVE FOR FEBUXOSTAT : 
 
a) Preparation of dissolution medium 
 
Acid buffer PH 1.2 (Indian pharmacopoeia 1996, volume: 2, page no: A-144) 
 
Place 50ml of 0.2M potassium chloride in a 200ml volumetric flask, add the 
Specified volume of 0.2M hydrochloric acid and then add water to volume. 
Preparation of 0.2M potassium chloride 
 
Dissolve 14.911gm of potassium chloride in water and dilute with water to 1000ml. 
 
Preparation of 0.2M Hydrochloric acid 
 
Hydrochloric acid diluted with water to contain 17ml of HCl in 1000ml. 
 
 
b) Estimation of absorption maximum (λ max) for Febuxostat by UV Spectroscopy 
 
The standard stock solution of  Febuxostat having concentration 1000μg/ml is 
prepared by dissolving 100mg of Febuxostat is dissolved in little amount of methanol 
and diluted with Acid buffer pH 1.2 up to 100ml. The stock solution is further diluted 
using acid buffer pH 1.2 to produce 10μg/ml concentration. The resultant solution is 
scanned between wavelengths of 200-400 nm by UV Spectrophotometer. (UV-1700 
Shimadzu Corporation, Japan) to get absorption maximum (λ max). 
c) Preparation of standard calibration curve for Febuxostat 
 
From the above stock solution , aliquots are taken into different volumetric 
flasks and volume are made up to 100 ml with Acid buffer pH 1.2 solution, so as to 
get concentration of  2 to 20 μg/ml. The absorbance of these solutions are 
measured at 317 nm by UV Spectrophotometer. A calibration curve is plotted by 
taking concentration on X-axis and absorbance on Y-axis to obtain the standard 
curve. (US Pharmacopeia). 
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2. DRUG-POLYMER COMPATIBILITY STUDIES 
 
The compatibility studies are carried out by Infrared spectroscopy and 
Differential scanning calorimetry in order to evaluate the drug polymer interaction. 
a) Fourier Transform Infrared Spectroscopic studies (FTIR) 
 
Drug- polymer/excipients interactions play a vital role in the release of drug 
from formulation. Fourier transform infrared spectroscopy (FTIR) has been used to 
study the physical and chemical interactions between drug and the excipients used. 
The study is carried out by KBR pellet technique. Materials are compressed under 
10 tones pressure in a  hydraulic press to form a homogeneous sample/KBr pellet. 
The pellet is scanned over the frequency range from 4000 to 450 cm-1 and peaks 
obtained are identified. (Narayana Raju .P, et al., 2009; Solanki. D, et al., 2013) 
 
b) Differential scanning calorimetric studies (DSC) 
 
The DSC measurements are performed using a Perkin Elmer Pyris (Shelton, 
CT) equipped with an intracooler 2P cooling accessory. Samples of 4 mg are placed 
in standard aluminum pans and sealed with a lid. Heating scans by 10˚C/min is 
applied with a nitrogen purge of 20 ml/min, over a temperature range of 35ºC to 
380ºC. An empty aluminum pan is used as reference. (Solanki. D, et al., 2013) 
3. FORMULATION OF FEBUXOSTAT FLOATING  
TABLETS: 
  Preparation of solid dispersion by fusion method: 
 
Solid dispersions of Febuxostat with PEG-6000 in different weight ratios were 
prepared by fusion method in three different ratios 1:1, 1:2, 1:3. PEG-6000 was 
melted at 60oC and Febuxostat was added to the melted carrier and stirred 
continuously to form a homogenous mixture. The resulting homogenous 
CHAPTER  10  EXPERIMENTAL PROTOCOL 
 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY,MMC,MADURAI. Page 94  
preparation was rapidly cooled in a freezing mixture of ice and sodium chloride, 
and stored in desiccators for 24 h. Subsequently, the dispersion was ground in a 
mortar and sieved through 100 # and stored in a dessicator. 
 
 
 Preparation of Hydrodynamically Balanced System of Febuxostat: 
 
EFFERVESCENT  AND NON-EFFERVESCENT TECHNIQUES 
 
Preparation: In this work, direct compression method has been employed to 
prepare HBS of Febuxostat with Hydroxy propyl methyl cellulose (HPMC) of two 
different grades (HPMC K4M and HPMC K100M) and Methyl cellulose for 
Effervescent formulations and  along with 10% Ethyl cellulose in case of Non-
effervescent formulations. 
 
Procedure: All the ingredients were accurately weighed and passed through 
mesh # 60. In order to mix the ingredients thoroughly drug and polymer were 
blended geometrically in a mortar and pestle for 15 minutes then sodium 
bicarbonate, citric acid, mcc, talc and magnesium stearate were mixed one by 
one. After thoroughly mixing these ingredients, the powder blend was passed 
through # 44 mesh. 
Tablets were compressed on a tablet machine (FLUID PACK) using 10mm 
concave punches. 
4. EVALUATION OF FEBUXOSTAT FLOATING MATRIX TABLETS 
 
a) Pre compressional evaluation of powder blend: (Dongre et al., 2015: 
AvaruGeetha Dutt et al., 2014) 
i) Angle of repose 
 
The flow characteristics are evaluated by determining angle of repose. 
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Improper Flow of powder is due to frictional forces between the particles. These 
frictional forces are quantified by angle of repose. Angle of repose is defined as the 
maximum angle possible between the surface of a pile of the powder and the 
horizontal plane. Angle of repose is calculated using the equation. 
tan θ = h/r,  θ= tan-1h/r 
Where h = height of pile 
 
r = radius of the base of the pile θ 
= angle of repose. 
Angle of repose Type of flow 
<20˚ Excellent 
20˚-30˚ Good 
30˚-35˚ Moderate 
35˚-40˚ Poor 
>40˚ Very poor 
 
ii) Bulk Density 
 
Apparent bulk density is determined by pouring pre sieved drug excipients 
blend into a graduated cylinder and measuring the volume and weight “as it is”. It 
is expressed in g/mL and is given by,  Db = M / Vo 
Where, Db is the bulk density, M is the mass of powder and  Vo is the Bulk 
volume of the powder. 
iii) Tapped density 
 
It is determined by placing a graduated cylinder, containing a known mass 
of drug excipients blend, on mechanical tapping apparatus. The tapped volume is 
measured by tapping the powder to constant volume. It is expressed in g/mL. 
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Dt = M / Vt  Where, Dt is the tapped density, M is the mass of powder and 
Vt is the tapped volume of the powder. 
iv) Compressibility index (or) Carr’s Index (I) 
 
Compressibility index is an important measure that can be obtained from 
the bulk and tapped densities. A material having values less than 20 to 30% is 
defined as the free flowing material, based on the apparent bulk density and 
tapped density. 
The percentage compressibility of the bulk drug is determined by using the 
following formula   I = Dt – Db / Dt × 100 
 
Where, I is the Compressibility index, Dt is the tapped density of the powder 
and Db. is he bulk density of the powder. 
  
Compressibility 
index (%) 
Type of 
flow 
10 Excellent 
11-15 Good 
15-20 Fair 
21-25 Passable 
26-31 Poor 
32-37 very poor 
v) Hausner’s ratio 
 
It indicates the flow properties of the powder. The ratio of Tapped density to 
bulk density of the powder or granules is called Hausner’s ratio. 
 
H = Dt / Db 
CHAPTER  10  EXPERIMENTAL PROTOCOL 
 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY,MMC,MADURAI. Page 97  
 
Where, H is the Hausner’s ratio, Dt is the tapped density of the powder and 
Db is the bulk density of the powder. 
Hausner’s ratio Type of flow
1-1.11 Excellent 
1.12-1.18 Good 
1.19-1.25 Fair 
1.26-1.34 Passable 
1.35-1.45 Poor 
1.46-1.54 very poor 
>1.60 very very poor 
  
vi) Drug content 
 
Weight of the powder material equivalent to 40 mg of Febuxostat is taken 
and transferred into 100 ml volumetric flask. Then 30 ml of Acid buffer PH 1.2 is 
added slowly, mixed properly and the volume is made up to 100 ml with Acid buffer 
PH 1.2. The above solution is filtered and 10 ml of filtrate is taken into 100 ml 
volumetric flask and made up to final volume with Acid buffer PH 1.2 and the drug 
content is estimated by measuring the absorbance at λ max 317 nm using a UV- 
spectrophotometer. 
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s 
b) Post compressional evaluation of floating matrix 
tablets: (Dongre et al., 2015; Jaimini M, et al., 2007) 
i) General appearance 
 
The formulated tablets are evaluated for general appearance. Viz., color, 
odour, 
 
 shape. 
 
ii) Tablet Dimension 
 
The thickness and diameter of the tablets are carried out using digital vernier 
caliper. 
 
Three tablets are used from each batch and results are expressed in 
millimeter (mm). 
 
 
iii) Weight variation test 
 
Twenty tablets are selected at random, individually weighed in a 
single pan electronic balance and the average weight is calculated. The 
uniformity of weight is determined according to I.P. specification. As per IP 
not more than two of individual weights should deviate from average weight 
by more than 5% and none deviate more than twice that Percentage.  
The following percentage deviation in weight variation is shown in the 
table. (IP.2007). 
Average weight of a tablet Percentage deviation
Less than 80mg ± 10% 
More than 80mg to less 
than 250mg 
± 7.5% 
250mg or more ± 5% 
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iv) Hardness test 
 
Tablet requires a certain amount of strength or hardness and resistance 
to friability to withstand mechanical shocks of handling in manufacture, packing 
and shipping. Monsanto hardness tester is used to measure the hardness of 
tablet. Three tablets from each batch are used for hardness test and results are 
expressed in Kg/cm2. 
v) Friability test 
 
It is done in Roche friabilator apparatus where the tablets are subjected to 
the combined effect of abrasion and shock by utilizing a plastic chamber that 
revolves at 25 rpm for dropping the tablets at a distance of six inches with each 
revolution. Pre weighed samples of 20 tablets are placed in the friabilator, which 
is then operated for 100 revolutions. The tablets are then dusted and reweighed. 
Compressed tablets that loss less than 0.5 to 1.0% of their weight are generally 
considered acceptable. The percentage friability is calculated by  the following  
  
vi) Drug content uniformity 
 
Ten tablets are weighed and taken in a mortar and crushed to make powder 
form. A quantity of powder weighing equivalent to 40mg of drug is taken in a 
100ml volumetric flask and Acid buffer PH 1.2 is added. The solution is filtered 
using membrane filter (0.45μm) and 10 ml of filtrate is taken into 100 ml 
volumetric flask and made up to final volume with Acid buffer PH 1.2. Then its 
absorbance is measured at 317nm using UV Visible spectrometer. The amount 
of drug present in one tablet is calculated using standard graph. 
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%Purity = Absorbance of unknown(Au)/Absorbance of 
standard (As)*10C, 
 
 
Where, C is Concentration. 
 
 
vii) In vitro floating lag time (Deepika B. et al., 2013) 
 
The in vitro buoyancy was determined by floating lag time (FLT). The 
tablets were placed in a 250 ml beaker containing 0.1N HCl. The media 
was kept in stagnant condition and the temperature was maintained at 370 
C. The time required for the tablet to rise to the surface and float was 
determined as floating lag time. 
viii) In vitro floating duration time 
 
The floating capacity of the tablets was determined using USP 
Dissolution apparatus II containing 900ml of simulated gastric fluid. The time 
interval between introduction of the tablet in to the dissolution medium and 
its buoyancy to the dissolution medium was taken as buoyancy lag time/ 
Total floating time(TFT) and for which time the tablet constantly floats on the 
surface of the medium was observed visually and taken as floating duration. 
 
ix)Determination of Swelling Index:  
  Swelling of tablet excipients particles involves the absorption of a 
liquid resulting in an increase in weight and volume. Liquid uptake by the 
particle may be due to saturation of capillary spaces within the particles or 
hydration of macromolecule. The liquid enters the particles through pores 
and bind to large molecule, breaking the hydrogen bond and resulting in the 
swelling of particle. The extent of swelling can be measured in terms of % 
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weight gain by the tablet. 
Method: 
 
For each formulation batch, one tablet was weighed and placed 
in a beaker containing 200 ml of buffer media. After each interval the 
tablet was removed from beaker and weighed again up to 12 hours. 
The swelling index was calculated using following formula. 
Swelling Index (S.I.) = (Wt-Wo)/Wo 
 
Where, S.I. = Swelling index 
 
Wt = Weight of tablet at time t 
 
Wo = Weight of tablet before placing in the beaker 
 
 
ix) In vitro drug release studies: (Karthik raja .M et al., 2012) 
 
`Dissolution characteristics of the formulated floating tablets of 
Febuxostat are carried out using USP Type II (paddle) dissolution test 
apparatus for 12hrs. 
Method: 
 
900 ml of acid buffer pH 1.2 was filled in dissolution vessel and 
temperature of the medium is set at 37°C ± 0.5°C. One tablet of different 
batch is placed in each dissolution vessel and the rotational speed of paddle 
was set at 75rpm. 5ml of sample is withdrawn at pre-determined time 
interval of every one hour for up to 12 hours and same volume of fresh 
medium is replaced immediately. The withdrawn sample is diluted to 10ml in 
volumetric flask and filtered through 0.45μ membrane filter. The resultant 
samples are analyzed for drug content at 317nm using UV-Visible 
spectrophotometer. 
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Parameter Specifications 
Dissolution 
Medium 
Buffer 0.1N hydrochloric Acid 
Temperature 37.0 ± 0.5 °C 
Initial Volume 900ml 
Rotation Speed 75rpm 
Drawn Volume 5ml 
Running Time 12 hrs. in 0.1N hydrochloric 
Acid 
 
 
 
X) IN-VITRO DRUG RELEASE KINETICS (Reddy et. al., 2012) 
 
To analyze the In-vitro release data various kinetic models were used to 
describe the release kinetics. The zero order rate describes the systems 
where the drug release rate is independent of its concentration. The first 
order describes the release from the system where release rate is 
concentration dependent. Higuchi described the release of drugs from 
insoluble matrix as a square root of time dependent process based on the 
Fickian diffusion. The Hixson-Crowell root law describes the release from the 
systems where there is a change in surface area and diameter of particles. 
The Koresmeyer-peppas describes the mode of release of drug from swell 
able matrices. 
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Release Kinetics Model Equation 
Zero Order Qt = Q0 + K0.t 
First Order In Qt = In Q0 + K0.t 
Hixson-Crowell Q 01/3 – Qt 1/3 + K.t 
Higuchi Q = KH. t1/2 
Korsmeyer – Peppas Mt / M0 = a.tn 
 
Fitness of release profiles to linear equations is assessed by 
comparing the coefficients of determination (r) values. (Harris Shoaib 
et al., 2006: Praveen Kumar Mandapali et al., 2012). 
Diffusion exponent values indicating drug release mechanism 
 
S. 
No. 
Diffusion exponent 
value (n) 
Drug release 
mechanism 
1 < 0.5 Fickian release 
2 0.5 to 1.00 Non-Fickian 
transport 
3 1.00 Case II transport 
4 > 1.00 Super case II 
transport 
 
The in-vitro release data are fitted to the above mathematical models 
and the applying data are, 
 Cumulative % drug release vs. time for zero order kinetic. 
 
 Log cumulative of % drug remaining vs. time for first order kinetic. 
 
 Cumulative % drug release vs. Square root of time for Higuchi model. 
 
 Log cumulative % drug release vs. log time for Korsmeyer-Peppas model and 
 
 Cube root of drug % remaining in matrix vs. time for Hixson-Crowell cube root 
time. 
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xi) Selection of best formulation: 
 
The best formulation is selected in accordance with the results 
obtained from floating behavior, swelling index, invitro drug release 
studies and kinetic analysis. 
xii) Evaluation of selected best formulation: 
 
a) Infrared spectroscopic studies: 
 
The interaction between the drug and excipient / polymer are 
studied by FT-IR as per the procedure as mentioned in 2(a). 
(b) Differential scanning calorimetric studies (DSC): 
 
Differential scanning calorimetry is carried out to find out any 
incompatibility between the drug and excipients used. 
c)  Powder X-Ray Diffraction Method: 
Powder X-Ray diffraction method is carried out to find out the 
crystalline nature of drug through out the formulation. 
Comparison with marketed  Formulation: 
 
The release of the best formulation is compared with the 
marketed formulation (Pare A et al., 2008: Mahajan P et al., 2011). 
In vivo x – ray studies: 
 
The in vivo studies approved by Institutional Animal Ethical 
Committee and are performed on healthy albino rabbit weighing 2-2.5 kg. 
The animal is fasted overnight but allowed to take water ad libitum (Londhe 
S et al., 2010). Then 30 ml of 5 % dextrose solution is given immediately 
before administering the tablets by using stomach tube (No. 12 French 
Catheter) and 20 ml syringes. 
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The tablets are made opaque by incorporating barium sulphate (BaSO4) 
instead of drug. The rabbit is exposed to X-ray imaging in the abdominal 
region, and photographs are taken at 0, 2, 4, 6, 8, 10 & 12 hrs. After 
administration of tablet. At hourly intervals 30 ml of 5% dextrose solution is 
given to maintain optimum fluid level in the stomach (Dinesh Kumar et al., 
2010). The gastric residence time is observed. 
 
STABILITY STUDIES 
 
Stability studies were carried out by using selected formulation i.e F4. The 
formulation is kept in accelerated stability condition at 400C temperature 75 ± 
5% relative humidity for a period of 2 months as per International Conference 
on Hormonization guidelines (Mathews, 1999; International Conference on 
Harmonization Steering Committee,1999).The samples were withdrawn at 
every 15 days intervals and evaluation was carried out for appearance, 
thickness, hardness, buoyancy lag time, drug content and In-vitro release 
studies (60 days). 
 
CHAPTER 11 
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RESULTS AND DISCUSSION 
 
 
1.STANDARD CALIBRATION CURVE FOR FEBUXOSTAT: 
 
a) Preparation of dissolution medium2 
 
  The  dissolution medium was prepared by using Acid buffer PH 1.2. 
 
(Indian pharmacopoeia 1996, volume: 2, page no: A-144) 
 
 
Estimation of absorption maximum (λ max) for  by Ultraviolet     
Spectroscopy(UV) 
The absorption maximum (λ max) of Febuxostat was estimated by scanning the 
drug solution (10μg/ml) between 200-400nm regions on UV spectrophotometer. 
The obtained spectrum showed that the absorption maximum (λ max) was 317 
with Acid buffer PH 1.2.  
The result was shown in Fig.1. 
b)Preparation of standard calibration curve for Febuxostat 
 
The standard calibration curve for Febuxostat was prepared by using acid    buffer 
PH  1.2. The absorbance was measured at λ max of 317nm.The correlation 
coefficient was found to be 0.99976 , which indicate linearity. Febuxostat obeys 
beer’s law within the concentration range of 2 - 20μg/ml. Calibration plot of 
Febuxostat in acid buffer was shown in Table.1 & Fig.2. 
 
2.DRUG-POLYMER COMPATIBILITY STUDIES 
 
a)Fourier Transform Infrared Spectroscopic studies (FT-IR) 
 
Infrared spectroscopic analysis was performed to check out the compatibility 
between the drug (Febuxostat) and the hydrophilic polymers (HPMC K4M, HPMC 
K100M,) and Methyl cellulose, hydrophobic polymer (Ethyl cellulose) used in the 
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formulation of floating matrix tablets. IR spectrum of the pure drug and the 
physical mixtures of drug with polymers of optimized formulation were studied. 
The results were shown in the Fig 3A-D. Mixtures of drug and polymers showed 
that there was no shifting of functional peaks. 
 
 THE FT-IR SPECTRA OF PURE DRUG FEBUXOSTAT 
 
S.NO
. 
Functional 
group 
Peak in cm-
1 
Peak 
observed 
(cm-1) 
 
1 
 
-NH2 streching
 
 
 3539.41-
3462.95 
 
3462.22 
 
2 
 
C=O 
Stretching 
( Carboxylic 
acid) 
 
 
 
1670 
 
1678.07 
3 
 
OH-C 
Stretching 
 
1375.61 
 
1382.96 
4 
C-C 
Stretching 
 
( Aromatic 
ring) 
 
1455-1592 
 
1467.83 
5 
 
C-H 
stretching 
(alkanes) 
  2957.68  2939.52 
6 
 
N-C 
Stretching 
 
1603.25 
 
1604.77 
 
All the major peaks present in the spectrum of pure drug were clearly observed in 
the spectrum of physical mixtures with negligible changes. The obtained results 
clearly showed that there was no interaction between the drug and polymers. 
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b)Differential Scanning Calorimetric (DSC) Studies 
The DSC studies were carried out to detecting the drug- polymer incompatibility. 
Febuxostat exhibits a sharp endothermic peak at 1920 C. An endothermic peak 
corresponding to the melting point of pure drug was prominent in all the drug 
polymer mixture, which suggested clearly that there was no interaction between the 
drug and polymer and the drug was existed in its unchanged form.  The results 
were shown in  Figure4 A-B. 
3.FORMULATION OF SUSTAINED  RELEASE FLOATING MATRIX    TABLET 
FORMULATUION OF SOLID DISPERSION: The solubility of    FEBUXOSTAT 
is enhanced by preparing solid dispersion using PEG6000 in the ( 1:1,1:2, 1:3) 
ratios by melting method and comparing the results with pure drug and marketed 
formulation. Table 2-5, Figure 6A-C. 
EFFERVESCENT TECHNIQUE  
The Febuxostat floating tablets were prepared by effervescent technique used the 
hydrophilic polymers (HPMC K4M, HPMC K100M,) and Methyl cellulose. Sodium bi 
carbonate & citric acid used as gas generating agent. The polymers were chosen  
as they are well established in the similar studies and have great swelling and 
sustained release properties respectively. From the trial studies, the formula was 
optimized depending on the floating behavior of the tablets and  the  optimized  
formula  was  shown  in  the  Table 6A. 
 
NON –EFFERVESCENT TECHNIQUE 
The tablet excipients and polymers were chosen after comprehensive drug-
polymers interaction studies. The floating tablets of  Febuxostat were prepared by 
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direct compression method. Accurately weighed quantities of drug, Hydrophilic 
polymers ( HPMC K4M,  HPMC K100M) , Methyl cellulose, hydrophobic polymers ( 
ethyl cellulose ) and Microcrystalline cellulose were manually blended 
homogenously in a mortar; the powderblend was passed through sieve no.22, and 
adequately lubricated with talc and magnesium stearate. It was then compressed 
into10mm biconvex tablets by using a multi punch tablet machine. and  the  
optimized  formula  was  shown  in  the  Table 6B. 
 
4.EVALUATION OF FEBUXOSTAT FLOATING SUSTAINED RELEASE MATRIX 
TABLETS 
A) Pre compressional evaluation of powder blend: 
 (Lingaraj S.danki et al.,2010) 
Effervescent technique and Non-Effervescent technique 
The powder blend of all the formulations were evaluated for the pre compression 
parameters such as Angle of repose, Bulk density, Tapped density, 
Compressibility index, and Hausner’s ratio. The results were shown in Table 7A-
B. 
i) Angle of repose (θ) 
 
The angle of repose was used to determine the flow properties of 
powder blend. The angle of repose of the formulations ranged from 27˚.38’ 
to 31˚.78’.The results indicated that the formulations with the diluents 
exhibited good flow properties .The results of angle of repose for all the 
formulations were shown in Table 7A-B and FIG. 7A. 
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ii) Bulk density (gm/ml) 
 
The bulk density is used as an index of the ability of the powder to flow. 
The bulk density of the formulations was in the range of 0.76 – 0.82 g/cm3. 
The values of bulk density showed that the blend was not tightly packed 
and indicated good flow properties for coprocessed and organic diluents . 
The results of bulk density for all the formulations were shown in Table 7A-
B and FIG. 7B 
iii) Tapped density (gm/ml) 
 
The tapped density was used to access the free flowing properties of 
powder blend. The tapped density of the formulations were in the range of 
0.78-0.88 g/cm3. The results of tapped density for all the formulations were 
shown in Table 7A-B and FIG.7C.. 
iv) Compressibility index (%) 
 
The Carr’s compressibility index was used to access the free flowing 
properties of powder blend. The compressibility index of all the formulations 
ranged from 11.92 -18.57%. indicates that the powder has a good flow 
property  and good propensity of compression shown in Fig:7D. 
 v) Hausner’s ratio 
 
The Hausner’s ratio was an indirect index of ease of powder flow. 
The Hausner’s  ratio of all the formulations ranged from 1.12-1.20. This 
indicates better flow property of blend. The results of Hausner’s ratio for all 
the formulations were shown in Table 7 and FIG.7E. 
vi) Drug content (%) 
 
The percentage drug content of formulations (F1-F9) was found to be in 
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between 97.18 – 98.18%  and (G1 – G9) was found to be between 98.12 – 
99.23% ensured the uniformity of drug content. The results were shown in Table 
7 and  Fig.7F. 
B) Post compressional evaluation of floating matrix tablets: 
(Sucharitha. M et al., 2013) 
Effervescent and Non-Effervescent technique 
Tablets of different formulations were subjected to evaluation tests such as general 
appearance, tablet dimension, hardness, friability, weight variation, drug content. 
The results were shown in the Table9A & 9B. 
i) General appearance 
 
The formulated tablets were off-white in colour, biconvex and round shaped 
without any scoring on both sides. All the tablets were elegant in appearance.  
ii) Tablet dimension 
 
The thickness and diameter of all formulations were found to be in between 4.36 to 
4.49mm & 10.3mm respectively, indicates that the tablets having uniform particle 
size distribution and no deformity. The results were shown in the  Table9A & 9B. 
iii) Hardness 
 
The hardness of all formulations were found to be in between 4.76 to 
5.12kg/cm2 which indicates good mechanical strength with an ability to withstand 
physical and chemical stress conditions while handling. The results were shown in 
the Table9A & 9B. 
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iv)Friability 
 
The friability of all formulations were found to be in between 0.356 to 0.395 
%, (as per I.P Limit is less than 1%), which indicates good mechanical resistance 
of the tablet. The results were shown in the Table9A & 9B. 
v) Weight variation 
 
In all the formulations, the weight variation of floating tablets was ranges 
between 348.92-351.7mg. All the formulated tablets were passed the weight 
variation test as the % weight variation was within the pharmacopoeia limits of 
±7.5% of the average weight, which proved good uniformity. The results were 
shown in the Table9A & 9B. 
vi)Estimation of drug content 
 
The percentage drug content of formulations (F1-F9) was found to be in 
between 97.18 – 98.18%  and (G1 – G9) was found to be between 98.12 – 
99.23% ensured the uniformity of drug content. which is within acceptable limits, 
showed that the drug was uniformly distributed in all formulations. Hence the 
percentage of drug content of all formulations complies with official specifications 
as per I.P (Limits: not less than 85% and not more than 115%). The results were 
shown in Table9A & 9B.  And  Fig.7F. 
vii)IN VITRO BUOYANCY TEST (CHANDRA SEKHARA RAO. ET AL., 
2011) 
 
The prepared tablets were subjected to in vitro buoyancy test by placing 
them in 250 ml beaker containing 200 ml of 0.1 N HCl (pH 1.2, temp. 37±0.5ºC). 
The time between introduction of the dosage form and its buoyancy in the 
medium and the floating durations of tablets was noted for the determination of 
lag time and total buoyancy time by visual observation. The Time taken for 
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dosage form to emerge on surface of medium is called Floating Lag Time (FLT) 
or Buoyancy Lag Time (BLT) and total duration of time the dosage form 
remained buoyant is called Total Floating Time (TFT). The result were shown in 
the Table 11A-11B  and Figure 8A. 
EFFERVESCENT 
 
The floating lag time may be explained as a result of the time required for 
dissolution medium to penetrate the  tablet matrix and develop the swollen 
layer.(Garg Shiv Kumar et al.,2011). 
The formulations containing HPMCK4M, F1-F3 (10 %( 49sec), 20%(52sec), 
30%(48sec), HPMC K100M, F4-F6 (10%(23sec),20%(35sec) and 30%(39sec), 
Methyl cellulose, F7-F9(10% (95),20%(106sec), 30%(89sec)) floats in Medium 
of acid buffer. TABLE 11A. 
 
NON-EFFERVESCENT  
The tablet floating lag time (FLT) was found to be less than 203sec and total 
floating time up to 12hr. The floating lag time may be explained as a result of the 
imbibitions of gastric fluid to an extent that it prevents their exit from the stomach. 
The formulations containing HPMCK4M, G1-G3 (20 %( 302sec), 30%(296sec), 
40%(305sec), HPMC K100M, G4-G6 (20%(198sec),30%(155sec) and 
40%(203sec), Methyl cellulose, G7-G9(20% (504),30%(512sec), 
40%(621sec)) floats in Medium of acid buffer. All the formulations contained 10% 
of Ethyl cellulose as buoyancy increasing agents. TABLE 11B. 
Effervescent formulation: (Narang et al., 2011) 
 
The combination of sodium bi carbonate and citric acid provided desired 
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floating ability and therefore this combination was selected for the formulation of 
the gastro retentive tablets. The gas generated is trapped and protected within 
the gel formed by hydration of the polymer (HPMC), thus decreasing the 
density of the tablet below 1gm/ml, and the tablet becomes buoyant.  
HPMCK100M showed delayed floating lag time as compared with other 
excipients due to its higher viscosity owing to more polymer entanglement and 
gel strength. 
 
Non-effervescent formulation: (Ravi kumar et al., 2009) 
With reference to buoyancy studies results it can be concluded that the batch 
containing HPMC polymers  and its combination with ethyl cellulose showed 
good floating lag time. The buoyancy of the tablet varies from polymer to 
polymer which is governed by both the swelling of the hydrocolloid upon contact 
with the dissolution fluid and the presence of voids in the centre of the tablet 
(Ramesh C. Nagarwal et al., 2010).  The formulation containing F5( 
HPMCK100M) floated within 35sec whereas the minimum floating lag time for 
the non-effervescent formulations is G5 (155 sec).  
 
viii) SWELLING INDEX STUDIES: (LINGARAJ S.DANKI ET AL., 2010: 
NAYAK  
R.K et al.,2011)   TABLE 10A-11B. 
 
Effervescent  formulations: . 
The formulation containing HPMC K4M F1-F3 (10%,20%,30%) showed the 
swelling index of 12 hours 76.91%, 78.51%, 76.82%. The formulations 
containing HPMC K100M, F4-F6 (10%,20%,30%, ) showed the swelling index 
of 80.57%, 89.56%, 87.24%, ).    The formulations containing Methyl cellulose, 
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F6-F9 (10%,20%30%) showed the swelling index of (71.97%,72.64%,70.50%).  
From the above results, the overall swelling index was found to be in the 
following order       HPMC K100M > HPMC K4M > Methyl cellulose  were 
shown in TABLE 11A and  Fig 7G. 
 
Non-effervescent  formulations: .  
The formulation containing HPMC K4M G1-G3 (10%,20%,30%) showed the 
swelling index of 12 hours 70.35%, 73.51%, 66.69%.The formulations 
containing HPMC K100M, G4-G6 (10%,20%,30%, ) showed the swelling index 
of 75.23%, 72.23%, 70.24%, ).  The formulations containing Methyl cellulose, 
G6-G9 (10%,20%30%) showed the swelling index of (71.5%,68.04%,74.25%). 
From the above results, the overall swelling index was found to be in the 
following order, 
  HPMC K100M > HPMC K4M > Methyl cellulose were shown in  Fig 7G. 
The in-vitro Swelling index of  formulation containing F5 (HPMC K100M-
89.56%) and G4 (HPMCK100M-75.23)  showed that highest swelling index 
compared to all other formulations. The results were shown in the Table 11B. 
 
 Effect of hydrophilic and hydrophobic polymers on swelling index: 
 
It was observed that, the tablets containing combination of both hydrophilic and 
hydrophobic polymers having less swelling index than that of the formulations 
containing hydrophilic polymers alone. This could be due to the less 
permeability of water into the hydrophobic polymer, which minimized the 
swelling of the matrix tablets (Doddayya et al., 2011).  
Among all the 18 formulations, F5(HPMC K100M) ,figure 8B formulation 
showed the maximum swelling index of 89.56% at the end of 12hours, due to 
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high viscosity and high water retention property of HPMC K100M. The viscosity 
of the polymer had a major influence on swelling process and matrix integrity. It 
was concluded that, there exists a linear relationship between swelling process 
and polymer viscosity ( Margret Chandira R et al., 2010; Deshbhratar R. M. 
et al., 2010; Praveen Kumar Mandapalli et al., 2012). 
 
ix) IN VITRO RELEASE STUDIES: 
 
In vitro dissolution studies of all the formulations of floating tablets of Febuxostat  
were carried out in Acid buffer (0.1 N HCl). The study was performed for 12 hrs, 
and cumulative drug release was calculated at different time intervals. 
Effects of various ingredients and their concentration on drug release were 
studied. It was observed that the type of polymer influences the drug release 
pattern. (F1 to F9) and (G1 to G9)  . (Jinal Patel et al., 2012). 
The in‐vitro drug release profiles for the formulations (F1-F9)  and (G1-G9)were 
tabulated in Table.12A-13B. The plot of cumulative drug release (vs) time (hr) 
was plotted (F1-F9) and depicted as shown in Fig.14A-14D. 
Effervescent formulations: TABLE 12A. 
In vitro drug release studies of formulations containing HPMC K4M (F1-F3) 
(20%,30%, 40%, ) showed the drug release of 75.3%, 74.6%, 73.6 %  at the end 
of 12hrs respectively. In vitro drug release studies of formulations containing 
HPMC K100M (F4- F6) (20%,30%, 40%, ) showed the drug release of 71.8%, 
68.31 %, 85.8 %,  at the end of 12hrs respectively. In vitro drug release studies of 
formulations containing Methyl cellulose (F7- F9) (20%,30%, 40%, ) showed the 
drug release of 84.2 %, 83.7 %, 82.0 %,  at the end of 12hrs respectively. 
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Sustained release profiles were observed in the following order, 
 HPMC K100M > HPMC K4M > Methyl cellulose 
  irrespective of the type of polymer. This was due to the high viscosity of the 
polymer (HPMC K100M) than the others. The high viscosity grades induce the 
formation of strong viscous gel layer when they come in contact with the 
aqueous media that slowed down the rate of diffusion of medium into the 
tablet, which may results in the retardation or decrease the drug release. 
(Anilkumar J. Shinde et al., 2010; Margret Chandira R et al., 2010; Amit 
Kumar Nayak et al., 2011; Ramesh C. Nagarwal et al., 2010).  
 
Non-effervescent formulations: TABLE 12B. 
In vitro drug release studies of formulations containing HPMC K4M (G1-G3) 
(20%,30%, 40%, ) showed the drug release of 85.2%,89.6%, 92.6 %  at the end 
of 12hrs respectively. In vitro drug release studies of formulations containing 
HPMC K100M (G4- G6) (20%,30%, 40%, ) showed the drug release of 77.7 %, 
90.9 %, 89.7 %,  at the end of 12hrs respectively. In vitro drug release studies of 
formulations containing Methyl cellulose (G7- G9) (20%,30%, 40%, ) showed the 
drug release of 88.2 %, 87.5 %, 86.8 %,  at the end of 12hrs respectively.The 
drug release retarded in the following order, 
HPMC K100M & EC  > HPMC K4M & EC > MC & EC 
 
 
 
Ethyl cellulose is hydrophobic in nature, which restricts the penetration of 
dissolution medium inside the matrix and also restricts the formation of gel layer 
around the matrix. So that, the drug release from the hydrophobic matrix 
decreased as compared to the hydrophilic polymers. Nearly all the formulations 
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showed a drug release .Hence, it was concluded that the floating matrix tablets 
prepared with effervescent techniques exhibited better drug release properties.  
Among all the formulations, F5 (HPMC K100M-20%) is choosen as the best      
formulation on the basis of in vitro drug release, floating lag time, total floating 
time and swelling index. It showed maximum drug release in a sustained 
release manner (68.03% in 12hrs) because the formation of strong viscous 
gel layer that slowed down the rate of diffusion of medium into the tablet. The 
results are shown in TABLE13A-13B and FIGURE  9A-9F. 
 
x) INVITRO RELEASE KINETICS STUDIES: 
 
To analyze the release mechanism as well as to select the formulation for in 
vivo studies, the invitro release data were fitted into various release equations 
and kinetic models (zero order, first order, Higuchi, Hixson-Crowell, 
Korsemeyer-Peppas).  
The release kinetic data for all the formulations were shown in the T able: 14A 
&14B & Figure: 10A-1-10E-6.The kinetic studies of all the formulations showed 
that zero ord er plots were fairly linear as indicated by their high regression 
values. Therefore it was ascertained that the drug release from all the 
formulations followed zero order kinetics (Regression coefficient values (R2) 
between 0.938 – 0.991) (Praveen Kumar Mandapalli et al., 2012). 
 
 
Diffusion is related to the transport of drug from the dosage form into the 
invitro study fluid depending on the concentration (Ravikumar et al., 2009). 
This was explained by Higuchi’s model. The release profiles of drug from all 
the formulations could be best expressed by Higuchi’s equations (Amit 
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Kumar Nayak et al., 2011), as the plot showed high linearity with regression 
coefficient values (R2) between 0.939 – 0 .996. 
The kinetic data of all the formulations showed good fit in Korsmeyer equation 
which showed the combined effect of diffusion and erosion mechanism for 
controlled drug release. By using Korsmeyer-peppas model, if n= 0.45 it 
indicates Fickian diffusion controlled drug release (Mina Ibrahim Tadros et al., 
2010), if n=0.89 it indicates swelling controlled drug release, if n values 
between 0.45 to 0.89 can be regarded as an indicator for both the phenomena 
(Anomalous transport or Non-Fickian diffusion) (Ramesh C. Nagarwal et al., 
2010; Amit Kumar Nayak et al., 2011; Praveen Kuma r et al., 2011).  
It was found that the mechanism for all formulations were Anomalous Non-
Fickian diffusion (the release from initially dry, hydrophilic glassy polymers that 
swell when added to water and become rubbery show anomalous diffusion as 
a result of the rearrangement of macromolecular chains) (Sasa Baumgartner 
et al., 2000). 
 
xi)SELECTION OF BEST FORMULATION: 
 
From the above results, F5 was selected the best formulation based on 
following character, 
 Floating lag time :   35 seconds. 
 
 Total floating time :   up to 18hrs. 
 
 swelling index :  89.56 % (12hrs). 
 
 In-vitro release profile :  68.03% (12hrs). 
 
 . In-vitro release kinetics :  Zero order kinetics (r2= 0.991). 
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xii)EVALUATION OF BEST FORMULATION: 
 
A)Infrared spectroscopy: 
 
 
IR spectrum of the best formulation F5 (HPMC K100M-20%) was recorded and 
shown in the Fig11. Pure Febuxostat  spectra showed sharp characteristic peaks 
represented below..All the below characteristic peaks appear in the IR spectrum 
of best formulation which indicates that there was no modification or interaction 
between drug and polymers. 
B) Differential Scanning Calorimetric (DSC) Studies: 
 
DSC thermogram of the best formulation   F5 (Febuxostat, HPMC K100M) were 
recorded. Pure Febuxostat  exhibits a sharp endothermic peak at 2100C. (Figure 
4A).  The peaks observed  after solid dispersion technique is 70.0, 206.1.  
An endothermic peak corresponding to the melting point of pure drug was 
prominent in best formulation (F5) (Figure 12), (192.110C,65.950C, 56.450C,)  
which suggested clearly that there was no interaction between the drug and the 
polymers and the drug was existed in its unchanged form. 
 
C)Powder x-Ray Diffraction study(PXRD): 
The XRD technique was performed to evaluate the physical characteristics of the 
active ingredient. This method is usually used to determine the physical 
characteristics of drugs and polymers, and can therefore investigate whether a 
drug is molecularly dispersed in tablet or drug is changed as an ionic interaction. 
Also, the presence of polymers (indicated by some small sharp peaks) suggests 
that the polymer structure is crystalline or semi-crystalline. XRD studies of the 
pure drug has peaks at 11.7, 12, 14.5, 15.9, 17.6,  24.3. XRD of pure drug with 
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PEG6000 gave peaks at  12.8, 14.4, 16.9, 23.4, 24.6. The peaks for the best 
formulation gave 11.6,12.9, 14.4, , 20.8,  25.9. Thus, it can be concluded  that, 
compared with all ﬁgures, the drug  is present in the formulation and  has a less 
crystalline character as it is evident from the graph that it has less sharp peaks as 
compared with Pure drug and SD. The results are shown in Figure: 5A, 13. 
D)Comparison  of Marketed  formulation with best formulation: 
 
The promising formulation (F5) as found by evaluation studies was compared with 
marketed formulation.The Cumulative % drug release of the best formulation (F5) 
was found to be 68.03% in 12hours when compared to the  tablet whose 
cumulative % drug release was 98.2% in hours.Thus the formulation F5 showed 
sustained release profile than the marketed  tablet. The results were shown in 
Figure: 14. 
 
E)IN-VIVO X-RAY STUDIES: 
 
Based on the results obtained after performing physicochemical characteristics, 
In- vitro buoyancy, In vitro drug release and swelling index, among all 
formulations, F5 containing HPMC K100M polymer have shown best and 
satisfactory results. Hence, this formulation was selected for further In vivo 
evaluations.  
The in-vivo x-ray studies were carried out after getting clearance from Institutional 
Animal Ethical Committee. X-ray studies were conducted to find out the gastric 
retention of tablet.  
The in-vivo radiographic studies were performed in healthy male albino rabbit at 
periodic time intervals (0, 2, 4, 6, 8, 10 & 12hrs) using x-ray machine. The 
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appearance of the tablet in the upper part of the stomach confirms its in-vivo 
floating behaviour. The Change in position of the formulations in the 2nd hour x-
ray and 4th hour x-ray proves that they does not adhere to the mucosa  and 
remains floating. Also the swelling of the tablet can be visualized from the increase 
in its size when compared to 2nd hrs. 4th hrs. 6th hrs. 8th hrs. 10th hrs. & 12th 
hrs. X-rays. The results were  shown in Fig 15. 
 
F) EVALUATION OF STABILITY STUDIES  FOR THE BEST 
FORMULATION (F5) 
 
Stability studies were carried out for the best formulation (F5). The formulation is 
kept in accelerated stability condition at 400C temperature 75 ± 5% relative 
humidity for a period of 2 months as per International Conference on Harmonization 
guidelines (Mathews, 1999; International Conference on Harmonization Steering 
Committee,1999).The samples were withdrawn at every 15 days intervals and 
evaluation was carried out for appearance, thickness, hardness, buoyancy lag time, 
drug content and In-vitro release studies (60days). The result were shown 
inFig16A-D&Table15. 
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TABLE 1: CALIBRATION OF FEBUXOSTAT BY USING ACID BUFFER OF 
Ph1.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n=3* Regression Value – 0.99976 
 
CONCENTRATION 
 
ABSORBANCE 
 
2 
 
0.058±0.010 
 
4 
 
0.121±0.016 
 
6 
 
0.179±0.022 
 
8 
 
0.238±0.031 
 
10 
 
0.301±0.045 
 
12 
 
0.353±0.051 
 
14 
 
0.411±0.048 
 
16 
 
0.469±0.060 
 
18 
 
0.528±0.058 
 
20 
 
0.601±0.062 
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TABLE 2: COMPOSITION OF SOLID DISPERSION 
 
 
 
 
 
TABLE 3 : PERCENTAGE YIELD AND DRUG CONTENT OF SOLID 
DISPERSION 
 
 
 
S.no 
 
Formulation 
Code 
 
Method 
 
Ratio 
 
Percentage 
of yield 
± SD 
Drug 
content ± 
SD 
 
1 
 
A1 
 
Melting 
 
1 : 1 
 
87.09±0.01 
 
95.38 ± 0.20 
 
2 
 
A2 
 
Melting 
 
1 : 2 
 
88.21±0.16 
 
96.61 ± 0.07 
 
3 
 
A3 
 
Melting 
 
1 : 3 
 
94.75±0.03 
 
98.55 ± 0.80 
 
 
n=3* 
 
 
 
 
 
 
 
 
 
S.NO 
Formulation 
code 
 
Method 
 
Ratio 
 
Composition 
 
1 
 
A1 
 
Melting 
 
1:1 
 
Drug : PEG6000 
 
2 
 
A2 
 
Melting 
 
1:2 
 
Drug : PEG6000 
 
3 
 
A3 
 
Melting 
 
1:3 
 
Drug : PEG6000 
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TABLE 4: CUMULATIVE PERCENTAGE OF DRUG RELEASE OF PHYSICAL 
MIXTURE OF FEBUXOSTAT WITH PEG6000. 
 
 
 
 
 
Time 
(min) 
 
Percentage of drug release ± SD 
 
 
A1 
 
1 :1 
 
A2 
 
1 :2 
 
A3 
 
1:3 
MARKETED 
FORMULATION 
 
 
PURE            
DRUG 
 
10 
 
11.9 ±1.87 
 
22.4 ±1.95
 
31.2 ± 2.08 13.6±2.55 
 
9.16±2.97 
 
20 
 
19.5± 2.47 
 
31.8 ±2.71
 
38.5 ± 3.05 24.5±0.007 
 
19.25 ±0.95 
 
30 
 
29.1 ±1.18 
 
39.5 ± 3.05
 
47.2 ± 2.78 29.5±1.25 
 
29.34±3.06 
 
40 
 
34.2 ±1.08 
 
43.2 ± 2.49 
 
54.9± 2.3 33.8±1.28 
 
36.71 ±1.75 
 
50 
 
41.4 ±1.54 
 
51.9 ± 1.52 
 
61.8 ± 2.54 46.4±2.57 
 
42.4 ±3.27 
 
60 
 
44.5 ±2.48 
 
59.4 ± 2.24 
 
67.2 ± 2.78 53.6±3.08 
 
49.1 ±1.70 
 
 
n=3* 
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TABLE 4: CUMULATIVE PERCENTAGE OF DRUG RELEASE OF  
FEBUXOSTAT WITH PEG6000 AFTER SOLID DISPERSION BY MELTING 
METHOD 
 
 
 
 
 
n=3* 
 
 
 
 
 
 
 
 
 
Time 
(min) 
 
Percentage of drug release ± SD 
 
 
A1 
 
1 :1 
 
A2 
 
1 : 2 
 
A3 
 
1:3 
MARKETED 
FORMULATION 
 
 
PURE           
DRUG 
 
10 
 
26.7 ±1.66 
 
31.1 ± 2.42 
 
42.9±1.25 13.6±2.55 
 
9.16±2.97 
 
20 
 
33.7 ±3.36 
 
39.2 ± 1.40 
 
50.6 ± 1.42
 
24.5±0.007  19.25 ±0.95 
 
30 
 
43.7 ±2.70 
 
46.2 ± 1.63 
 
64.4±3.39 29.5±1.25 
 
29.34±3.06 
 
40 
 
47.9 ±2.04 
 
51.4 ± 2.08 
 
74.8 ± 4.05 33.8±1.28 
 
36.71 ±1.75 
 
50 
 
54.1 ±2.37 
 
58.8 ± 2.97 
 
86.9 ± 3.15 46.4±2.57 
 
42.4 ±3.27 
 
60 
 
59.4 ±2.50 
 
66.7 ± 3.37 
 
92.9 ± 1.82 53.6±3.08 
 
27.1 ±1.70 
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TABLE 6A:FORMULATION OF EFFERVESCENT FLOATING SUSTAINED RELEASE MATRIX      TABLET 
Quantity (mg) for I tablet (Average weight -350mg) 
INGREDIENTS F1 F2 F3 F4 F5 F6 F7 F8 F9 
SOLID DISPERSION IN 1:3 
RATIO (mg) 
 
[CONTAINING 40 MG 
FEBUXOSTAT] 
160 160 160 160 160 160 160 160 160 
HPMC K4M (mg) 35 70 105       
HPMC K100M (mg)    35 70 105    
METHYL CELLULOSE (mg)       35 70 105 
PVP K30 (mg) 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 
SODIUM BICARBONATE 
(mg) 
35 35 35 35 35 35 35 35 35 
CITRIC ACID (mg) 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 
MCC (mg) 78 43 8 78 43 8 73 43 8 
MAGNESIUM STEARATE 
(mg) 
3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 
TALC (mg) 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 
TOTAL WEIGHT OF EACH 
TABLET (mg) 
350 350 350 350 350 350 350 350 350 
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TABLE 6B--FORMULATION OF NON- EFFERVESCENT FLOATING SUSTAINED RELEASE MATRIX TABLETS 
 
Average Weight 200mg / Tablet 
 
 
INGREDIENTS F1 F2 F3 F4 F5 F6 F7 F8 F9 
SOLID DISPERSION IN 1:3 
RATIO (mg) 
 
[CONTAINING 40 MG 
FEBUXOSTAT] 
160 160 160 160 160 160 160 160 160 
HPMC K4M (mg) 70 105 140       
HPMC K100M (mg)    70 105 140    
METHYL CELLULOSE (mg)       70 105 140 
ETHYL CELLULOSE (mg) 35 35 35 35 35 35 35 35 35 
MCC (mg) 78 43 8 78 43 8 78 43 8 
MAGNESIUM STEARATE 
(mg) 
3.5 3.5 3.5 3.5 3.5 3.5 35 3.5 3.5 
TALC (mg) 3.5 3.5 3.5 3. 3.5 3.5 3.5 3.5 3.5 
TOTAL WEIGHT OF EACH 
TABLET (mg) 
350 350 350 350 350 350 350 350 350 
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TABLE 7A- PRECOMPRESSIONAL EVALUATION OF POWDER BLEND 
(EFFERVESCENT TECHNIQUE) 
  
 
S.no 
 
 
Formulation 
code 
 
 
Angle of 
repose 
± SD 
 
 
Bulk 
density 
(gm/ml)± 
SD 
 
 
Tapped 
density 
(g/ml) ± SD 
 
1 
 
F1 
 
28 047’ ± 0.5 
 
0.736± 0.01 
 
0.84 ± 0.02 
 
2 
 
F2 
 
29019’ ± 0.49 
 
0.777 ±0.01 0.87 ± 0.011 
 
3 
 
F3 
 
25084’ ± 0.65 
 
0.80 ± 0.02 0.91 ± 0.035 
 
4 
 
F4 
 
30057’ ± 1.56 
 
0.764 ± 0.02
 
0.84 ± 0.02 
 
5 
 
F5 
 
31009’ ± 1.87 
 
0.721 ± 0.03 0.87± 0.023 
 
6 
 
F6 
 
29034’ ± 0.98 
 
0.827± 0.01 0.94 ± 0.034 
 
7 
 
F7 
 
31010’ ± 0.51 
 
0.914 ± 0.01
 
1.03 ± 0.02 
 
8 
 
F8 
 
25058’ ± 1.55 
 
0.775 ± 0.02
 
0.89 ± 0.02 
 
9 
 
F9 
 
28072’ ± 1.35 
 
0.784 ± 0.03 0.94 ± 0.025 
 
 
               n=3* 
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TABLE 7B- PRECOMPRESSIONAL EVALUATION OF POWDER BLEND 
(NON-EFFERVESCENT TECHNIQUE) 
 
 
 
 
         n=3* 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.no 
 
 
Formulation 
code 
 
 
Angle of 
repose 
± SD 
 
 
Bulk 
density 
(gm/ml)± 
SD 
 
 
Tapped 
density 
(g/ml) ± SD 
 
1 G1  27 008’ ± 0.5 
 
0.747 ± 0.01
 
0.87 ± 0.02 
 
2 G2  29053’ ± 0.49 
 
0.754 ± 0.01 0.88 ± 0.011 
 
3 G3  28024’ ± 0.65 
 
0.674 ± 0.02 0.78 ± 0.035 
 
4 G4  29054’ ± 1.56 
 
0.725 ± 0.02
 
      0.86 ± 0.02 
 
5 G5  30026’ ± 1.87 
 
0.871 ± 0.03 1.08± 0.023 
 
6 G6  28050’ ± 0.98 
 
0.768± 0.01   0.94 ± 0.034 
 
7 G7  28034’ ± 0.51 
 
0.684 ± 0.01
 
0.76 ± 0.02 
 
8 G8  28035’ ± 1.55 
 
0.789 ± 0.02
 
0.95± 0.02 
 
9 G9  28024’ ± 1.35 
 
0.725 ± 0.03 0.88 ± 0.025 
CHAPTER 11  TABLES AND FIGURES 
 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI. Page 131 
 
TABLE 8A- PRECOMPRESSIONAL EVALUATION OF POWDER BLEND 
(EFFERVESCENT TECHNIQUE) 
 
 
S.no  Formulation 
Code 
 
Compressibility 
index(%) 
±SD 
Hausners ratio 
(HR)±SD 
 
1 
 
F1 
 
13.09 ± 2.74 
 
1.15 ± 0.03 
 
2 
 
F2 
 
11.49 ± 0.24 
 
1.12 ± 0.31 
 
3 
 
F3 
 
12.08 ± 1.55 
 
1.13 ± 0.05 
 
4 
 
F4 
 
13.69± 2.09 
 
1.10 ± 0.03 
 
5 
 
F5 
 
17.24 ± 2.23 
 
1.20± 0.05 
 
6 
 
F6 
 
12.76 ± 0.15 
 
1.14 ± 0.01 
 
7 
 
F7 
 
11.26 ± 1.08 
 
1.13 ± 0.01 
 
8 
 
F8 
 
13.48 ± 1.96 
 
1.15 ± 0.32 
 
9 
 
F9 
 
17.02 ± 0.52 
 
1.20 ± 0.14 
 
 
 
           n=3* 
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TABLE 8B- PRECOMPRESSIONAL EVALUATION OF POWDER BLEND 
(NON-EFFERVESCENT TECHNIQUE) 
 
 
 
S.no 
 
Formulation 
code 
Compressibility 
index(%) 
±SD 
Hausners ratio 
(HR)±SD 
 
1 
 
G1 
 
14.94 ± 0.32 
 
1.17 ± 0.05 
 
2 
 
G2 
 
14.77 ± 0.15 
 
1.17 ± 0.33 
 
3 
 
G3 
 
14.10± 1.41 
 
1.16 ± 0.02 
 
4 
 
G4 
 
16.27 ± 2.06 
 
1.19 ± 0.03 
 
5 
 
G5 
 
19.44 ± 2.03 
 
1.24 ± 0.05 
 
6 
 
G6 
 
19.14 ± 0.14 
 
1.23 ± 0.05 
 
7 
 
G7 
 
10.52 ± 1.02 
 
1.11 ± 0.09 
 
8 
 
G8 
 
17.89 ± 1.45 
 
1.21 ± 0.32 
 
9 
 
G9 
 
18.18 ± 0.23 
 
1.22 ± 0.04 
 
 
 
n=3* 
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TABLE 9A-POSTCOMPRESSIONAL EVALUATION OF FEBUXOSTAT  
FLOATING SUSTAINED RELEASE MATRIX TABLET 
(EFFERVESCENT TECHNIQUE) 
 
 
              n=3* 
 
 
 
 
 
 
S.no 
 
Formulation 
code 
 
Hardness 
Kg/cm2 
 
Friability (%) 
± SD 
Drug    
content  
(%)± SD 
 
1 
 
F1 
 
4.26 ±0.47  0.359±0.028 
 
99.68±0.35 
 
2 
 
F2 
 
4.76±0.26  0.393±0.120 
 
98.79±0.846 
 
3 
 
F3 
 
5.1±0.235  0.326±0.132 
 
98.49±0.446 
 
4 
 
F4 
 
5.2±0.475  0.395±0.123 
 
99.59±0.446 
 
5 
 
F5 
 
5.0±0.365  0.333±0.065 
 
99.59±0.386 
 
6 
 
F6 
 
5.0±0.332  0.326±0.050 
 
97.69±0.65 
 
7 
 
F7 
 
5.9±0.345 0.34±0.01 
 
98.19±0.356 
 
8 
 
F8 
 
5.7±0.26  0.356±0.025 
 
98.59±0.332 
 
9 
 
F9 
 
5.1±0.248  
0.396±0.075 
 
99.16±0.326 
CHAPTER 11  TABLES AND FIGURES 
 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI. Page 134 
 
 
TABLE 9B-POSTCOMPRESSIONAL EVALUATION OF FEBUXOSTAT  
FLOATING SUSTAINED RELEASE MATRIX TABLET 
(NON-EFFERVESCENT TECHNIQUE) 
 
 
 
             n=3* 
 
 
  
 
S.no 
 
Formulation 
code 
 
Hardness 
Kg/cm2 
Friability (%) 
± SD 
 
Drug 
content 
(%)± SD 
 
1 G1  
5.16 ±0.34 
 
0.369±0.035  
97.84±0.332 
 
2 
 
G2  4.78±0.291 
 
0.353±0.010  98.64±0.374 
 
3 G3  5.12±0.224 
 
0.386±0.135  98.68±0.398 
 
4 G4  4.21±0.358 
 
0.394±0.156  
98.48±0.356 
 
5 
 
G5  4.03±0.578 
 
0.359±0.0656  99.29±0.348 
 
6 G6  4.63±0.621 
 
0.369±0.050  99.89±0.62 
 
7 G7  5.21±0.315 
 
0.347±0.53  
97.29±0.345 
 
8 G8  5.36±0.231 
 
0.368±0.053  97.59±0.33 
 
9 
 
G9  5.27 ±0.298 
 
0.377±0.135  99.59±0.344 
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TABLE 10A- INVITRO SWELLING INDEX OF FLOATING SUSTAINED RELEASE 
MATRIX TABLETS OF FEBUXOSTAT ( EFFERVESCENT TECHNIQUE) 
 
 
 
 n=3* 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO 
 
 
 
 
Formulation 
code 
Percentage of swelling in time ( hours) ± SD 
 
 
3hrs 
 
 
6hrs 
 
 
9hrs 
 
 
12hrs 
1  F1 
 
39.02 ± 1.5969 
 
52.87 ± 0.2928 
 
68.42 ±0.3894 
 
76.91 ± 2.3081 
2  F2 
 
34.13 ± 1.5085 
 
58.66 ± 1.7230 
 
62.26 ±0.7823 
 
78.51 ± 2.5517 
3  F3 
 
30.68 ± 1.931 
 
56.79 ± 0.7552 
 
69.42 ±0.7550 
 
76.82 ± 1.0524 
4  F4 
 
34.35 ± 0.6908 
 
54.87 ± 1.2206 
 
64.34 ±1.3388 
 
80.57 ± 1.0850 
5  F5 
 
38.06 ± 0.1789 
 
55.44 ± 0.5645 
 
62.66 ±0.5565 
 
89.56 ± 1.2988 
6  F6 
 
38.57 ± 0.9500 
 
56.12 ± 0.4712 
 
60.71 ±0.4912 
 
87.24 ± 1.0208 
7  F7 
 
37.78 ± 0.7937 
 
57.73 ± 1.2833 
 
63.11 ±1.2457 
 
71.97 ± 1.1511 
8  F8 
 
39.00 ± 0.3750 
 
52.56 ± 0.4467 
 
66.62 ± 1.088 
 
72.64 ± 0.84 
9  F9 
 
36.9 ± 0.6090 
 
51.61± 1.1801 
 
66.31 ±1.2234 
 
70.50 ± 0.94384 
      
CHAPTER 11  TABLES AND FIGURES 
 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY, MMC, MADURAI. Page 136 
 
TABLE 10B- INVITRO SWELLING INDEX OF FLOATING SUSTAINED RELEASE 
MATRIX TABLETS OF FEBUXOSTAT (NON- EFFERVESCENT TECHNIQUE) 
 
 
 
     n=3* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO 
 
 
 
 
Formulation 
code 
Percentage of swelling in time ( hours) ± SD 
 
 
3hrs 
 
 
6hrs 
 
 
9hrs 
 
 
12hrs 
1  G1 
 
64.02 ± 1.59 
 
69.87±0.2478 
 
88.42 ±0.3964 
 
70.35 ± 2.205 
2  G2 
 
59.04 ± 1.55 
 
70.3 ± 1.6530 
 
84.33 ±0.5823 
 
73.51 ± 2.552 
3  G3 
 
   56.21 ± 1.99 
 
70.02±0.9852 
 
89.66 ±0.5850 
 
66.69 ± 1.084 
4  G4 
 
53.21 ± 0.65 
 
64.7 ± 1.406 
 
96.22 ±1.8988 
 
75.23 ± 1.070 
5  G5 
 
57.3 ± 0.174 
 
69.5 ± 0.5785 
 
99.36 ± 0.565 
 
72.23 ± 1.27 
6  G6 
 
54.7± 0.960 
 
67.2 ± 0.4754 
 
102.5 ± 0.452 
 
70.24 ± 1.078 
7  G7 
 
59.78 ± 0.798 
 
69.47±1.5833 
 
86.52 ± 1.287 
 
71.5 ± 1.121 
8  G8 
 
 54.88 ± 0.3730 
 
67.23±0.4487 
 
88.85 ± 1.568 
 
68.04 ± 0.841 
9  G9 
 
  59.24± 0.609 
 
61.85± 1.185 
 
91.25 ± 1.284 
 
74.25± 0.9584 
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TABLE 11A -INVITRO  BUOYANCY LAG TIME, TOTAL FLOATING TIME, SWELLING 
INDEX OF FLOATING SUSTAINED RELEASE TABLETS OF FEBUXOSTAT 
(EFFERVESCENT TECHNIQUE) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                               n=3* 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation 
code 
 
 
Buoyancy lag 
time (in 
minutes) 
 
 
Total floating 
time (in 
hours) 
 
 
Swelling index 
(%) 
(12hours) 
 
F1 
 
49 sec 
>18  
76.91 ± 2.3081 
 
F2 
 
52sec 
>18  
78.51 ± 2.5517 
 
F3 
 
48sec 
>18  
76.82 ± 1.0524 
 
F4 
 
23 sec 
>18  
80.57 ± 1.0850 
 
F5 
 
35sec 
>18  
89.56 ± 1.2988 
 
F6 
 
39sec 
>18  
87.24 ± 1.0208 
 
F7 
 
95sec 
>18  
71.97 ± 1.1511 
 
F8 
 
106sec 
>18  
72.64 ± 0.84 
 
F9 
 
89sec 
>18  
70.50 ± 0.94384 
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TABLE 11B -INVITRO  BUOYANCY LAG TIME, TOTAL FLOATING TIME, SWELLING 
INDEX OF FLOATING SUSTAINED RELEASE TABLETS OF FEBUXOSTAT 
(NON-EFFERVESCENT TECHNIQUE) 
 
 
 
 
Formulation 
code 
 
 
Buoyancy lag 
time (in 
minutes) 
 
 
Total floating 
time (in 
hours) 
 
 
Swelling index 
(%) 
(12 hours) 
 
G1 
 
302 sec 
 
Not more than12 
 
70.35 ± 2.205 
 
G2 
 
296 sec 
 
Not more than12 
 
73.51 ± 2.552 
 
G3 
 
305 sec 
 
Not more than12 
 
66.69 ± 1.084 
 
G4 
 
198sec 
 
Not more than12 
 
75.23 ± 1.070 
 
G5 
 
155sec 
 
Not more than12 
 
72.23 ± 1.27 
 
G6 
 
203sec 
 
Not more than12 
 
70.24 ± 1.078 
 
G7 
 
504sec 
 
Not more than12 
 
71.5± 1.121 
 
G8 
 
512sec 
 
Not more than12 
 
68.04 ± 0.841 
 
G9 
 
621sec 
 
Not more than12 
 
74.25± 0.9584 
 
n=3*  
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TABLE 12 A- IN VITRO  DRUG RELEASE PROFILE OF FLOATING SUSTAINED 
RELEASE MATRIX TABLETS OF FEBUXOSTAT ( EFFERVESCENT TECHNIQUE) 
 
 
 
 
 
S.no 
 
 
Time in 
hours 
 
Formulation code Drug release in 
(%) ±   SD 
 
F1 F2 F3
 
1 
 
1 
 
     26.9±0.45 
 
29.3±0.18 
 
27.9±0.58 
 
2 
 
2 
 
32.7±0.33 
 
34.6±0.32 
 
31.8±0.68 
 
3 
 
3 
 
36.9±0.07 
 
38.8±0.17 
 
35.8±0.47 
 
4 
 
4 
 
41.9±0.36 
 
41.8±0.32 
 
39.2±0.77 
 
5 
 
5 
 
44.7±0.58 
 
44.3±0.08 
 
42.6±0.42 
 
6 
 
6 
 
48.03±0.37 
 
46.7±0.36 
 
44.9±0.32 
 
7 
 
7 
 
52.6±0.14 
 
52.5±0.17 
 
50.8±0.39 
 
8 
 
8 
 
62.6±0.98 
 
57.9±1.89 
 
54.6±0.6 
 
9 
 
9 
 
66.7±0.35 
 
62.3±0.35 
 
58.7±0.78 
 
10 
 
10 
 
67.8±0.77 
 
65.4±0.65 
 
63.2±0.77 
 
11 
 
11 
 
71.9±0.96 
 
70.6±0.17 
 
68.8±1.99 
 
12 
 
12 
 
75.3±0.17 
 
74.6±0.45 
 
73.6±1.79 
 
n=3* 
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TABLE 12 A- IN VITRO  DRUG RELEASE PROFILE OF FLOATING SUSTAINED 
RELEASE MATRIX TABLETS OF FEBUXOSTAT ( EFFERVESCENT TECHNIQUE) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 n=3* 
 
 
S.no 
 
Time in 
hours 
 
Formulation code Drug release in 
(%) ± SD 
F4 F5 F6 
 
 
1 
 
1 
 
27.2±0.57 
 
23.6±0.29 
 
28.6±1.12 
 
2 
 
2 
 
29.3±0.28 
 
27.5±0.67 
 
33.6±0.69 
 
3 
 
3 
 
34.1±0.16 
 
30.3±0.25 
 
37.6±1.05 
 
4 
 
4 
 
38.1±1.03 
 
33.6±0.44 
 
43.2±1.13 
 
5 
 
5 
39.2±0.77  
36.6±0.16 
 
47.4±2.36 
 
6 
 
6 
 
43.8±0.61 
 
40.2±0.21 
 
53.3±2.68 
 
7 
 
7 
 
47.2±0.14 
 
 
44.0±0.23 
 
58.3±2.79 
 
8 
 
8 
 
49.6±0.20 
 
47.8±0.29 
 
62.7±2.89 
 
9 
 
9 
 
55.8±0.41 
 
50.5±0.12 
 
68.6±1.75 
 
10 
 
10 
 
62.9±0.82 
 
56.9±0.78 
 
72.6±2.01 
 
11 
 
11 
 
63.6±0.30 
 
62.3±0.29 
 
80.3±2.36 
 
12 
 
12 
 
71.8±0.88 
 
68.3±0.36 
 
85.8±1.76 
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TABLE 12 A- IN VITRO  DRUG RELEASE PROFILE OF FLOATING SUSTAINED 
RELEASE MATRIX TABLETS OF FEBUXOSTAT ( EFFERVESCENT TECHNIQUE) 
 
 
 
n=3* 
 
 
 
 
 
Formulation code Drug release in (%) ± SD 
F7 F8 F9 
1  1 28.9±0.73 
 
23.5±1.90 
 
25.3±0.47 
 
2 
 
2 
 
32.6±0.35 
 
27.8±2.45 
28.4±2.97 
 
3 
 
3 
 
36.5±0.47 32.6±3.30 
33.4±3.23 
 
4 
 
4 
 
43.2±0.56 36.8±3.47 
35.9±3.26 
 
5 
 
5 
 
47.1±0.26 
38.9±3.31 40.7±4.00 
 
6 
 
6 
 
52.5±0.84 
43.8±3.21 44.5±3.63 
 
7 
 
7 
 
57.5±1.15 
49.3±3.16 51.2±3.63 
 
8 
 
8 
 
63.9±1.21 
58.2±3.77 53.9±4.51 
 
9 
 
9 
 
69.5±0.96 
60.9±3.72 60.2±4.46 
 
10 
 
10 
 
74.4±0.30 
69.3±2.90 65.5±3.66 
 
11 
 
11 
 
79.6±0.56 75.5±2.35 
 
73.1±3.28 
 
12 
 
12 
 
81.2±0.21 
 
83.7±2.36 
 
82.0±2.78 
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TABLE 12 B- IN VITRO  DRUG RELEASE PROFILE OF FLOATING SUSTAINED 
RELEASE MATRIX TABLETS OF FEBUXOSTAT 
 ( NON-EFFERVESCENT TECHNIQUE) 
 
 
 
 
S.no 
 
 
Time in 
hours 
 
 
Formulation code Drug release in 
(%) ±   SD 
G1 G2 G3 
 
1 
 
1 
 
27.2±0.87 
 
25.3±0.57 
 
27.0±0.28 
 
2 
 
2 
 
31.6±1.12 
 
29.5±0.36 
 
33.4±0.20 
 
3 
 
3 
 
34.8±1.18 
 
33.2±1.51 
 
37.5±0.40 
 
4 
 
4 
 
40.8±1.06 
 
40.2±0.58 
 
42.8±0.53 
 
5 
 
5 
 
45.5±1.69 
 
44.8±0.36 
 
45.8±0.28 
 
6 
 
6 
 
50.9±2.12 
 
51.8±0.45 
 
47.8±0.24 
 
7 
 
7 
 
55.9±2.68 
 
55.7±0.59 
 
52.4±0.69 
 
8 
 
8 
 
64.2±1.74 
 
59.4±1.92 
 
59.6±1.06 
 
9 
 
9 
 
72.6±1.10 
 
65.5±1.63 
 
63.7±1.39 
 
10 
 
10 
 
74.2±1.12 
 
70.8±2.14 
 
68.2±1.84 
 
11 
 
11 
 
79.2±1.12 
 
73.4±2.17 
 
73.6±0.60 
 
12 
 
12 
 
85.2±0.39 
 
89.6±0.78 
 
92.6±0.58 
 
n=3* 
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TABLE 12 B- IN VITRO  DRUG RELEASE PROFILE OF FLOATING SUSTAINED 
RELEASE MATRIX TABLETS OF FEBUXOSTAT 
 (NON- EFFERVESCENT TECHNIQUE) 
 
 
 
 
 
S.no 
 
 
 
Time in 
hours 
 
 
Formulation code Drug release in 
(%) ±   SD 
 
G4 G5 G6 
 
1 
 
1 
 
24.6±0.29 
 
27.2±0.63 
 
27.9±0.28 
 
2 
 
2 
 
28.0±0.98 
 
33.8±1.00 
 
33.9±0.47 
 
3 
 
3 
 
31.5±1.04 
 
39.2±0.54 
 
40.5±0.16 
 
4 
 
4 
 
37.8±0.97 
 
44.5±0.67 
 
44.9±2.40 
 
5 
 
5 
 
42.8±0.66 
 
46.9±0.23 
 
49.3±1.66 
 
6 
 
6 
 
47.8±0.45 
 
51.5±0.63 
 
56.4±1.48 
 
7 
 
7 
 
51.6±0.16 
 
57.5±0.49 
 
62.9±1.14 
 
8 
 
8 
 
56.9±0.60 
 
62.9±0.17 
 
71.8±1.38 
 
9 
 
9 
 
62.8±0.39 
 
68.8±0.50 
 
76.8±1.58 
 
10 
 
10 
 
67.8±0.7 
 
75.2±0.49 
 
80.9±0.75 
 
11 
 
11 
 
72.8±0.59 
 
83.9±0.87 
 
84.9±1.11 
 
12 
 
12 
 
77.7±0.30 
 
90.9±0.65 
 
89.7±0.36 
 
n=3* 
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TABLE 12 B- IN VITRO  DRUG RELEASE PROFILE OF FLOATING SUSTAINED 
RELEASE MATRIX TABLETS OF FEBUXOSTAT (NON- EFFERVESCENT 
TECHNIQUE) 
 
 
 
S.no 
 
 
Time in 
hours 
 
Formulation code Drug release in 
(%) ±   SD 
G7 G8 G9 
 
1 
 
1 
 
25.9±1.52 
 
26.8±0.20 
 
24.3±1.31 
 
2 
 
2 
 
30.8±1.18 
 
32.8±0.38 
 
28.6±2.15 
 
3 
 
3 
 
36.7±1.60 
 
38.9±0.28 
 
33.6±2.28 
 
4 
 
4 
 
42.8±1.79 
 
41.8±0.29 
 
38.9±2.15 
 
5 
 
5 
 
48.1±3.08 
 
47.5±0.74 
 
43.9±1.87 
 
6 
 
6 
 
55.6±2.00 
 
55.6±0.42 
 
47.5±2.53 
 
7 
 
7 
 
61.2±3.69 
 
61.5±0.20 
 
54.2±2.36 
 
8 
 
8 
 
67.8±2.28 
 
67.9±0.37 
 
59.9±2.69 
 
9 
 
9 
 
72.8±1.98 
 
72.5±0.26 
 
65.8±2.56 
 
10 
 
10 
 
76.5±0.86 
 
76.8±0.22 
 
72.8±2.36 
 
11 
 
11 
 
84.8±0.53 
 
80.6±0.48 
 
78.9±2.04 
 
12 
 
12 
 
88.2±0.69 
 
87.5±0.37 
 
86.8±1.39 
 
n=3*   
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TABLE 13A- IN VITRO  SUSTAINED DISSOLUTION STUDIES OF FLOATING 
SUSTAINED RELEASE MATRIX  TABLETS OF  FEBUXOSTAT  
(EFFERVESCENT TECHNIQUE) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  n=3* 
 
 
 
 
 
 
 
 
S.no 
 
Time in hours 
 
 
 
Formulation 
code 
 
 
Drug release in (%) ± 
SD  12 hours 
 
1 
 
 
1 
 
 
F1 
 
 
75.3±0.17 
 
 
2 
 
 
2 
 
 
F2 
 
 
74.6±0.45 
 
3 
 
3 
 
   F3 
 
              73.6±1.79 
 
4 
 
4 
 
F4 
 
71.8±0.88 
 
5 
 
5 
 
F5 
 
68.3±0.36 
 
6 
 
6 
 
F6 
 
75.8±1.76 
 
7 
 
7 
 
F7 
 
81.2±0.21 
 
8 
 
8 
 
F8 
 
83.7±2.36 
 
9 
 
9 
 
F9 
 
82.0±2.78 
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TABLE 13B- IN VITRO  SUSTAINED DISSOLUTION STUDIES OF FLOATING 
SUSTAINED RELEASE MATRIX  TABLETS OF  FEBUXOSTAT  
(NON-EFFERVESCENT TECHNIQUE) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 n=3* 
 
 
S.no 
 
Time in hours 
 
 
Formulation code 
 
 
Drug release in (%) ± SD 
 
12 hours
 
 
1 
 
 
1 
 
 
             G1 
 
 
              85.2±0.39 
 
 
2 
 
 
2 
 
 G2 
 
              89.6±0.78 
 
3 
 
3 
 
  G3 
 
92.6±0.58 
 
4 
 
4 
 
G4 
 
77.7±0.30 
 
5 
 
5 
 
G5 
 
90.9±0.65 
 
6 
 
6 
 
G6 
 
81.7±0.36 
 
7 
 
7 
 
G7 
 
88.2±0.69 
 
8 
 
8 
 
G8 
 
87.5±0.37 
 
9 
 
9 
 
G9 
 
86.8±1.39 
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TABLE14A- IN VITRO  KINETIC RELEASE STUDY DATA  FOR FEBUXOSTAT SUATAINED RELEASE FLOATING TABLETS(EFFERVESCENT) 
FORMULATION 
CODE 
ZERO ORDER FIRST ORDER HIGHUCHI 
MODEL 
KORES-MEYER AND  
PEPPAS MODEL 
HIXON-CROWELL 
MODEL 
 r2 k0(h-1) r2 k1 (h-1) r2 kh(h-1/2) r2 n r2 KHC(h-1/3) 
F1 
0.9179 5.2004 0.9829 -4.4586 0.9795 20.818 0.9534 0.3987 0.9769 -0.1163 
F2 
0.9813 4.5932 0.9625 -3.7942 0.9463 18.399 0.8886 0.3542 0.929 -0.0971 
F3 
0.9133 4.7536 0.9946 -4.0732 0.9751 19.206 0.936 0.3852 0.9758 -0.1028 
F4 
0.9071 4.5592 0.9819 -3.8363 0.9635 18.155 0.9136 0.3852 0.9576 -0.0942 
F5 
0.9338 4.5373 0.9841 -3.9502 0.9623 17.795 0.926 0.4316 0.9575 -0.0931 
F6 
0.9424 5.8657 0.9963 -5.1206 0.9814 23.124 0.9577 0.4586 0.9664 -0.147 
F7 
0.9381 5.7661 0.9971 -5.0027 0.9852 22.831 0.9581 0.4521 0.9861 -0.1404 
F8 
0.9489 5.5259 0.9758 -4.9617 0.9472 21.332 0.9534 0.4307 0.9214 -0.1316 
F9 
0.9608 5.8384 0.9819 -5.321 0.9493 22.422 0.9282 0.5126 0.9389 -0.143 
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FORMULATION 
CODE 
ZERO ORDER FIRST ORDER HIGHUCHI 
MODEL 
KORES-MEYER AND  
PEPPAS MODEL 
HIXON-CROWELL 
MODEL 
 r2 k0(h-1) r2 k1 (h-1) r2 kh(h-1/2) r2 n r2 KHC(h-1/3) 
G1 0.9557 6.1134 0.991 -5.4692 0.9684 23.777 0.9356 0.4884 0.9632 -0.1567 
G2 0.9532 5.9907 0.9799 -5.3972 0.9591 23.218 0.9382 0.5034 0.8966 -0.1546 
G3 0.9196 5.703 0.9497 -5.002 0.9394 22.27 0.9197 0.4412 0.8184 -0.1504 
G4 0.9573 5.5089 0.9977 -4.9112 0.9767 21.499 0.9478 0.4899 0.9805 -0.1268 
G5 0.9475 6.1288 0.9892 -5.4229 0.969 23.946 0.9527 0.4726 0.9252 -0.1649 
G6 0.952 6.5045 0.994 -5.7703 0.9826 25.532 0.9604 0.4945 0.9808 -0.1787 
G7 0.9659 6.5323 0.9981 -5.9023 0.9806 25.431 0.9659 0.5336 0.9752 -0.1768 
G8 0.9523 6.2293 0.9945 -5.5267 0.9836 24.46 0.9654 0.498 0.9786 -0.162 
G9 0.9654 6.0796 0.9907 -5.5323 0.9587 23.408 0.9405 0.5136 0.9419 -0.1551 
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TABLE 15A- EVALUATION OF FEBUXOSTAT FLOATING TABLETS                  
KEPT  IN STABILITY AT 40OC/75RH RELATIVE HUMIDITY 
 
 
 
n=3* 
 
Formulation 
Parameters 
 
 
Initial 
 
 
15 days 
 
 
30days 
 
 
45days 
 
 
60days 
 
Average 
weight        
(mg) 
 
 
346.73 
 
 
346.73 
 
 
346.72 
 
 
346.72 
 
 
346.72 
 
 Thickness 
(mg) 
 
4.26 
 
4.26 
 
4.26 
 
4.26 
 
4.26 
 
Hardness  
(kg/cm2) 
 
 
10.3 
 
 
10.3 
 
 
10.3 
 
 
10.3 
 
 
10.3 
 
Floating lag 
Time(sec) 
 
 
35sec 
 
 
39sec 
 
 
32sec 
 
 
42 sec 
 
 
40sec 
 
Swelling 
Index (8 
Hours) (%) 
 
 
89.56 
 
 
88.02 
 
 
87.18 
 
 
87.03 
 
 
86.09 
 
Drug content 
in 
% 
 
 
99.59±0.38 
 
 
99.59±0.3
4 
 
 
99.23±0.28 
 
 
99.21±0.20 
 
 
98.04±0.18 
 
% drug 
release at 
12hrs 
 
 
68.3±0.36 
 
 
----- 
 
 
------ 
 
 
---- 
 
 
63.3±0.28 
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TABLE 1: CALIBRATION OF FEBUXOSTAT BY USING ACID BUFFER OF 
Ph1.2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n=3* Regression Value – 0.99976 
 
CONCENTRATION 
 
ABSORBANCE 
 
2 
 
0.058±0.010 
 
4 
 
0.121±0.016 
 
6 
 
0.179±0.022 
 
8 
 
0.238±0.031 
 
10 
 
0.301±0.045 
 
12 
 
0.353±0.051 
 
14 
 
0.411±0.048 
 
16 
 
0.469±0.060 
 
18 
 
0.528±0.058 
 
20 
 
0.601±0.062 
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TABLE 2: COMPOSITION OF SOLID DISPERSION 
 
 
 
 
 
TABLE 3 : PERCENTAGE YIELD AND DRUG CONTENT OF SOLID 
DISPERSION 
 
 
 
S.no 
 
Formulation 
Code 
 
Method 
 
Ratio 
 
Percentage 
of yield 
± SD 
Drug 
content ± 
SD 
 
1 
 
A1 
 
Melting 
 
1 : 1 
 
87.09±0.01 
 
95.38 ± 0.20 
 
2 
 
A2 
 
Melting 
 
1 : 2 
 
88.21±0.16 
 
96.61 ± 0.07 
 
3 
 
A3 
 
Melting 
 
1 : 3 
 
94.75±0.03 
 
98.55 ± 0.80 
 
 
n=3* 
 
 
 
 
 
 
 
 
 
S.NO 
Formulation 
code 
 
Method 
 
Ratio 
 
Composition 
 
1 
 
A1 
 
Melting 
 
1:1 
 
Drug : PEG6000 
 
2 
 
A2 
 
Melting 
 
1:2 
 
Drug : PEG6000 
 
3 
 
A3 
 
Melting 
 
1:3 
 
Drug : PEG6000 
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TABLE 4: CUMULATIVE PERCENTAGE OF DRUG RELEASE OF PHYSICAL 
MIXTURE OF FEBUXOSTAT WITH PEG6000. 
 
 
 
 
 
Time 
(min) 
 
Percentage of drug release ± SD 
 
 
A1 
 
1 :1 
 
A2 
 
1 :2 
 
A3 
 
1:3 
MARKETED 
FORMULATION 
 
 
PURE            
DRUG 
 
10 
 
11.9 ±1.87 
 
22.4 ±1.95
 
31.2 ± 2.08 13.6±2.55 
 
9.16±2.97 
 
20 
 
19.5± 2.47 
 
31.8 ±2.71
 
38.5 ± 3.05 24.5±0.007 
 
19.25 ±0.95 
 
30 
 
29.1 ±1.18 
 
39.5 ± 3.05
 
47.2 ± 2.78 29.5±1.25 
 
29.34±3.06 
 
40 
 
34.2 ±1.08 
 
43.2 ± 2.49 
 
54.9± 2.3 33.8±1.28 
 
36.71 ±1.75 
 
50 
 
41.4 ±1.54 
 
51.9 ± 1.52 
 
61.8 ± 2.54 46.4±2.57 
 
42.4 ±3.27 
 
60 
 
44.5 ±2.48 
 
59.4 ± 2.24 
 
67.2 ± 2.78 53.6±3.08 
 
49.1 ±1.70 
 
 
n=3* 
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TABLE 4: CUMULATIVE PERCENTAGE OF DRUG RELEASE OF  
FEBUXOSTAT WITH PEG6000 AFTER SOLID DISPERSION BY MELTING 
METHOD 
 
 
 
 
 
n=3* 
 
 
 
 
 
 
 
 
 
Time 
(min) 
 
Percentage of drug release ± SD 
 
 
A1 
 
1 :1 
 
A2 
 
1 : 2 
 
A3 
 
1:3 
MARKETED 
FORMULATION 
 
 
PURE           
DRUG 
 
10 
 
26.7 ±1.66 
 
31.1 ± 2.42 
 
42.9±1.25 13.6±2.55 
 
9.16±2.97 
 
20 
 
33.7 ±3.36 
 
39.2 ± 1.40 
 
50.6 ± 1.42
 
24.5±0.007  19.25 ±0.95 
 
30 
 
43.7 ±2.70 
 
46.2 ± 1.63 
 
64.4±3.39 29.5±1.25 
 
29.34±3.06 
 
40 
 
47.9 ±2.04 
 
51.4 ± 2.08 
 
74.8 ± 4.05 33.8±1.28 
 
36.71 ±1.75 
 
50 
 
54.1 ±2.37 
 
58.8 ± 2.97 
 
86.9 ± 3.15 46.4±2.57 
 
42.4 ±3.27 
 
60 
 
59.4 ±2.50 
 
66.7 ± 3.37 
 
92.9 ± 1.82 53.6±3.08 
 
27.1 ±1.70 
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TABLE 6A:FORMULATION OF EFFERVESCENT FLOATING SUSTAINED RELEASE MATRIX      TABLET 
Quantity (mg) for I tablet (Average weight -350mg) 
INGREDIENTS F1 F2 F3 F4 F5 F6 F7 F8 F9 
SOLID DISPERSION IN 1:3 
RATIO (mg) 
 
[CONTAINING 40 MG 
FEBUXOSTAT] 
160 160 160 160 160 160 160 160 160 
HPMC K4M (mg) 35 70 105       
HPMC K100M (mg)    35 70 105    
METHYL CELLULOSE (mg)       35 70 105 
PVP K30 (mg) 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 
SODIUM BICARBONATE 
(mg) 
35 35 35 35 35 35 35 35 35 
CITRIC ACID (mg) 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 17.5 
MCC (mg) 78 43 8 78 43 8 73 43 8 
MAGNESIUM STEARATE 
(mg) 
3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 
TALC (mg) 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 3.5 
TOTAL WEIGHT OF EACH 
TABLET (mg) 
350 350 350 350 350 350 350 350 350 
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TABLE 6B--FORMULATION OF NON- EFFERVESCENT FLOATING SUSTAINED RELEASE MATRIX TABLETS 
 
Average Weight 200mg / Tablet 
 
 
INGREDIENTS F1 F2 F3 F4 F5 F6 F7 F8 F9 
SOLID DISPERSION IN 1:3 
RATIO (mg) 
 
[CONTAINING 40 MG 
FEBUXOSTAT] 
160 160 160 160 160 160 160 160 160 
HPMC K4M (mg) 70 105 140       
HPMC K100M (mg)    70 105 140    
METHYL CELLULOSE (mg)       70 105 140 
ETHYL CELLULOSE (mg) 35 35 35 35 35 35 35 35 35 
MCC (mg) 78 43 8 78 43 8 78 43 8 
MAGNESIUM STEARATE 
(mg) 
3.5 3.5 3.5 3.5 3.5 3.5 35 3.5 3.5 
TALC (mg) 3.5 3.5 3.5 3. 3.5 3.5 3.5 3.5 3.5 
TOTAL WEIGHT OF EACH 
TABLET (mg) 
350 350 350 350 350 350 350 350 350 
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TABLE 7A- PRECOMPRESSIONAL EVALUATION OF POWDER BLEND 
(EFFERVESCENT TECHNIQUE) 
  
 
S.no 
 
 
Formulation 
code 
 
 
Angle of 
repose 
± SD 
 
 
Bulk 
density 
(gm/ml)± 
SD 
 
 
Tapped 
density 
(g/ml) ± SD 
 
1 
 
F1 
 
28 047’ ± 0.5 
 
0.736± 0.01 
 
0.84 ± 0.02 
 
2 
 
F2 
 
29019’ ± 0.49 
 
0.777 ±0.01 0.87 ± 0.011 
 
3 
 
F3 
 
25084’ ± 0.65 
 
0.80 ± 0.02 0.91 ± 0.035 
 
4 
 
F4 
 
30057’ ± 1.56 
 
0.764 ± 0.02
 
0.84 ± 0.02 
 
5 
 
F5 
 
31009’ ± 1.87 
 
0.721 ± 0.03 0.87± 0.023 
 
6 
 
F6 
 
29034’ ± 0.98 
 
0.827± 0.01 0.94 ± 0.034 
 
7 
 
F7 
 
31010’ ± 0.51 
 
0.914 ± 0.01
 
1.03 ± 0.02 
 
8 
 
F8 
 
25058’ ± 1.55 
 
0.775 ± 0.02
 
0.89 ± 0.02 
 
9 
 
F9 
 
28072’ ± 1.35 
 
0.784 ± 0.03 0.94 ± 0.025 
 
 
               n=3* 
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TABLE 7B- PRECOMPRESSIONAL EVALUATION OF POWDER BLEND 
(NON-EFFERVESCENT TECHNIQUE) 
 
 
 
 
         n=3* 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.no 
 
 
Formulation 
code 
 
 
Angle of 
repose 
± SD 
 
 
Bulk 
density 
(gm/ml)± 
SD 
 
 
Tapped 
density 
(g/ml) ± SD 
 
1 G1  27 008’ ± 0.5 
 
0.747 ± 0.01
 
0.87 ± 0.02 
 
2 G2  29053’ ± 0.49 
 
0.754 ± 0.01 0.88 ± 0.011 
 
3 G3  28024’ ± 0.65 
 
0.674 ± 0.02 0.78 ± 0.035 
 
4 G4  29054’ ± 1.56 
 
0.725 ± 0.02
 
      0.86 ± 0.02 
 
5 G5  30026’ ± 1.87 
 
0.871 ± 0.03 1.08± 0.023 
 
6 G6  28050’ ± 0.98 
 
0.768± 0.01   0.94 ± 0.034 
 
7 G7  28034’ ± 0.51 
 
0.684 ± 0.01
 
0.76 ± 0.02 
 
8 G8  28035’ ± 1.55 
 
0.789 ± 0.02
 
0.95± 0.02 
 
9 G9  28024’ ± 1.35 
 
0.725 ± 0.03 0.88 ± 0.025 
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TABLE 8A- PRECOMPRESSIONAL EVALUATION OF POWDER BLEND 
(EFFERVESCENT TECHNIQUE) 
 
 
S.no  Formulation 
Code 
 
Compressibility 
index(%) 
±SD 
Hausners ratio 
(HR)±SD 
 
1 
 
F1 
 
13.09 ± 2.74 
 
1.15 ± 0.03 
 
2 
 
F2 
 
11.49 ± 0.24 
 
1.12 ± 0.31 
 
3 
 
F3 
 
12.08 ± 1.55 
 
1.13 ± 0.05 
 
4 
 
F4 
 
13.69± 2.09 
 
1.10 ± 0.03 
 
5 
 
F5 
 
17.24 ± 2.23 
 
1.20± 0.05 
 
6 
 
F6 
 
12.76 ± 0.15 
 
1.14 ± 0.01 
 
7 
 
F7 
 
11.26 ± 1.08 
 
1.13 ± 0.01 
 
8 
 
F8 
 
13.48 ± 1.96 
 
1.15 ± 0.32 
 
9 
 
F9 
 
17.02 ± 0.52 
 
1.20 ± 0.14 
 
 
 
           n=3* 
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TABLE 8B- PRECOMPRESSIONAL EVALUATION OF POWDER BLEND 
(NON-EFFERVESCENT TECHNIQUE) 
 
 
 
S.no 
 
Formulation 
code 
Compressibility 
index(%) 
±SD 
Hausners ratio 
(HR)±SD 
 
1 
 
G1 
 
14.94 ± 0.32 
 
1.17 ± 0.05 
 
2 
 
G2 
 
14.77 ± 0.15 
 
1.17 ± 0.33 
 
3 
 
G3 
 
14.10± 1.41 
 
1.16 ± 0.02 
 
4 
 
G4 
 
16.27 ± 2.06 
 
1.19 ± 0.03 
 
5 
 
G5 
 
19.44 ± 2.03 
 
1.24 ± 0.05 
 
6 
 
G6 
 
19.14 ± 0.14 
 
1.23 ± 0.05 
 
7 
 
G7 
 
10.52 ± 1.02 
 
1.11 ± 0.09 
 
8 
 
G8 
 
17.89 ± 1.45 
 
1.21 ± 0.32 
 
9 
 
G9 
 
18.18 ± 0.23 
 
1.22 ± 0.04 
 
 
 
n=3* 
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TABLE 9A-POSTCOMPRESSIONAL EVALUATION OF FEBUXOSTAT  
FLOATING SUSTAINED RELEASE MATRIX TABLET 
(EFFERVESCENT TECHNIQUE) 
 
 
              n=3* 
 
 
 
 
 
 
S.no 
 
Formulation 
code 
 
Hardness 
Kg/cm2 
 
Friability (%) 
± SD 
Drug    
content  
(%)± SD 
 
1 
 
F1 
 
4.26 ±0.47  0.359±0.028 
 
99.68±0.35 
 
2 
 
F2 
 
4.76±0.26  0.393±0.120 
 
98.79±0.846 
 
3 
 
F3 
 
5.1±0.235  0.326±0.132 
 
98.49±0.446 
 
4 
 
F4 
 
5.2±0.475  0.395±0.123 
 
99.59±0.446 
 
5 
 
F5 
 
5.0±0.365  0.333±0.065 
 
99.59±0.386 
 
6 
 
F6 
 
5.0±0.332  0.326±0.050 
 
97.69±0.65 
 
7 
 
F7 
 
5.9±0.345 0.34±0.01 
 
98.19±0.356 
 
8 
 
F8 
 
5.7±0.26  0.356±0.025 
 
98.59±0.332 
 
9 
 
F9 
 
5.1±0.248  
0.396±0.075 
 
99.16±0.326 
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TABLE 9B-POSTCOMPRESSIONAL EVALUATION OF FEBUXOSTAT  
FLOATING SUSTAINED RELEASE MATRIX TABLET 
(NON-EFFERVESCENT TECHNIQUE) 
 
 
 
             n=3* 
 
 
  
 
S.no 
 
Formulation 
code 
 
Hardness 
Kg/cm2 
Friability (%) 
± SD 
 
Drug 
content 
(%)± SD 
 
1 G1  
5.16 ±0.34 
 
0.369±0.035  
97.84±0.332 
 
2 
 
G2  4.78±0.291 
 
0.353±0.010  98.64±0.374 
 
3 G3  5.12±0.224 
 
0.386±0.135  98.68±0.398 
 
4 G4  4.21±0.358 
 
0.394±0.156  
98.48±0.356 
 
5 
 
G5  4.03±0.578 
 
0.359±0.0656  99.29±0.348 
 
6 G6  4.63±0.621 
 
0.369±0.050  99.89±0.62 
 
7 G7  5.21±0.315 
 
0.347±0.53  
97.29±0.345 
 
8 G8  5.36±0.231 
 
0.368±0.053  97.59±0.33 
 
9 
 
G9  5.27 ±0.298 
 
0.377±0.135  99.59±0.344 
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TABLE 10A- INVITRO SWELLING INDEX OF FLOATING SUSTAINED RELEASE 
MATRIX TABLETS OF FEBUXOSTAT ( EFFERVESCENT TECHNIQUE) 
 
 
 
 n=3* 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO 
 
 
 
 
Formulation 
code 
Percentage of swelling in time ( hours) ± SD 
 
 
3hrs 
 
 
6hrs 
 
 
9hrs 
 
 
12hrs 
1  F1 
 
39.02 ± 1.5969 
 
52.87 ± 0.2928 
 
68.42 ±0.3894 
 
76.91 ± 2.3081 
2  F2 
 
34.13 ± 1.5085 
 
58.66 ± 1.7230 
 
62.26 ±0.7823 
 
78.51 ± 2.5517 
3  F3 
 
30.68 ± 1.931 
 
56.79 ± 0.7552 
 
69.42 ±0.7550 
 
76.82 ± 1.0524 
4  F4 
 
34.35 ± 0.6908 
 
54.87 ± 1.2206 
 
64.34 ±1.3388 
 
80.57 ± 1.0850 
5  F5 
 
38.06 ± 0.1789 
 
55.44 ± 0.5645 
 
62.66 ±0.5565 
 
89.56 ± 1.2988 
6  F6 
 
38.57 ± 0.9500 
 
56.12 ± 0.4712 
 
60.71 ±0.4912 
 
87.24 ± 1.0208 
7  F7 
 
37.78 ± 0.7937 
 
57.73 ± 1.2833 
 
63.11 ±1.2457 
 
71.97 ± 1.1511 
8  F8 
 
39.00 ± 0.3750 
 
52.56 ± 0.4467 
 
66.62 ± 1.088 
 
72.64 ± 0.84 
9  F9 
 
36.9 ± 0.6090 
 
51.61± 1.1801 
 
66.31 ±1.2234 
 
70.50 ± 0.94384 
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TABLE 10B- INVITRO SWELLING INDEX OF FLOATING SUSTAINED RELEASE 
MATRIX TABLETS OF FEBUXOSTAT (NON- EFFERVESCENT TECHNIQUE) 
 
 
 
     n=3* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.NO 
 
 
 
 
Formulation 
code 
Percentage of swelling in time ( hours) ± SD 
 
 
3hrs 
 
 
6hrs 
 
 
9hrs 
 
 
12hrs 
1  G1 
 
64.02 ± 1.59 
 
69.87±0.2478 
 
88.42 ±0.3964 
 
70.35 ± 2.205 
2  G2 
 
59.04 ± 1.55 
 
70.3 ± 1.6530 
 
84.33 ±0.5823 
 
73.51 ± 2.552 
3  G3 
 
   56.21 ± 1.99 
 
70.02±0.9852 
 
89.66 ±0.5850 
 
66.69 ± 1.084 
4  G4 
 
53.21 ± 0.65 
 
64.7 ± 1.406 
 
96.22 ±1.8988 
 
75.23 ± 1.070 
5  G5 
 
57.3 ± 0.174 
 
69.5 ± 0.5785 
 
99.36 ± 0.565 
 
72.23 ± 1.27 
6  G6 
 
54.7± 0.960 
 
67.2 ± 0.4754 
 
102.5 ± 0.452 
 
70.24 ± 1.078 
7  G7 
 
59.78 ± 0.798 
 
69.47±1.5833 
 
86.52 ± 1.287 
 
71.5 ± 1.121 
8  G8 
 
 54.88 ± 0.3730 
 
67.23±0.4487 
 
88.85 ± 1.568 
 
68.04 ± 0.841 
9  G9 
 
  59.24± 0.609 
 
61.85± 1.185 
 
91.25 ± 1.284 
 
74.25± 0.9584 
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TABLE 11A -INVITRO  BUOYANCY LAG TIME, TOTAL FLOATING TIME, SWELLING 
INDEX OF FLOATING SUSTAINED RELEASE TABLETS OF FEBUXOSTAT 
(EFFERVESCENT TECHNIQUE) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                               n=3* 
 
 
 
 
 
 
 
 
 
 
 
 
 
Formulation 
code 
 
 
Buoyancy lag 
time (in 
minutes) 
 
 
Total floating 
time (in 
hours) 
 
 
Swelling index 
(%) 
(12hours) 
 
F1 
 
49 sec 
>18  
76.91 ± 2.3081 
 
F2 
 
52sec 
>18  
78.51 ± 2.5517 
 
F3 
 
48sec 
>18  
76.82 ± 1.0524 
 
F4 
 
23 sec 
>18  
80.57 ± 1.0850 
 
F5 
 
35sec 
>18  
89.56 ± 1.2988 
 
F6 
 
39sec 
>18  
87.24 ± 1.0208 
 
F7 
 
95sec 
>18  
71.97 ± 1.1511 
 
F8 
 
106sec 
>18  
72.64 ± 0.84 
 
F9 
 
89sec 
>18  
70.50 ± 0.94384 
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TABLE 11B -INVITRO  BUOYANCY LAG TIME, TOTAL FLOATING TIME, SWELLING 
INDEX OF FLOATING SUSTAINED RELEASE TABLETS OF FEBUXOSTAT 
(NON-EFFERVESCENT TECHNIQUE) 
 
 
 
 
Formulation 
code 
 
 
Buoyancy lag 
time (in 
minutes) 
 
 
Total floating 
time (in 
hours) 
 
 
Swelling index 
(%) 
(12 hours) 
 
G1 
 
302 sec 
 
Not more than12 
 
70.35 ± 2.205 
 
G2 
 
296 sec 
 
Not more than12 
 
73.51 ± 2.552 
 
G3 
 
305 sec 
 
Not more than12 
 
66.69 ± 1.084 
 
G4 
 
198sec 
 
Not more than12 
 
75.23 ± 1.070 
 
G5 
 
155sec 
 
Not more than12 
 
72.23 ± 1.27 
 
G6 
 
203sec 
 
Not more than12 
 
70.24 ± 1.078 
 
G7 
 
504sec 
 
Not more than12 
 
71.5± 1.121 
 
G8 
 
512sec 
 
Not more than12 
 
68.04 ± 0.841 
 
G9 
 
621sec 
 
Not more than12 
 
74.25± 0.9584 
 
n=3*  
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TABLE 12 A- IN VITRO  DRUG RELEASE PROFILE OF FLOATING SUSTAINED 
RELEASE MATRIX TABLETS OF FEBUXOSTAT ( EFFERVESCENT TECHNIQUE) 
 
 
 
 
 
S.no 
 
 
Time in 
hours 
 
Formulation code Drug release in 
(%) ±   SD 
 
F1 F2 F3
 
1 
 
1 
 
     26.9±0.45 
 
29.3±0.18 
 
27.9±0.58 
 
2 
 
2 
 
32.7±0.33 
 
34.6±0.32 
 
31.8±0.68 
 
3 
 
3 
 
36.9±0.07 
 
38.8±0.17 
 
35.8±0.47 
 
4 
 
4 
 
41.9±0.36 
 
41.8±0.32 
 
39.2±0.77 
 
5 
 
5 
 
44.7±0.58 
 
44.3±0.08 
 
42.6±0.42 
 
6 
 
6 
 
48.03±0.37 
 
46.7±0.36 
 
44.9±0.32 
 
7 
 
7 
 
52.6±0.14 
 
52.5±0.17 
 
50.8±0.39 
 
8 
 
8 
 
62.6±0.98 
 
57.9±1.89 
 
54.6±0.6 
 
9 
 
9 
 
66.7±0.35 
 
62.3±0.35 
 
58.7±0.78 
 
10 
 
10 
 
67.8±0.77 
 
65.4±0.65 
 
63.2±0.77 
 
11 
 
11 
 
71.9±0.96 
 
70.6±0.17 
 
68.8±1.99 
 
12 
 
12 
 
75.3±0.17 
 
74.6±0.45 
 
73.6±1.79 
 
n=3* 
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TABLE 12 A- IN VITRO  DRUG RELEASE PROFILE OF FLOATING SUSTAINED 
RELEASE MATRIX TABLETS OF FEBUXOSTAT ( EFFERVESCENT TECHNIQUE) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 n=3* 
 
 
S.no 
 
Time in 
hours 
 
Formulation code Drug release in 
(%) ± SD 
F4 F5 F6 
 
 
1 
 
1 
 
27.2±0.57 
 
23.6±0.29 
 
28.6±1.12 
 
2 
 
2 
 
29.3±0.28 
 
27.5±0.67 
 
33.6±0.69 
 
3 
 
3 
 
34.1±0.16 
 
30.3±0.25 
 
37.6±1.05 
 
4 
 
4 
 
38.1±1.03 
 
33.6±0.44 
 
43.2±1.13 
 
5 
 
5 
39.2±0.77  
36.6±0.16 
 
47.4±2.36 
 
6 
 
6 
 
43.8±0.61 
 
40.2±0.21 
 
53.3±2.68 
 
7 
 
7 
 
47.2±0.14 
 
 
44.0±0.23 
 
58.3±2.79 
 
8 
 
8 
 
49.6±0.20 
 
47.8±0.29 
 
62.7±2.89 
 
9 
 
9 
 
55.8±0.41 
 
50.5±0.12 
 
68.6±1.75 
 
10 
 
10 
 
62.9±0.82 
 
56.9±0.78 
 
72.6±2.01 
 
11 
 
11 
 
63.6±0.30 
 
62.3±0.29 
 
80.3±2.36 
 
12 
 
12 
 
71.8±0.88 
 
68.3±0.36 
 
85.8±1.76 
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TABLE 12 A- IN VITRO  DRUG RELEASE PROFILE OF FLOATING SUSTAINED 
RELEASE MATRIX TABLETS OF FEBUXOSTAT ( EFFERVESCENT TECHNIQUE) 
 
 
 
n=3* 
 
 
 
 
 
Formulation code Drug release in (%) ± SD 
F7 F8 F9 
1  1 28.9±0.73 
 
23.5±1.90 
 
25.3±0.47 
 
2 
 
2 
 
32.6±0.35 
 
27.8±2.45 
28.4±2.97 
 
3 
 
3 
 
36.5±0.47 32.6±3.30 
33.4±3.23 
 
4 
 
4 
 
43.2±0.56 36.8±3.47 
35.9±3.26 
 
5 
 
5 
 
47.1±0.26 
38.9±3.31 40.7±4.00 
 
6 
 
6 
 
52.5±0.84 
43.8±3.21 44.5±3.63 
 
7 
 
7 
 
57.5±1.15 
49.3±3.16 51.2±3.63 
 
8 
 
8 
 
63.9±1.21 
58.2±3.77 53.9±4.51 
 
9 
 
9 
 
69.5±0.96 
60.9±3.72 60.2±4.46 
 
10 
 
10 
 
74.4±0.30 
69.3±2.90 65.5±3.66 
 
11 
 
11 
 
79.6±0.56 75.5±2.35 
 
73.1±3.28 
 
12 
 
12 
 
81.2±0.21 
 
83.7±2.36 
 
82.0±2.78 
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TABLE 12 B- IN VITRO  DRUG RELEASE PROFILE OF FLOATING SUSTAINED 
RELEASE MATRIX TABLETS OF FEBUXOSTAT 
 ( NON-EFFERVESCENT TECHNIQUE) 
 
 
 
 
S.no 
 
 
Time in 
hours 
 
 
Formulation code Drug release in 
(%) ±   SD 
G1 G2 G3 
 
1 
 
1 
 
27.2±0.87 
 
25.3±0.57 
 
27.0±0.28 
 
2 
 
2 
 
31.6±1.12 
 
29.5±0.36 
 
33.4±0.20 
 
3 
 
3 
 
34.8±1.18 
 
33.2±1.51 
 
37.5±0.40 
 
4 
 
4 
 
40.8±1.06 
 
40.2±0.58 
 
42.8±0.53 
 
5 
 
5 
 
45.5±1.69 
 
44.8±0.36 
 
45.8±0.28 
 
6 
 
6 
 
50.9±2.12 
 
51.8±0.45 
 
47.8±0.24 
 
7 
 
7 
 
55.9±2.68 
 
55.7±0.59 
 
52.4±0.69 
 
8 
 
8 
 
64.2±1.74 
 
59.4±1.92 
 
59.6±1.06 
 
9 
 
9 
 
72.6±1.10 
 
65.5±1.63 
 
63.7±1.39 
 
10 
 
10 
 
74.2±1.12 
 
70.8±2.14 
 
68.2±1.84 
 
11 
 
11 
 
79.2±1.12 
 
73.4±2.17 
 
73.6±0.60 
 
12 
 
12 
 
85.2±0.39 
 
89.6±0.78 
 
92.6±0.58 
 
n=3* 
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TABLE 12 B- IN VITRO  DRUG RELEASE PROFILE OF FLOATING SUSTAINED 
RELEASE MATRIX TABLETS OF FEBUXOSTAT 
 (NON- EFFERVESCENT TECHNIQUE) 
 
 
 
 
 
S.no 
 
 
 
Time in 
hours 
 
 
Formulation code Drug release in 
(%) ±   SD 
 
G4 G5 G6 
 
1 
 
1 
 
24.6±0.29 
 
27.2±0.63 
 
27.9±0.28 
 
2 
 
2 
 
28.0±0.98 
 
33.8±1.00 
 
33.9±0.47 
 
3 
 
3 
 
31.5±1.04 
 
39.2±0.54 
 
40.5±0.16 
 
4 
 
4 
 
37.8±0.97 
 
44.5±0.67 
 
44.9±2.40 
 
5 
 
5 
 
42.8±0.66 
 
46.9±0.23 
 
49.3±1.66 
 
6 
 
6 
 
47.8±0.45 
 
51.5±0.63 
 
56.4±1.48 
 
7 
 
7 
 
51.6±0.16 
 
57.5±0.49 
 
62.9±1.14 
 
8 
 
8 
 
56.9±0.60 
 
62.9±0.17 
 
71.8±1.38 
 
9 
 
9 
 
62.8±0.39 
 
68.8±0.50 
 
76.8±1.58 
 
10 
 
10 
 
67.8±0.7 
 
75.2±0.49 
 
80.9±0.75 
 
11 
 
11 
 
72.8±0.59 
 
83.9±0.87 
 
84.9±1.11 
 
12 
 
12 
 
77.7±0.30 
 
90.9±0.65 
 
89.7±0.36 
 
n=3* 
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TABLE 12 B- IN VITRO  DRUG RELEASE PROFILE OF FLOATING SUSTAINED 
RELEASE MATRIX TABLETS OF FEBUXOSTAT (NON- EFFERVESCENT 
TECHNIQUE) 
 
 
 
S.no 
 
 
Time in 
hours 
 
Formulation code Drug release in 
(%) ±   SD 
G7 G8 G9 
 
1 
 
1 
 
25.9±1.52 
 
26.8±0.20 
 
24.3±1.31 
 
2 
 
2 
 
30.8±1.18 
 
32.8±0.38 
 
28.6±2.15 
 
3 
 
3 
 
36.7±1.60 
 
38.9±0.28 
 
33.6±2.28 
 
4 
 
4 
 
42.8±1.79 
 
41.8±0.29 
 
38.9±2.15 
 
5 
 
5 
 
48.1±3.08 
 
47.5±0.74 
 
43.9±1.87 
 
6 
 
6 
 
55.6±2.00 
 
55.6±0.42 
 
47.5±2.53 
 
7 
 
7 
 
61.2±3.69 
 
61.5±0.20 
 
54.2±2.36 
 
8 
 
8 
 
67.8±2.28 
 
67.9±0.37 
 
59.9±2.69 
 
9 
 
9 
 
72.8±1.98 
 
72.5±0.26 
 
65.8±2.56 
 
10 
 
10 
 
76.5±0.86 
 
76.8±0.22 
 
72.8±2.36 
 
11 
 
11 
 
84.8±0.53 
 
80.6±0.48 
 
78.9±2.04 
 
12 
 
12 
 
88.2±0.69 
 
87.5±0.37 
 
86.8±1.39 
 
n=3*   
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TABLE 13A- IN VITRO  SUSTAINED DISSOLUTION STUDIES OF FLOATING 
SUSTAINED RELEASE MATRIX  TABLETS OF  FEBUXOSTAT  
(EFFERVESCENT TECHNIQUE) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  n=3* 
 
 
 
 
 
 
 
 
S.no 
 
Time in hours 
 
 
 
Formulation 
code 
 
 
Drug release in (%) ± 
SD  12 hours 
 
1 
 
 
1 
 
 
F1 
 
 
75.3±0.17 
 
 
2 
 
 
2 
 
 
F2 
 
 
74.6±0.45 
 
3 
 
3 
 
   F3 
 
              73.6±1.79 
 
4 
 
4 
 
F4 
 
71.8±0.88 
 
5 
 
5 
 
F5 
 
68.3±0.36 
 
6 
 
6 
 
F6 
 
75.8±1.76 
 
7 
 
7 
 
F7 
 
81.2±0.21 
 
8 
 
8 
 
F8 
 
83.7±2.36 
 
9 
 
9 
 
F9 
 
82.0±2.78 
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TABLE 13B- IN VITRO  SUSTAINED DISSOLUTION STUDIES OF FLOATING 
SUSTAINED RELEASE MATRIX  TABLETS OF  FEBUXOSTAT  
(NON-EFFERVESCENT TECHNIQUE) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 n=3* 
 
 
S.no 
 
Time in hours 
 
 
Formulation code 
 
 
Drug release in (%) ± SD 
 
12 hours
 
 
1 
 
 
1 
 
 
             G1 
 
 
              85.2±0.39 
 
 
2 
 
 
2 
 
 G2 
 
              89.6±0.78 
 
3 
 
3 
 
  G3 
 
92.6±0.58 
 
4 
 
4 
 
G4 
 
77.7±0.30 
 
5 
 
5 
 
G5 
 
90.9±0.65 
 
6 
 
6 
 
G6 
 
81.7±0.36 
 
7 
 
7 
 
G7 
 
88.2±0.69 
 
8 
 
8 
 
G8 
 
87.5±0.37 
 
9 
 
9 
 
G9 
 
86.8±1.39 
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TABLE14A- IN VITRO  KINETIC RELEASE STUDY DATA  FOR FEBUXOSTAT SUATAINED RELEASE FLOATING TABLETS(EFFERVESCENT) 
FORMULATION 
CODE 
ZERO ORDER FIRST ORDER HIGHUCHI 
MODEL 
KORES-MEYER AND  
PEPPAS MODEL 
HIXON-CROWELL 
MODEL 
 r2 k0(h-1) r2 k1 (h-1) r2 kh(h-1/2) r2 n r2 KHC(h-1/3) 
F1 
0.9179 5.2004 0.9829 -4.4586 0.9795 20.818 0.9534 0.3987 0.9769 -0.1163 
F2 
0.9813 4.5932 0.9625 -3.7942 0.9463 18.399 0.8886 0.3542 0.929 -0.0971 
F3 
0.9133 4.7536 0.9946 -4.0732 0.9751 19.206 0.936 0.3852 0.9758 -0.1028 
F4 
0.9071 4.5592 0.9819 -3.8363 0.9635 18.155 0.9136 0.3852 0.9576 -0.0942 
F5 
0.9338 4.5373 0.9841 -3.9502 0.9623 17.795 0.926 0.4316 0.9575 -0.0931 
F6 
0.9424 5.8657 0.9963 -5.1206 0.9814 23.124 0.9577 0.4586 0.9664 -0.147 
F7 
0.9381 5.7661 0.9971 -5.0027 0.9852 22.831 0.9581 0.4521 0.9861 -0.1404 
F8 
0.9489 5.5259 0.9758 -4.9617 0.9472 21.332 0.9534 0.4307 0.9214 -0.1316 
F9 
0.9608 5.8384 0.9819 -5.321 0.9493 22.422 0.9282 0.5126 0.9389 -0.143 
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FORMULATION 
CODE 
ZERO ORDER FIRST ORDER HIGHUCHI 
MODEL 
KORES-MEYER AND  
PEPPAS MODEL 
HIXON-CROWELL 
MODEL 
 r2 k0(h-1) r2 k1 (h-1) r2 kh(h-1/2) r2 n r2 KHC(h-1/3) 
G1 0.9557 6.1134 0.991 -5.4692 0.9684 23.777 0.9356 0.4884 0.9632 -0.1567 
G2 0.9532 5.9907 0.9799 -5.3972 0.9591 23.218 0.9382 0.5034 0.8966 -0.1546 
G3 0.9196 5.703 0.9497 -5.002 0.9394 22.27 0.9197 0.4412 0.8184 -0.1504 
G4 0.9573 5.5089 0.9977 -4.9112 0.9767 21.499 0.9478 0.4899 0.9805 -0.1268 
G5 0.9475 6.1288 0.9892 -5.4229 0.969 23.946 0.9527 0.4726 0.9252 -0.1649 
G6 0.952 6.5045 0.994 -5.7703 0.9826 25.532 0.9604 0.4945 0.9808 -0.1787 
G7 0.9659 6.5323 0.9981 -5.9023 0.9806 25.431 0.9659 0.5336 0.9752 -0.1768 
G8 0.9523 6.2293 0.9945 -5.5267 0.9836 24.46 0.9654 0.498 0.9786 -0.162 
G9 0.9654 6.0796 0.9907 -5.5323 0.9587 23.408 0.9405 0.5136 0.9419 -0.1551 
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TABLE 15A- EVALUATION OF FEBUXOSTAT FLOATING TABLETS                  
KEPT  IN STABILITY AT 40OC/75RH RELATIVE HUMIDITY 
 
 
 
n=3* 
 
Formulation 
Parameters 
 
 
Initial 
 
 
15 days 
 
 
30days 
 
 
45days 
 
 
60days 
 
Average 
weight        
(mg) 
 
 
346.73 
 
 
346.73 
 
 
346.72 
 
 
346.72 
 
 
346.72 
 
 Thickness 
(mg) 
 
4.26 
 
4.26 
 
4.26 
 
4.26 
 
4.26 
 
Hardness  
(kg/cm2) 
 
 
10.3 
 
 
10.3 
 
 
10.3 
 
 
10.3 
 
 
10.3 
 
Floating lag 
Time(sec) 
 
 
35sec 
 
 
39sec 
 
 
32sec 
 
 
42 sec 
 
 
40sec 
 
Swelling 
Index (8 
Hours) (%) 
 
 
89.56 
 
 
88.02 
 
 
87.18 
 
 
87.03 
 
 
86.09 
 
Drug content 
in 
% 
 
 
99.59±0.38 
 
 
99.59±0.3
4 
 
 
99.23±0.28 
 
 
99.21±0.20 
 
 
98.04±0.18 
 
% drug 
release at 
12hrs 
 
 
68.3±0.36 
 
 
----- 
 
 
------ 
 
 
---- 
 
 
63.3±0.28 
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FIG.1 DETERMINATION OF  λ  max OF FEBUXOSTAT IN ACID BUFFER pH  1.2 
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FIG.2 CALIBRATION OF FEBUXOSTAT USING ACID BUFFER pH 1.2 
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FIG.3A-1 FTIR STUDY OF FEBUXOSTAT 
 
 
 
 
 
FIG.3A-2 FTIR STUDY OF FEBUXOSTAT AND PEG 6000 (1:3) SOLID 
DISPERSION 
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FIG.3A-3 FTIR STUDY OF FEBUXOSTAT WITH HPMCK4M 
 
 
 
 
 
FIG.3A-4  FTIR STUDY OF FEBUXOSTAT WITH HPMC K100M 
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FIG.3A-5 FTIR STUDY OF FEBUXOSTAT WITH METHYL CELLULOSE 
 
 
 
 
 
 
FIG.3A-6 FTIR STUDY OF FEBUXOSTAT WITH ETHYL CELLULOSE 
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FIG.3C FTIR STUDY OF FEBUXOSTAT + PEG6000+HPMCK4+ HPMC K 100+ 
METHYLCELLULOSE+PVPK30+SODIUM BICARBONATE+CITRIC 
ACID+MCC+TALC+MAGNESIUM STEARATE 
 
 
 
 
 
FIG.3D FTIR STUDY OF FEBUXOSTAT + PEG6000+HPMCK4+ HPMC K 100+ 
METHYLCELLULOSE+ETHYL CELLULOSE+MCC+TALC+MAGNESIUM 
STEARATE 
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FIGURE 4A: DSC THERMOGRAM  OF FEBUXOSTAT PURE DRUG 
 
 
 
 
 
FIGURE 4B: DSC THERMOGRAM  OF FEBUXOSTAT WITH PEG6000 SOLID 
DISPERSION (1:3) 
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FIGURE 5A: PXRD  PATTERN OF FEBUXOSTAT PURE DRUG 
 
 
 
 
FIGURE 5B: PXRD PATTERN OF FEBUXOSTAT AND PEG6000(1:3) 
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FIGURE 6A- PERCENTAGE YIELD AND DRUG CONTENT OF FEBUXOSTAT 
SOLID FISPERSION WITH PEG6000 
 
FIGURE 6B: CUMULATIVE PERCENTAGE DRUG RELEASE OF  
PHYSICAL MIXTURE OF FEBUXOSTAT WIH PEG6000
 
FIGURE 6C: CUMULATIVE PERCENTAGE DRUG RELEASE OF 
 SOLID DISPERSION OF FEBUXOSTAT WIH PEG6000 
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FIGURE 7A: COMPARITIVE ANGLE OF REPOSE FOR FORMULATIONS (F1-F9) 
AND (G1-G9) 
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FIGURE 7B: COMPARITIVE  BULK DENSITY   FOR FORMULATIONS 
 (F1-F9) AND (G1-G9) 
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FIGURE 7C: COMPARITIVE TAPPED DENSITY   FOR FORMULATIONS 
 (F1-F9) AND (G1-G9) 
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FIGURE 7D: COMPARITIVE COMPRESSIBILITY INDEX   FOR FORMULATIONS  
(F1-F9) AND (G1-G9) 
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FIGURE  7E: COMPARITIVE HAUSNERS RATIO  FOR FORMULATIONS 
 (F1-F9) AND (G1-G9) 
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FIGURE 7F: COMPARITIVE DRUG CONTENT  FOR FORMULATIONS 
 (F1-F9) AND (G1-G9) 
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FIGURE 8A  IN-VITRO BUOYANCY STUDIES OF FLOATING TABLET OF 
FEBUXOSTAT EFERVESCENT FORMULATION (BEST) F5 
 
 
                
                  
 
 AT 0 SECOND     AT 34TH SECOND 
 
 
 
 
AFTER 35TH SECOND 
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FIGURE 8B  IN-VITRO SWELLING INDEX STUDIES OF FLOATING TABLET OF 
FEBUXOSTAT EFERVESCENT FORMULATION (BEST) F5 
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FIGURE 9A IN VITRO DRUG RELEASE PROFILE OF FEBUXOSTAT AND  
HPMC K4M (F1-F3) AT DIFFERENT CONCENTRATIONS 
 
 
 
FIGURE 9B IN VITRO DRUG RELEASE PROFILE OF FEBUXOSTAT AND  
HPMC K100M (F4-F6) AT DIFFERENT CONCENTRATIONS 
 
 
FIGURE 9C IN VITRO DRUG RELEASE PROFILE OF FEBUXOSTAT AND  
METHYL CELLULOSE (F7-F9)  AT DIFFERENT CONCENTRATIONS 
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FIGURE 9D IN VITRO DRUG RELEASE PROFILE OF FEBUXOSTAT AND  
HPMC K4M  AND EC (G1-G3) AT DIFFERENT CONCENTRATIONS 
 
 
 
FIGURE 9E IN VITRO DRUG RELEASE PROFILE OF FEBUXOSTAT AND  
HPMC K100M AND EC (G4-G6) AT DIFFERENT CONCENTRATIONS 
 
 
 
FIGURE 9F IN VITRO DRUG RELEASE PROFILE OF FEBUXOSTAT AND  
METHYL CELLULOSE AND EC  (G7-G9) AT DIFFERENT CONCENTRATIONS 
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FIGURE 10A-1 COMPARISION OF INVITRO ZERO  ORDER RELEASE KINETICS 
OF FORMULATION CONTAINING FEBUXOSTAT AND HPMC K4M (F1-F3) AT 
DIFFERENT CONCENTRATIONS 
 
 
 
FIGURE 10A-2 COMPARISION OF INVITRO ZERO  ORDER RELEASE KINETICS 
OF FORMULATION CONTAINING FEBUXOSTAT AND HPMC K100M (F4-F6) AT 
DIFFERENT CONCENTRATIONS 
 
 
FIGURE 10A-3 COMPARISION OF INVITRO ZERO  ORDER RELEASE KINETICS 
OF FORMULATION CONTAINING FEBUXOSTAT AND METHYL CELLULOSE 
(F7-F9) AT DIFFERENT CONCENTRATIONS 
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FIGURE 10A-4COMPARISION OF INVITRO ZERO  ORDER RELEASE KINETICS 
OF FORMULATION CONTAINING FEBUXOSTAT AND HPMC K4M  AND EC 
(G1-G3) AT DIFFERENT CONCENTRATIONS 
 
 
 
FIGURE 10A-5 COMPARISION OF INVITRO ZERO  ORDER RELEASE KINETICS 
OF FORMULATION CONTAINING FEBUXOSTAT AND HPMC K100M AND EC 
(G4-G6) AT DIFFERENT CONCENTRATIONS 
 
 
 
FIGURE 10A-6  COMPARISION OF INVITRO ZERO  ORDER RELEASE 
KINETICS OF FORMULATION CONTAINING FEBUXOSTAT AND METHYL 
CELLULOSE  AND EC (G7-G9) AT DIFFERENT CONCENTRATIONS 
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FIGURE 10B-1 COMPARISION OF INVITRO FIRST ORDER RELEASE KINETICS 
OF FORMULATION CONTAINING FEBUXOSTAT AND HPMC K100M (F4-F6) AT 
DIFFERENT CONCENTRATIONS 
 
 
 
FIGURE 10B-2  COMPARISION OF INVITRO FIRST ORDER RELEASE KINETICS 
OF FORMULATION CONTAINING FEBUXOSTAT AND HPMC K100M (F4-F6) AT  
DIFFERENT CONCENTRATIONS 
 
 
FIGURE 10 B-3 COMPARISION OF INVITRO FIRST ORDER RELEASE KINETICS 
OF FORMULATION CONTAINING FEBUXOSTAT AND METHYL CELLULOSE 
(F7-F9) AT DIFFERENT CONCENTRATIONS 
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FIGURE 10B-4 COMPARISION OF INVITRO FIRST ORDER RELEASE KINETICS 
OF FORMULATION CONTAINING FEBUXOSTAT AND HPMC K4M AND EC  
(G1-G3)  AT DIFFERENT CONCENTRATIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 10B-5  COMPARISION OF INVITRO FIRST ORDER RELEASE KINETICS 
OF FORMULATION CONTAINING FEBUXOSTAT AND HPMC K100M AND EC 
(G4-G6)  AT DIFFERENT CONCENTRATIONS 
 
 
FIGURE 10B-6 COMPARISION OF INVITRO FIRST ORDER RELEASE KINETICS 
OF FORMULATION CONTAINING FEBUXOSTAT AND METHYL CELLULOSE 
AND EC   (G7-G9)  AT DIFFERENT CONCENTRATIONS 
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FIGURE 10C-1 COMPARISION OF INVITRO HIGUCHI MODEL RELEASE 
KINETICS OF FORMULATION CONTAINING FEBUXOSTAT AND HPMC K4M   
(F1-F3)  AT DIFFERENT CONCENTRATIONS 
 
 
 
FIGURE 10C-2 COMPARISION OF INVITRO HIGUCHI MODEL RELEASE 
KINETICS OF FORMULATION CONTAINING FEBUXOSTAT AND HPMC K100M  
(F4-F6)  AT DIFFERENT CONCENTRATIONS 
 
 
FIGURE 10C-3 COMPARISION OF INVITRO HIGUCHI MODEL RELEASE 
KINETICS OF FORMULATION CONTAINING FEBUXOSTAT AND 
 METHYL CELLULOSE  (F7-F9)  AT DIFFERENT CONCENTRATIONS 
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FIGURE 10C-4 COMPARISION OF INVITRO HIGUCHI MODEL RELEASE 
KINETICS OF FORMULATION CONTAINING FEBUXOSTAT AND 
HPMC K4M AND EC  (G1-G3)  AT DIFFERENT CONCENTRATIONS 
 
 
 
FIGURE 10C-5  COMPARISION OF INVITRO HIGUCHI MODEL RELEASE  
KINETICS OF FORMULATION CONTAINING FEBUXOSTAT AND 
 HPMC K100M AND EC  (G4-G6)  AT DIFFERENT CONCENTRATIONS 
 
 
 
FIGURE 10C-6 COMPARISION OF INVITRO HIGUCHI MODEL RELEASE 
KINETICS OF FORMULATION CONTAINING FEBUXOSTAT AND 
 METHYL CELLULOSE AND EC  (G7-G9)  AT DIFFERENT CONCENTRATIONS 
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FIGURE 10D-1 COMPARISION OF INVITRO KORESMEYER-PEPPAS MODEL 
RELEASE KINETICS OF FORMULATION CONTAINING FEBUXOSTAT AND 
 HPMC K4M   (F1-F3)  AT DIFFERENT CONCENTRATIONS 
 
 
 
FIGURE 10D-2 COMPARISION OF INVITRO KORESMEYER-PEPPAS MODEL 
RELEASE KINETICS OF FORMULATION CONTAINING FEBUXOSTAT AND 
 HPMC K100M   (F4-F6)  AT DIFFERENT CONCENTRATIONS 
 
 
FIGURE 10D-3 COMPARISION OF INVITRO KORESMEYER-PEPPAS MODEL 
RELEASE KINETICS OF FORMULATION CONTAINING FEBUXOSTAT AND 
 METHYL CELLULOSE  (F7-F9)  AT DIFFERENT CONCENTRATIONS 
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FIGURE 10D-4 COMPARISION OF INVITRO KORESMEYER-PEPPAS MODEL 
RELEASE KINETICS OF FORMULATION CONTAINING FEBUXOSTAT AND 
 HPMC K4M AND EC  (G1-G3)  AT DIFFERENT CONCENTRATIONS 
 
 
 
FIGURE 10D-5 COMPARISION OF INVITRO KORESMEYER-PEPPAS MODEL 
RELEASE KINETICS OF FORMULATION CONTAINING FEBUXOSTAT AND 
HPMC K100M AND EC  (G4-G6)  AT DIFFERENT CONCENTRATIONS 
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FIGURE 10E-1 COMPARISION OF INVITRO HIXON-CROWELL MODEL 
RELEASE KINETICS OF FORMULATION CONTAINING FEBUXOSTAT AND 
 HPMC K4M   (F1-F3)  AT DIFFERENT CONCENTRATIONS 
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FIGURE 10E-4 COMPARISION OF INVITRO HIXON-CROWELL MODEL 
RELEASE KINETICS OF FORMULATION CONTAINING FEBUXOSTAT AND 
HPMC K4M   (G1-G3)  AT DIFFERENT CONCENTRATIONS 
 
 
FIGURE 10E-5 COMPARISION OF INVITRO HIXON-CROWELL MODEL 
RELEASE KINETICS OF FORMULATION CONTAINING FEBUXOSTAT AND 
HPMC K100M   (G4-G6)  AT DIFFERENT CONCENTRATIONS 
 
 
 
FIGURE 10E-6 COMPARISION OF INVITRO HIXON-CROWELL MODEL 
RELEASE KINETICS OF FORMULATION CONTAINING FEBUXOSTAT AND 
METHYL CELLULOSE   (G7-G9)  AT DIFFERENT CONCENTRATIONS 
 
 
0
1
2
3
4
5
0 5 10 15
CD
R 
% 
DR
UG
 
RE
MA
IN
IN
G
TIME IN HOURS
HPMC K4M AND EC 1
HPMC K4M AND EC 2
HPMC K4M AND EC 3
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
0 5 10 15
CD
R 
 %
 D
RU
G 
RE
MA
IN
IN
G
TIME IN HOURS
HPMC K100M AND EC
1
HPMC K100M AND EC
2
HPMC K100M AND EC
3
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
0 5 10 15
CD
R 
% 
DR
UG
 
RE
MA
IN
IN
G
TIME IN HOURS
METHYL CELLULOSE
AND EC 1
METHYL CELLULOSE AND
EC 2
METHYL CELLULOSE AND
EC 3
CHAPTER  11  TABLES AND FIGURES 
 
DEPARTMENT OF PHARMACEUTICS, COLLEGE OF PHARMACY,MMC,MADURAI. 
 Page 175 
 
 
 
FIGURE 11: FTIR STUDY OF BEST FORMULATION (F5) 
 
 
 
 
 
FIGURE 12: DSC THERMOGRAM OF BEST FORMULATION (F5) 
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FIGURE13: PXRD PATTERNS  OF BEST FORMULATION (F5) 
 
 
 
 
 
 
 
FIGURE 14: COMPARISION OF BEST FORMULATION WITH MARKETED 
FORMULATION 
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FIGURE 15: IN VIVO X-RAY STUDIES ON BEST FORMULATION (F5) 
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 FIGURE 16: EVALUATION OF FEBUXOSTAT FLOATING SUSTAINED 
RELEASE MATRIX KEPT IN STABILITY AT 400C/75% RELATIVE HUMIDITY 
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SUMMARY AND CONCLUSION 
SUMMARY: 
  
 Floating  drug  delivery  system offers a simple and practical approach to 
achieve increased Gastric Residence Time(GRT) and to modify drug 
release profiles essential for sustained, site specific and  localized drug 
action. 
 An attempt was made to formulate and evaluate floating drug delivery 
system containing Febuxostat as model drug by both Effervescent  
technique and non-effervescent techniques. 
 The present work has aimed towards developing a floating drug delivery 
system of Febuxostat based on Novel approaches. 
 It was hypothesized that a system that combines advantages of both 
floating and  sustained release technology can be successful in the field 
of novel drug delivery system. 
 The solubility of Febuxostat was enhanced by the melting method using 
PEG 6000 as a carrier. 
 The λmax of Febuxostat was found to be 317nm in 0.1N HCl. 
 The Febuxostat obeys the Beer’s law within the concentration of 2 to 
20µg/ml. 
 DSC and FT-IR studies indicated that there was no interaction between 
drug and excipients. 
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 The formulations (F1 to F9) were  prepared by Effervescent technique 
and formulations (G1 to G9) were prepared by non- effervescent 
techniques using hydrophilic and hydrophobic polymers. 
 The formulated tablets were analysed for Pre-compression and Post- 
compression parameters, In vitro release studies, release kinetics, In vivo  
x-ray studies, stability studies. 
 The Pre-compression parameters of all the formulations were within the 
required limit that was suitable for formulation of the tablet. 
 The Post-compression parameters, such as Hardness, Friability, 
Uniformity in weight and Drug content of all the formulated tablets were 
within the acceptable limits. 
 The floating lag time and duration of buoyancy were found to be satisfied, 
for all the formulations. 
 Among all, formulation (F5) was selected as best formulation based on 
in-vitro release studies, Swelling index and in-vitro buoyancy studies. 
 The extent of drug release was found to be 68.34 in 12 hrs. 
 The drug release model of all the formulations complies with the Zero-
order kinetics followed by Non-Fickian diffusion mechanism. 
 The in-vivo X-Ray study was performed for the best formulation.It shows 
the gastric residence time of more than 12 hrs. 
 Selected formulation of Febuxostat was compared with marketed 
formulation. 
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CONCLUSION 
 The results of the present study clearly indicate the feasibility to develop 
Febuxostat in the form of floating drug delivery system with prolongation 
of gastric retention time and controlled release. 
 In my present study, the Effervescent formulations had better drug 
release, Floating Lag time, Swelling Index as compared to Non-
Effervescent formulations. 
 Increment in the concentration of swelling agent , decrement in the drug 
release. This may be due to increase in diffusion length of  drug from 
dosage form to the dissolution studies. 
 Increment in the concentration, of swelling agent, increment in Floating 
lag time, this may be due to gas generated by the gas generating agent 
was entangled between matrix formed by the swelling agent. 
 Polymer swelling was crucial in determining the drug release rate and 
also important for floatation. The viscosity of the polymer had a major 
influence on swelling process and matrix integrity. 
 Hydrophilic polymers induce the formation of strong viscous gel layer 
when they come in contact with the aqueous media that slowed down the 
rate of diffusion of medium into the tablet, which may result in the 
retardation or decrease in the drug release. 
 The combination of hydrophilic and hydrophobic polymers, which restricts 
the penetration of dissolution medium inside the matrix, also restricts the 
formation of gel ,layer around the matrix.So, that the drug release from 
the hydrophobic matrix tablets gets decreased. 
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 Thus, I conclude that both the techniques are equally potential and 
contribute in the development of floating drug delivery systems.Both the 
techniques equally have their own merits and de-merits.The mechanism 
and action of drug, selection of polymers ,stability factors .,Trial 
experiments.,  etc decide the best suitable technique. 
 The future studies may be extended to reveal the pharmacokinetic 
parameters related to bio-availability and clinical trial invesgtigations, that 
this type of formulations can be administered safely for the  treatment of 
Chronic Gout with improved therapeutic efficacy.   
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